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ABSTRACT 
Since the term “organocatalysis” was coined by MacMillan in 2000, it has become a major 
research topic with growing interest. The introduction of chiral Brønsted acid as an organocatalyst 
in particular has enabled the development of new asymmetric reactions to access chiral compounds 
that are difficult to access otherwise. Described herein is the application of chiral Brønsted acids 
as organocatalysts to selective glycosylation reactions and the development of new methods that 
improved the synthesis and characterization of chiral Brønsted acids.  
Chapter 1 is an introduction to phosphorus-based chiral Brønsted acids and an overview of 
different reaction mechanisms involving activation by chiral phosphoric acid. 
Chapter 2 describes the first example of the application of chiral Brønsted acids to control 
site-selective glycosylations of complex polyol compounds. Through judicious selection of 
catalysts and reaction conditions, regioisomeric glycoforms of 6-deoxy-erythronolide B and 
oleandomycin-derived macrolactones were selectively synthesized. Mechanistic investigation 
revealed that the mechanism of the reaction proceeded through a covalently linked anomeric 
phosphate intermediate.  
Chapter 3 describes a new method for the conversion of BINOL-derived chiral Brønsted 
acids to their H8-BINOL-based analogs through a single-step hydrogenation catalyzed by platinum 
(IV) oxide. Using the method, five new H8-BINOL-based chiral Brønsted acids were synthesized. 
Chapter 4 describes a new method to determine the enantiopurity of chiral phosphoric acids 
based on the use of chiral amines as the discriminating agent and 31P NMR analysis. This method 
was used to investigate the racemization stability of chiral phosphoric acids under hydrogenation 
conditions and thermal stress.
xix 
 
Chapter 5 describes the development of an efficient one-pot protocol for selective 
glycosylation of natural products containing a 1,3-diol moiety. The protocol relies on the use of 
simple boronic acid as the transient protecting group, which can be easily put on and taken off 
under mild conditions. The new protocol was used to synthesize various glycosides of antibiotic-
derived macrolactones, strophanthidol, and anhydro-ouabagenin.  
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CHAPTER 1 
Introduction 
(This chapter was partially published in: Tay, J. H.; Nagorny, P. “Brønsted Acid Catalysts 
Derived from Phosphorous” Book chapter in Non-nitrogenous Organocatalysis, Harned, A. M., 
Ed., CRC Press, 2017) 
 
1.1 Selected Milestones in Catalysis 
“It is, then proved that several simple or compound bodies, soluble and insoluble, have the 
property of exercising on other bodies an action very different from chemical affinity. By means 
of this action they produce, in these bodies, decompositions of these same elements to which 
they remain indifferent.” – J. J. Berzelius 
In an annual report published in 1836, titled “Quelques Idées sur une nouvelle Force 
agissant dans les Combinaisons des Corps Organiques,” (Some ideas about a new force acting in 
combinations of organic bodies), Swedish chemist Jöns Jacob Berzelius described what he termed 
the “catalytic force”.1 The report summarized prior observations in homogeneous and 
heterogenous systems where chemical bodies were found to have certain effects on the 
combination or decomposition of other chemical entities, while remaining unchanged themselves. 
The report marked first conceptualization of catalysis.  
Initially, the study and development of catalysis was centered around metallic compounds. 
A few years before Berzelius’s report, Louis Jacques Thénard recorded an early observation 
regarding the reactivity pattern of transition metals. He observed the decomposition of ammonia 
into nitrogen and hydrogen when passed over red-hot iron, copper, silver, gold and platinum 
decreased in the same order.2 Later, in 1909, Wilhelm Ostwald was awarded the Nobel Prize in 
Chemistry partly for his work on catalysis. He is most credited for developing the Ostwald process, 
which converts ammonia to nitric acid through oxidation in the presence of platinum as catalyst. 
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Subsequently, Karle Ziegler and Giulio Natta were recognized by the Nobel Committee in 1963 
for their discoveries in polymer science using transition metal-based catalysts.  
In the early 2000’s, organocatalyst (catalyst made up of hydrocarbon and other nonmetal 
elements) received attention from the chemistry community and has subsequently become a major 
focus in the research area of catalysis.3 However, at the time the idea of using a small organic 
molecule to catalyze asymmetric reactions certainly was not new. Notable examples of 
organocatalysis date as far  back as 1912, when German chemists Bredig and Fiske reported the 
use of cinchona alkaloids to catalyze the addition of hydrogen cyanide to benzaldehyde.4 Another 
famous example came from two independent reports in 1971 by Hajos and Parrish5, and Eder, 
Sauer and Wiechert6 on the application of proline, a natural amino acid, as chiral catalyst in Aldol 
reaction. In 2000, MacMillan coined the term “organocatalysis”, which marked an important 
turning point in the development of organocatalyst and  helped to more clearly define that area of 
research.7 Contemporaneous reports by List,8 Jacobsen,9 Corey,10 Denmark,11 Jørgensen12 and 
others further promoted the growing interest in the field of organocatalysis.  
 
1.2 Phosphorus-based Brønsted acid 
Phosphorus-based organic compounds, such as phosphine, phosphine oxide and 
phosphoric acid, represent one of the many subclasses of organocatalyst. Sir John Cornforth, who 
received the Nobel Prize in Chemistry in 1975 for his work on the stereochemistry of enzyme-
catalyzed reactions, reported the first systematic study and application of phosphorus (V) based 
acids in organocatalysis. In his 1978 lecture, titled “The imitation of enzymatic catalysis,” 
Cornforth describes on small molecule catalysts that can mimic the functionality of an enzyme to 
catalyze the hydration of olefins.13 He designed and synthesized a series of phosphinic acids with 
different structural backbones, based on several prescriptions that he composed: (1) the catalyst 
must be acidic; (2) it has a non-rigid cavity where the acidic group must be located and the olefin 
substrate could fit; (3) the acidic group must have the right acidity (not too strong or too weak); 
(4) the synthesis must be short, scalable and modular at late stage to provide different cavity shapes. 
Interestingly, the designs of more recent phosphorus-based Brønsted acid catalysts is essentially 
guided by the same blueprints laid out by Cornforth decades ago. 
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Figure 1.1. General structures of (a) phosphinic acid proposed by Cornforth in 1978 and (b) chiral 
phosphoric acid reported by Akiyama and Terada in 2004. (c) Enantiomeric pairs of axially chiral 
and C2-symmetric 1,1’-bi-2-naphthol (BINOL). 
 
Research on phosphorus-based acid experienced a spike in interest when the seminal and 
independent reports by Akiyama14 and Terada15 came out in 2004.  Both groups disclosed their 
findings on the application of phosphoric acids with a 1,1’-bi-2-naphthol (BINOL) backbone in 
catalyzing Mannich-type reactions (Scheme 1.1). One of the biggest advancements in catalyst 
design (compared to Cornforth’s), was the incorporation of an axially chiral BINOL backbone 
because it enabled the development of stereoselective reactions. Akiyama and Terada also noticed 
in their studies that the substituent groups on the 3,3’-position of the BINOL backbone had a 
significant impact on the enantioselectivity outcome of the reaction. In Akiyama’s example, the 
enantioselectivity increased as the size of the 3,3’-aromatic substituents increased. Interestingly, 
Terada was able to achieve the same level of enantioselectivity by using catalyst with electron-
withdrawing group. Their observations echoed Cornforth’s emphasis on the rigidity and shape of 
the active site cavity in his catalyst design.  
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Scheme 1.1. Effect of 3,3’-substituents of chiral phosphoric acid catalysts on the enantioselectivity 
for Mannich-type reactions reported by (a) Akiyama and (b) Terada in 2004. 
 
Since 2004, as chiral phosphorus-based acid catalysts continue to surge in popularity, the 
scope of reactions reported to be catalyzed by this class of organocatalyst has also significantly 
expanded.16 This growth is fueled in part by creative design of new catalysts with different chiral 
backbones and Brønsted acidic functionalities that encompass a wide range of acidity. Through 
computational and spectroscopy experimentation, the acidity of many of these phosphorus-based 
acids has been quantified.17 It emerged that the acidity of these acids may be modulated through 
several means, including changes in the substitution on the phosphorus atom, in the structure of 
the backbones, and by substitution on the backbones.   
5 
 
 
Figure 1.2. Effects of structural variations on the acidity of chiral phosphoric acids.  
 
1.3 Activation Modes Involving Chiral Phosphorus Acid 
Chiral phosphoric acid (CPA) with a pentavalent phosphorus center is a prevalent class of 
phosphorus-based acids seen in the literature.18 They are also the most studied for their reaction 
mechanisms. A typical CPA possesses both a Brønsted acidic proton and a Lewis basic lone pair, 
which allows them to engage in different modes of reaction. The Lewis basic lone pair can 
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participate in hydrogen bonding with nucleophiles possessing acidic protons, thereby increasing 
its nucleophilicity. On the other hand, the acidic proton can activate basic electrophile through 
either protonation or hydrogen bonding, and essentially enhances the electrophilicity of 
electrophiles by lowering their LUMO energies. In most cases, CPA engages in a bifunctional 
activation of substrates through hydrogen bonding and provides great stabilization to the 
intermediary complex or transition states. The highly directional nature of hydrogen bonding 
interactions also helps to maximize the asymmetric induction originated from the chiral backbone.  
 
Scheme 1.2. Example of enantioselective reaction catalyzed by CPA involving bifunctional 
hydrogen bonding activation of nucleophile and electrophile.19  
  
Besides acting as a hydrogen bonding catalyst, CPAs are involved in counterion catalysis, 
relying on electrostatic interactions between ionic species to control the course of a reaction. This 
is an especially appealing strategy in developing asymmetric reactions since a majority of organic 
transformations proceed through partially or fully charged transition states. In general, CPA can 
be introduced as a chiral phosphate counterion in one of several ways: (1) protonation of substrate20; 
(2) dehydration of substrate21; or (3) anion exchange with phosphate salt22 (Scheme 1.3). In 
addition, counterion catalysis relies on the formation of a tight or contact ion pair to achieve high 
degrees of asymmetric induction. Indeed, most methods using a CPA as counterion catalyst 
reported a higher selectivity in nonpolar media.  
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Scheme 1.3. Examples of counterion catalysis involving introduction chiral phosphate ion through 
(a) protonation20, (b) dehydration21, and (c) anion exchange22. 
 
CPA may also be thought of as a chiral surrogate for proton sources and involved in the 
formation of a new chiral center through enantioselective protonation. The idea of accessing chiral 
compounds through stereoselective protonation of π bonds is simple, but implementation as such 
is challenging. This is because of the fast rate of protonation that makes it hard to exert a high level 
of stereocontrol and the probability of newly formed stereocenters undergoing undesired 
racemization. With the recent introduction of CPA catalysts possessing a diverse range of pKa 
values, researchers such as Yamamoto23 and Rueping24 were able to mitigate previous obstacles 
8 
 
to develop several interesting transformations using CPA as a chiral proton source. These reaction 
mechanisms differ from other modes of activations, where CPA activates basic electrophile 
through protonation or it forms an ion pairs through the protonation of a substrate. In Rueping’s 
examples, the protonation step in the reaction mechanism is the enantio-determining step. In other 
words, protonation is the only viable step that leads to the formation of a new stereocenter (Scheme 
1.4).  
 
Scheme 1.4. Example of CPA catalyzed Nazarov cyclization involving enantioselective 
protonation.  
 
In 2011, Toste group reported a new transformation catalyzed by CPA that proceeded 
through a covalent phosphate intermediate (Scheme 1.5).25 Based on detailed mechanistic studies, 
Nagorny group26 and others27 also proposed similar covalent intermediates for their 
transformations, indicating that this is a general mode of reaction involving CPA.  The key feature 
of covalent catalysis is the formation of a transient covalent bond between a substrate and the 
catalyst, which undergoes further reaction, and subsequent breakage of the bond to regenerate the 
catalyst. The major advantage of catalysis proceeding through a covalent intermediate is the highly 
rigid and directional covalent linkage that helps to maximize asymmetric induction from the chiral 
catalyst. Nonetheless, one of the biggest challenges of developing covalent catalysis is to identify 
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a catalyst that is both sufficiently nucleophilic and possesses good leaving group ability. One 
solution presented by Toste is the use of chiral dithiophosphoric acid, a subclass of CPA, where in 
the phosphorus is substituted with two sulfur atoms, instead of oxygen. He proposes that 
dithiophosphoric acids are more nucleophilic and serve as a better leaving group than their 
oxygenated counterparts because of the substitution of more polarizable sulfur atoms. 
 
Scheme 1.5. Example of CPA catalyzed reaction proceeding through formation of covalent 
phosphate intermediate. 
 
Another distinct mode of action for CPA involves the addition of external Lewis acids to 
modulate the reactivity of CPA itself. The amphoteric nature of CPA allows Lewis acid to either 
exchange with the acidic proton or complex to the Lewis basic lone pair. Ishihara found that the 
combination of CPA with n-BuLi generated chiral lithium phosphate, which could catalyze the 
addition of trimethylsilyl cyanide (TMSCN) to ketone.28 He postulated that the lithium ion 
enhanced the Lewis basicity of phosphoryl oxygen, which in turn activated TMSCN more 
effectively.  
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Scheme 1.6. Example of CPA catalysis involving enhancement of phosphate basicity by lithium 
ion. 
 
In subsequent studies, Ishihara demonstrated the use of CPA in combination with BBr3 as 
Lewis acid to catalyze a Diels-Alder reaction.29 Through computational and NMR experiments, 
he was able to identify the active catalytic species, which had BBr3 bound to the phosphoryl oxygen.  
In additional, their computational analysis also suggested that existence of halogen bonds between 
bromine and C-H bond of acrolein Presumably, the complexation of BBr3 enhances the acidity of 
the CPA and provided addition stabilization through non-covalent bonding interactings, which 
consequently lead to excellent yield and stereoselectivity.  
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Scheme 1.7. Example of CPA catalysis involving enhancement of Brønsted acidity by additional Lewis 
acid.  
 
1.4 Summary 
As the field of catalysis progresses, so does the pursuit of new catalysts that meet higher 
standards. While new catalysts with high turnover number and great selectivity are highly sought 
after, other factors like ease of preparation, recyclability, environmental impact and toxicity are 
also gaining more considerations. In that regard, organocatalyst has proven its great potential, 
especially based on the growing studies that have been reported since the early 2000s. 
Organocatalysis, involving CPA in particular, stand out because of the catalyst’s versatility to 
engage in many distinct modes of activation and a highly tunable structure that is easily amendable 
to fit the needs of varying reactions. The following chapters of this dissertation discuss a new 
application of CPA catalysts in glycosylation reaction, and the development of new methods that 
improve the synthesis and characterization of CPA.
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CHAPTER 2 
Regiodivergent Glycosylations of 6-deoxy-Erythronolide B and Oleandomycin Derived 
Macrolactones Catalyzed by Chiral Brønsted Acids 
(This chapter was partially published in: Tay, J. H.; Arguelles, J. A.; DeMars, M. D.; 
Zimmerman, P. M; Sherman, D. H.; Nagorny, P. J. Am. Chem. Soc. 2017, 139, 8570.) 
 
2.1 Introduction 
Across different classes of natural products, many of them were isolated as glycosylated 
compounds, where the sugar moiety was found to play an essential role in determining their 
biological activities. According to a survey conducted by Thorson on 15,940 bacterial natural 
products, 21% of them (3,426 compounds) are found to be glycosides (Figure 2.1).1 Among the 
bacterial glycosides, glycosylated macrolactones and macrolactams represent the largest subclass 
(738 compounds), and over 344 distinct sugar structures were identified. In other words, 
glycosylated natural products, especially those produced by bacteria, exist in great number and 
diversity.  
 
Figure 2.1. Pie chart showing numbers of glycosylated and non-glycosylated natural products 
produced by bacteria according to survey by Thorson.
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Nature relies on enzymes such as glycosyltransferases to catalyze the formation of a 
glycosidic bond that links the sugar or glycone to the aglycone. Like most enzymatic reactions, 
enzymatic glycosylation typically proceeds with exclusive regio- and stereocontrol.2 However, the 
same transformation is formidably challenging to accomplish with the same level of selectivity in 
a flask. This is especially true for glycosylation of complex natural products that are highly 
functionalized and contain multiple reactive sites. In order to prevent the formation of multiple 
regio- and stereoisomeric glycosides during the reaction, most synthetic strategies rely on 
multistep protection and deprotection sequences to achieve selective glycosylation of natural 
products. Nonetheless, these extra steps often also present additional synthetic challenges during 
the process of development and optimization. Ideally, a convergent approach based on a catalyst-
controlled glycosylation reaction to selectively access glycoform of complex natural products 
would be more effective.  
 
Figure 2.2. Examples of complex natural product possessing sugar side-chain. 
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2.2 Prior Art Related to Site-Selective Functionalization of Polyol Compounds 
Many research groups have reported remarkable examples of selective functionalization of 
polyol compounds based on catalyst-controlled reactions (Figure 2.3). Being one of the pioneers 
in the field, Miller focuses on research using small peptide chain as organocatalyst to 
regioselectively functionalize complex natural products, such as erythromycin3, vancomycin4 and 
apoptolidin A5. In 2013, the Tan group reported the design of a pair of pseudo-enantiomeric 
organocatalysts, which catalyzed the regiodivergent mesylation or acylation of unprotected 
monosaccharides, and natural products, such as mupirocin and digoxin.6 Around the same time, 
the Nagorny group also published their findings on the application of CPA to discriminate 
monosaccharide substrates with 1,2-diol for regioselective acetalization reactions.7  
 
Figure 2.3. Applications of organocatalysis towards regiodivergent functionalization of poly-ol 
compounds reported by (a) Miller, (b) Tan, and (c) Nagorny.  
 
Aside from the simple functionalization with common protecting groups, there are also 
many excellent examples of strategies focus on selective glycosylation of unprotected polyol 
compounds. In 2011, the Taylor group reported a highly regioselective glycosylation method using 
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borinic acid as the catalyst to generate disaccharides.8 The catalyst was proposed to form a cyclic 
complex with monosaccharide substrate, and selectively activate one of the three hydroxy groups 
for glycosylation. The Montgomery group developed a method based on the formation of a silane 
intermediate in combination with an intramolecular aglycone delivery to selectively synthesize 
1,6-linked disaccharides.9 More recently, Miller reported their studies on selective glycosylation 
of polysaccharides in an aqueous solution using calcium salt as the catalyst.10 Under the reaction 
conditions, sugar moiety was selectively delivered to oligosaccharide with up to 14 free hydroxy 
groups.  
 
Scheme 2.1. Examples of site-selective glycosylations reported by (a) Taylor, (b) Montgomery, 
and (c) Miller. 
 
A detailed survey of the literature reveals that most catalyst-controlled regioselective 
functionalization of polyol compounds focus on selective installation of a common protecting 
group. On the other hand, almost all methods for regioselective glycosylation of polyol compounds 
rely on substrate control for the observed selectivity. In other words, the exclusive selectivity is 
achieved based on enhancement of the substrate innate bias in terms of reactivity. Notably, there 
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is a lack of research in regioselective glycosylation of polyol compounds based on catalyst-
controlled reactions. 
 
2.3 Experimental Designs 
The goal of the following studies was to develop a regiodivergent glycosylation method, 
which would enable access to all regioisomeric glycoforms of the same polyol compounds based 
on judicious selection of catalyst and reaction condition. We hypothesized that CPA would provide 
a chiral pocket where the glycosyl donor is activated and glycosylation reaction takes place, and 
the local chiral environment would lead to discrimination of hydroxy groups with different 
stereoelectronic properties on the acceptor for selective glycosylation. To test our hypothesis, we 
selected 6-deoxy-erythronolide B (6-dEB) 1 as our initial substrate. 6-dEB is medicinally 
important, and it has three secondary hydroxy groups with similar stereoelectronic properties, 
which is crucial for verifying and testing the limit of our proposed strategy.   
 
Scheme 2.2. Biosynthetic pathway of erythromycin A from 6-deoxy-erythronolide B.  
 
6-dEB is a precursor in the biosynthesis of the 14-membered macrolide antibiotics 
erythromycin A and B.11 Studies on the biogenic pathway reveal that 6-dEB undergoes sequential 
glycosylations first at the C3 position and then at the C5 position (Scheme 2.2). Previous attempts 
to replicate the selective installation of sugars on 6-dEB using engineered glycosyltransferase or 
glycosylation of similar macrolactones using various chemical methods were unsuccessful. In 
2008, Liu reported a study on the substrate specificity of macrolide glycosyltransferase Des 
VII/DesVIII.12 While the enzyme showed excellent regiospecificity in catalyzing the attachment 
of desosamine to various macrolactones and linear substrates, the in-vitro glycosylation of 6-dEB 
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catalyzed by the same enzyme led to formation of a mixtures of isomers with low conversion. 
(Scheme 2.3) In Woodward’s total synthesis of erythromycin, the desosamine moiety was 
introduced to a 14-membered macrolactone intermediate through a silver triflate mediated 
glycosylation with a desosamine-derived thioglycoside donor.13a (Scheme 2.4) While the reaction 
produced the desired C5-glycoside as the major product, three other unidentified glycosides were 
also isolated. These circumstances provided additional motivation for us to develop a new method 
to allow the selective formation of regioisomeric glycosides from unprotected 6-dEB and to 
demonstrate the potential of CPA organocatalyst as a powerful tool in the selective synthesis of 
glycosylated natural products.   
 
Scheme 2.3. In-vitro glycosylation of 6-dEB catalyzed by Glycosyltransferase DesVII/DesVIII. 
 
 
Scheme 2.4. Silver triflate mediated glycosylation of macrolactone with desosamine-derived 
thioglycoside donor reported by Woodward.  
  
2.4 Glycosylation of 6-dEB Catalyzed by Achiral Lewis and Brønsted Acids 
The 6-dEB used in the following studies was harvested from a culture of an Escherichia 
Coli strain that had previously been engineered and optimized for production of the 
macrolactone.14 First, control experiments were carried out to establish the inherent reactivity 
pattern of the three hydroxy groups on 6-dEB. 6-dEB (1) was subjected to glycosylation reactions 
20 
 
with a trichloroacetimidate glycosyl donor derived from D-6-deoxyglucose 2, and typical 
activators for trichloroacetimidate donor were used (Table 2.1). The reaction catalyzed by 
TMSOTf resulted in formation of the α-C5 glycoside 4 as the major product, along with the bis-
glycosylated product 5 at the C3 and C11 positions (entry 1). BF3•OEt2, another common Lewis 
acid catalyst for trichloroacetimidate donor activation, lead to formation of the C5-glycoside as 
the major regioisomer, while a mixture of diastereomers with α and β glycosidic linkages were 
formed (entry 2). In addition, Brønsted acids such as diphenylphosphoric acid and anhydrous 
tosylic acid were tested; both tests still lead to the glycosylation at the C5 position preferably (entry 
3 and 4). In short, the results from the glycosylation of 6-dEB with achiral Lewis and Brønsted 
acids as activators indicate that the C5-hydroxy group is the most reactive towards the 
glycosylation reactions, followed by the C3-hydroxy group. The C11-hydroxy group is the least 
reactive. 
 
Table 2.1. Glycosylation of 6-dEB with donor 2 catalyzed by achiral Lewis and Brønsted acids.   
 
2.5 Glycosylation of 6-dEB Catalyzed by Chiral Brønsted Acids 
With the baseline reactivity established, subsequent experiments focused on evaluating 
various chiral Brønsted acids with the goal of enhancing the selectivity for glycosylation at the 
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C5-hydroxy group of 6-dEB (Table 2.2). Reactions with catalysts 6 – 17 (entries 1 – 16) in 
nonpolar solvents identified catalyst (S)-17 (entry 16) as the optimum catalyst for promoting the 
formation of α-C5 glycoside 4 of 6-dEB with an excellent yield and selectivity. When the catalyst 
(R)-17 (with the same substituent but opposite chirality) was used, the reaction lead to the 
formation of 1:1 mixtures of C3 and C5-glycosides, but the formation of the α-glycosidic linkage 
was retained (entry 15).  These combined results supported our initial hypothesis that the chirality 
of the CPA catalyst (or the chiral pocket it possesses) had a significant impact on the 
regioselectivity outcome of the glycosylation of polyol compounds such as 6-dEB. During the 
screening process, a commercially available chiral bis-sulfonimide acid, (R)-18 developed by 
List,15 was also found to promote exclusive glycosylation at the C5-hydroxy group, albeit in lower 
yield (entry 17).  
In the biosynthesis of erythromycin A, 6-dEB first undergoes glycosylation at the C3 
position. However, the results from our control experiments indicate that such a transformation 
would be difficult to accomplish in a flask since the C5-hydroxy group of 6-dEB is inherently 
more reactive. Therefore, the goal for the subsequent set of experiments was to identify th catalysts 
that could mimic the functionality of glycosyltransferase and catalyze the glycosylation of the less 
reactive C3-hydroxy group. Previous experiments have shown that CPA with (R) chirality could 
override the inherent reactivity bias of C5-hydroxy group, to a certain extend. Therefore, CPAs 
with (R) chirality but different substituents at the 3,3’-position were tested next (Table 2.2). As the 
meta-substituents of the 3,3’-phenyl ring changes from -SF5 > -CF3 > -Cl > -F groups, we observed 
a gradual increase in regioselectivity favoring glycosides at the C3-position (entries 12, 15, 19 and 
20). Furthermore, we observed even higher regioselectivity for C3-glycosylation when the 
backbone of the meta-fluoro substituted CPA was switched from a BINOL to a SPINOL backbone 
(entries 21 – 24). Previous computational studies suggested that SPINOL-based CPA, which has 
a rigid spirobiindane backbone, is better at differentiating the diastereomeric transition states, and 
consequently leads to higher selectivity.16  
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Table 2.2. Glycosylation of 6-dEB (1) with glycosyl donor 2 catalyzed by chiral Brønsted acids.   
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Figure 2.4. Chiral Brønsted acids screened for regioselective glycosylations of macrolactones. 
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After the optimum catalysts for selective glycosylation at the C3 and C5-position were 
identified, we proceeded to investigate the scope and limitations of the method (Table 2.3). When 
6-dEB (1) was subjected to TMSOTf catalyzed glycosylation with the D-Fucose derived glycosyl 
donor 22, it resulted, as expected, in a selective formation of the C5-glycoside 24 and a complex 
mixture of bis-glycosylated products (entry 1). In contrast, the use of catalyst (S)-21 lead to the 
formation of the C3-glycoside 23 that was not observed in the control experiment (entry 2). Just 
like the glycosylation with D-6-deoxyglucose donor 2, catalyst (S)-17 lead to exclusive formation 
of C5-glycoside 24 with no traces of a bis-glycosylated product (entry 3). However, we did observe 
erosion in diastereoselectivity for the reaction. 
 
Table 2.3. Glycosylation of 6-dEB with D-Fucose derived glycosyl donor 22.  
In addition, the benzylated glycoside can be easily converted to the fully deprotected 
macrolactone glycoside through hydrogenolysis over Pd/C. (Scheme 2.5)  
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Scheme 2.5. Debenzylation of 6-dEB glycoside under hydrogenolysis condition.  
 
2.6 Glycosylation of Oleandomycin-derived Macrolactone Catalyzed by Chiral Brønsted 
Acids 
 
To further demonstrate the applicability of the strategy, we targeted selective glycosylation 
of other macrolatone as our next substrate. We identified a 14-membered macrolactone 25, derived 
from oleandomycin, that is structurally similar to 6-dEB. Interestingly, macrolactone 25 exhibited 
a different reactivity profile compared to the reactions with 6-dEB (Table 2.4). When it was 
subjected to the glycosylation with the D-6-deoxyglucose donor 2 and TMSOTf, macrolactone 25 
was converted to the C5-glycoside 28 and the hemiacetalized C3-glycoside 29 (entry 1). The 
results indicated that the C3 and C5-hydroxy groups of 25 were almost equally reactive. However, 
the resulting C3-glycoside 27 was unstable and subsequently underwent intramolecular 
acetalization to form the by-product 29. When the reaction was promoted by catalyst (S)-21 or 
(R)-21, the C3-glycoside 27 was formed as the major product for both cases, but (R)-21 led to 
higher regioselectivity (entry 2 and 3). Through further screening and optimization, catalyst (R)-
18 was found to be the optimum promoter for the selective glycosylation of macrolactone 25 at 
the C5-position (entry 4).  
Even though switching the substrate to macrolactone 25 required re-screening of the 
catalyst, the regioselecitivity profile exhibited by the identified catalysts was conserved when 25 
was subjected to glycosylation with different sugar donor (Table 2.4). When 25 was coupled with 
the D-fucose derived trichloroacetimidate donor 22, catalyst (R)-21 promoted the formation of β-
C3-glycoside 30 with excellent regio- and diastereoselectivity (entry 6). Similarly, catalyst (R)-18 
led to selective glycosylation at the C5-hydroxy group (entry 7). Similar trends were observed for 
glycosylation of macrolactone 25 with the L-fucose derived trichloroacetimidate donor 26 (entry 
8 and 9).  
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Table 2.4. Glycosylation of Oleandomycin-derived macrolactone.  
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Figure 2.5. Structures of glycosides generated from glycosylation of macrolactone 25.  
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2.7 Glycosylation of 6-dEB with Desosamine-derived Trichloroacetimidate Donor 
Next, we studied the glycosylation of 6-dEB with a trichloroacetimidate donor derived 
from desosamine, which is the native sugar moiety on erythromycin. When 6-dEB was subjected 
to glycosylation with desosamine donor 36 and BF3•OEt2 as activator, we observed formation of 
a mixture of C3- and C5-glycosides (37a and 37b) in 43:57 regioisomeric ratio. (Table 2.5, entry 
1) Similar regioisomeric ratio (37a:37b = 31:69 r.r.) was observed when diphenylphosphoric acid 
was used as the activator (entry 2).  
When catalyst (S)-17 was used to catalyze the glycosylation of 6-dEB with desosamine 
donor 36, we observed a significant improvement in the regioisomeric ratio, up to 37a:37b = 16:84 
r.r. (entry 3) However, same regioisomeric ratio was obtained when catalyst (R)-17 was used in 
the reaction. (entry 4) In addition, the reactions also resulted in formation of bis-glycosylated 
product (~10%) and orthoester (~15%) by-product.  
 
Table 2.5. Glycosylation of 6-dEB with desosamine-derived trichloroacetimidate donor. 
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2.8 Mechanistic Studies on Glycosylation Catalyzed by Chiral  Brønsted Acids   
The results from the glycosylation of 6-dEB (1) and macrolactone 25, catalyzed by chiral 
Brønsted acid, suggests that the catalyst has a significant control over the regioselectivity outcome 
of the reaction. To better understand the reaction mechanism, we monitored the reaction of 
macrolactone 25 with donor 22 under a CPA catalyzed condition by NMR (Figure 2.6). We 
observed the selective formation of the C3-glycoside β-30 as expected at various time intervals, 
and there were no changes in the product’s regioisomeric composition throughout the experiments. 
The results indicated that we did not observe high regioselectivity because the minor regioisomer 
underwent decomposition under the reaction conditions.  
 
 
Figure 2.6. Conversion of 25 to glycoside β-30 monitored by NMR. 
 
Furthermore, the isolated C3-glycoside β-30 was re-subjected to reaction condition with 
catalyst (R)-18, which favors formation of the C5-glycoside 31, and we did not observe any 
formation of the C5-glycoside 31 at the end of the reaction. The experiment ruled out the 
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possibility that the regioisomeric glycosides undergo isomerization in the presence of chiral 
Brønsted acid.  
To further elucidate the mechanism of the reaction, we turned to computational analysis, 
which was done in cooperation with the Zimmerman group. Modern reaction path-searching 
algorithms17 were used to study a simplified model system of the glycosylation reaction (Figure 
2.7). The result of that analysis suggested that most likely the α-trichloroacemtimidate donor (38) 
first underwent a facile SN2-like displacement by the phosphoric acid to generate a covalent β-
phosphate intermediate (38a). The glycosyl phosphate then underwent another SN2-like 
substitution by the alcohol nucleophile to generate the α-glycoside product (38b). The computed 
mechanism explained the experimental results, where α-glycoside 3 and 4 were formed in the 
reaction of 6-dEB with the α-trichloroacetimidate donor 2 under CPA catalyzed reaction 
conditions. The formation of the retentive product was most likely due to a double inversion 
mechanism.  
 
Figure 2.7. Computed reaction mechanism for glycosylation of trichloroacetimidate donor 
catalyzed by phosphoric acid.  
 
Since the computational analysis predicted that the glycosyl phosphate was relatively stable, 
we decided to verity the formation of the intermediate in the actual reaction. When 
trichloroacetimidate donor 2 was mixed with CPA (R)-21 in deuterated toluene, we observed the 
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formation of a new species by NMR that was consistent with a covalent phosphate intermediate 
(Figure 2.8). The 6 Hz coupling constant of the anomeric carbon signal in 13C NMR was consistent 
with the two-bond carbon-phosphorus coupling reported for similar compounds. The one-bond 
coupling between anomeric carbon and its hydrogen (166 Hz) suggested the β-linkage 
configuration.18 When excess deuterated methanol was added to the solution containing the β-
glycosyl phosphate 39, α-glycoside 40 was formed as the major product. In summation, the 
experimental results supported the computed mechanism in which the glycosylation reaction 
proceeded through the formation of a phosphate intermediate and the double inversion 
substitutions.  
 
Figure 2.8. Formation of glycosyl phosphate from reaction of glycosyl donor 2 and CPA (R)-21. 
 
While the investigation so far explained the results we observed for glycosylation of 6-dEB 
(1) with the D-6-deoxyglucose donor 2, the low diastereoselectivity that we observed when the 
fucose derived donor 22 was used instead encouraged us to probe the mechanism further. In this 
case, the L-fucose derived tricholoacetimidate donor 26 was mixed with CPA (R)-21, and the 
reaction generated a glycosyl phosphate intermediate 41 with the α-configuration (Figure 2.9). The 
α-glycosyl phosphate 41 then underwent substitution with deuterated methanol to produce β-
glycosides 42. Since the α-trichloroacetimidate donor derived from 6-deoxyglucose and fucose led 
to formation of the glycosyl phosphate with opposite anomeric configuration, these results 
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suggested that the mechanism for the formation of anomeric phosphate from trichloroacetimidates 
may not always be SN2-like. 
 
Figure 2.9. Formation of glycosyl phosphate from reaction of donor 26 and CPA (R)-21. 
 
To probe the effect of the anomeric configuration of the trichloroacetimidate donor on the 
diastereoselectivity outcome, macrolactone 25 was subjected to CPA catalyzed glycosylation with 
α-trichloroacetimidate (α-22) and β-trichloroacetimidate (β-22) derived from D-fucose (Scheme 
2.6). The same regio- and diastereoselectivity was observed for both reactions, which suggested 
both reactions proceeded through the formation of the same intermediate. Altogether, the results 
indicated that the mechanism for the formation of anomeric phosphate was driven by the 
configuration of the sugar. Furthermore, the results also implied that the diastereoselectivity 
outcome of the glycosylation reaction was partly determined by the stereoselectivity of the 
phosphate intermediate formation step.  
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Scheme 2.6. Glycosylation of 25 with D-fucose derived α- or β-trichloroacetimidate donor under 
the same CPA catalyzed condition.  
 
2.9 Conclusion 
In summary, the work described in this chapter represents the first example of a chiral 
catalyst controlled regiodivergent glycosylation of polyol compounds. The method is especially 
useful for the synthesis of regioisomeric glycosides of 6-dEB and other macrolactone. More 
importantly, all the results we gathered supported our initial hypothesis that chiral Brønsted acid 
can be used to control the regioselectivity of the glycosylation reaction with trichloroacetimidate 
donors. While the change in macrolactone substrate required reevaluation of the catalysts, the 
catalysts identified for selective glycosylation for specific macrolactone exhibited a consistent 
trend in the regioselectivity profile that tolerates changes in the structure of the sugar donor. Finally, 
mechanistic studies and computational analysis helped us to elucidate the mechanism of the 
reaction, which involved formation of an anomeric phosphate intermediate. We believe that all the 
important insights generated in this study will greatly facilitate future development of similar 
methods. 
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2.10 Experimental Information 
General Methods 
All reagents and solvents were purchased from Sigma-Aldrich, Fisher Scientific, and were 
used as received without further purification unless specified. 4Å molecular sieve was activated 
prior to use by heating under reduced pressure. Heating was achieved by use of a silicone bath 
with heating controlled by electronic contact thermometer. Cooling was achieved by use of 
cryocool machine. Deionized water was used in the preparation of all aqueous solutions and for 
all aqueous extractions. Solvents used for extraction and chromatography were ACS or HPLC 
grade. Purification of reactions mixtures was performed by flash chromatography using SiliCycle 
SiliaFlash P60 (230-400 mesh).  
 1H NMR spectra were recorded on Varian vnmrs 700 (700 MHz), Varian vnmrs 500 (500 
MHz), Varian INOVA 500 (500 MHz) or Varian MR400 (400 MHz) spectrometers and chemical 
shifts (δ) are reported in parts per million (ppm) with solvent resonance as the internal standard 
(CDCl3 at δ 7.26, C6D6 at δ 7.16). Data are reported as (br = broad, s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet; coupling constant(s) in Hz; integration). Proton-decoupled 13C 
NMR spectra were recorded on Varian vnmrs 700 (700 MHz), Varian vnmrs 500 (500 MHz), 
Varian INOVA 500 (500 MHz) or Varian MR400 (400 MHz) spectrometers and chemical shifts 
(δ) are reported in ppm with solvent resonance as the internal standard (CDCl3 at δ 77.16, C6D6 at 
128.06). High resolution mass spectra (HRMS) were recorded on Micromass AutoSpec Ultima or 
VG (Micromass) 70-250-S Magnetic sector mass spectrometers in the University of Michigan 
mass spectrometry laboratory. Infrared (IR) spectra were recorded as thin film on a Perkin Elmer 
Spectrum BX FT-IR spectrometer. Absorption peaks were reported in wavenumbers (cm-1).  
Optical rotations were measured in a solvent of choice on a JASCO P-2000 or Autopol III digital 
polarimeter at 589 nm (D-line). 
 
Production of 6-deoxy-Erythronolide B (6-dEB) 
The E. coli strain TB3 (pBP130/pBP144)14b was generously provided as a gift from Dr. Blaine 
Pfeifer (SUNY Buffalo) and was used to access the macrolactone 6-deoxyerythronolide B (6-dEB) 
via fermentation. Individual colonies plated on LB-agar containing kanamycin (50 μg/mL) and 
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ampicillin (100 μg/mL) were selected for overnight growth at 37 °C in 10 mL of LB supplemented 
with the same antibiotics. 6 x 1 L of 6-dEB production medium (2.8 L baffled Fernbach flasks) 
were inoculated with the 10 mL overnight seed cultures and incubated at 37 °C (180 rpm). When 
OD600 = 0.6-1.0, the cultures were allowed to cool at room temperature (~30 min) before IPTG 
(0.1 mL of 1 M stock solution), sodium propionate (20 mL of 1 M stock solution at pH 7.6), and 
Antifoam B (3 mL of 50% (v/v) stock solution) were added to initiate 6-dEB production. The 
cultures were subsequently incubated at 22 °C (180 rpm) for 5-7 days prior to centrifugation at 
7550 x g for 15 min to remove cells. The resulting supernatant was extracted by incubating with 
Amberlite XAD16 resin (30 g of washed wet resin per 1 L of culture supernatant) overnight with 
shaking. The resin was collected, rinsed with water, and extracted with 3 x 100 mL of ethyl acetate 
(per 30 g of resin). The combined organic extracts were washed with brine and dried over 
anhydrous Na2SO4. Solvent was removed under reduced pressure to yield crude 6-dEB (1), which 
was purified by flash column chromatography on silica gel (EtOAc:Hexanes, 30:70 v/v; followed 
by MeOH:CH2Cl2, 2:98 v/v). 
 
1H NMR (700 MHz, CDCl3) δ 5.15 (dd, J = 9.6, 2.7 Hz, 1H), 4.05 – 3.96 (m, 1H), 3.92 (d, J = 
10.4 Hz, 1H), 3.87 (s, 1H), 3.68 (d, J = 10.0 Hz, 1H), 2.86 (s, 1H), 2.82 – 2.72 (m, 2H), 2.62 (ddd, 
J = 12.9, 6.4, 3.5 Hz, 1H), 2.03 (dd, J = 11.9, 6.8 Hz, 2H), 1.87 (q, J = 6.4 Hz, 1H), 1.82 (ddd, J = 
14.2, 9.6, 7.2 Hz, 1H), 1.77 – 1.71 (m, 1H), 1.67 (ddd, J = 14.3, 11.2, 3.5 Hz, 1H), 1.52 (dtd, J = 
14.7, 7.4, 4.0 Hz, 1H), 1.30 (d, J = 6.7 Hz, 3H), 1.26 (td, J = 13.6, 4.2 Hz, 1H), 1.07 (d, J = 7.0 
Hz, 3H), 1.06 (d, J = 4.1 Hz, 3H), 1.05 (d, J = 4.9 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H), 0.93 (t, J = 
7.4 Hz, 3H), 0.89 (d, J = 7.0 Hz, 3H).  
13C NMR (176 MHz, CDCl3) δ 213.7, 178.5, 79.7, 76.6, 76.4, 71.1, 44.1, 43.6, 40.7, 39.4, 37.8, 
37.6, 35.7, 25.5, 16.7, 14.9, 13.4, 10.8, 9.3, 7.0, 6.4. 
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6-dEB Production Medium Recipe: 
This medium is the same as the “Enhanced Medium” previously described.19 To 830 mL of Milli-
Q water in a 2.8 L baffled Fernbach flask is added the following: 40 g tryptone, 14 g glycerol, 10 
g NaCl, 1 g yeast extract. The pH of the medium is adjusted to 7.6 (NaOH) prior to autoclaving. 
After the medium has cooled, the following components are added: 100 mL of 1 M HEPES buffer 
(pH = 7.6, filter sterilized), 5.625 mL of trace metal solution, 1.875 mL of vitamin solution, 1.0 
mL of kanamycin (50 mg/mL stock), and 1.0 mL of ampicillin (100 mg/mL stock). Trace metal 
solution contains the following components dissolved in water at a final volume of 1 L: 27.0 g 
FeCl3•6H2O, 2.0 g Na2MoO4•2H2O, 1.9 g CuSO4•5H2O, 1.3 g ZnCl2, 1.0 g CaCl2, 0.5 g H3BO3, 
100 mL 12.1 M HCl. The solution is stored at room temperature and filter sterilized prior to 
addition to cultures. Vitamin solution contains the following components dissolved in water at a 
final volume of 1 L: 6.0 g nicotinic acid, 5.9 g pantothenic acid (hemicalcium salt), 1.7 g 
pyridoxine (HCl salt), 0.42 g riboflavin, 0.06 g biotin, 0.04 g folic acid. The pH of the solution is 
adjusted to 7.6 prior to filter sterilization and addition to cultures. 
 
Synthesis of Trichloroacetimidate donor 2, 22 and 26 
 
Sugar donor 2, 22 and 26 were synthesized based on previously reported procedures.20 
 
Synthesis of Desosamine-derived Trichloroacetimidate Donor 36 
 
Scheme 2.7. Synthesis of desosamine-derived trichloroacetimidate donor 36.  
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Erythromycin hydrate (7.0 gr) was dissolved in 50mL ethanol, and 130mL of 6N HCl was added 
to the solution. The mixture was heated to reflux for 3h. After cooled down to room temperature, 
the reaction mixture was washed with 50mL of chloroform for three times. The aqueous layer was 
concentrated under reduced pressure to obtain a deep orange oil containing desosamine. The crude 
mixture was dissolved in MeOH and passed slowly through Amberlite resin (hydroxide form), and 
then concentrated under pressure.  
The crude mixture containing desosamine was azeotroped with toluene for three times and 
dissolved in 10mL of dry pyridine under nitrogen.  DMAP (67mg) and BzCl (6.4mL) were added 
to the reaction. After stirring at room temperature for overnight, the reaction was concentrated 
under reduced pressure. The crude was purified by flash column chromatography on silica gel 
(EtOAc:MeCN, 70:30 v/v, followed by EtOAc:MeCN:MeOH, 70:20:10 v/v) to obtain 1.35 gr of 
36a. 
36a (mixture of α and β anomers) 1H NMR (500 MHz, CDCl3) δ 8.08 (dd, J = 8.1, 1.5 Hz, 2H), 
8.03 – 7.95 (m, 3H), 7.92 (dd, J = 8.1, 1.5 Hz, 2H), 7.62 (td, J = 7.3, 1.4 Hz, 1H), 7.54 – 7.46 (m, 
6H), 7.40 – 7.31 (m, 6H), 6.59 (d, J = 3.6 Hz, 1H), 5.96 (d, J = 7.9 Hz, 1H), 5.47 – 5.39 (m, 2H), 
4.23 (dqd, J = 12.4, 6.2, 2.1 Hz, 1H), 3.89 (dtd, J = 10.4, 6.8, 6.2, 4.8 Hz, 1H), 3.44 (ddd, J = 12.2, 
10.9, 4.0 Hz, 1H), 3.07 (ddd, J = 12.2, 10.5, 4.3 Hz, 1H), 2.37 (s, 6H), 2.35 (s, 6H), 1.98 (ddd, J = 
13.3, 4.1, 2.3 Hz, 1H), 1.91 (ddd, J = 13.4, 4.4, 2.0 Hz, 1H), 1.67 – 1.53 (m, 2H), 1.35 (d, J = 6.1 
Hz, 3H), 1.27 (d, J = 6.2 Hz, 3H). 
36a was dissolved in THF (0.1M) and subjected to deprotection with 7N NH3 in MeOH (excess) 
at 0oC, and the reaction was slowly warmed up to room temperature. After the reaction was done 
as judged by TLC, the mixture was concentrated under reduced pressure. The crude was purified 
by flash column chromatography on silica gel (CH2Cl2:MeOH, 97:3 v/v) to obtain 36b. 
36b (mixture of α and β anomers) 1H NMR (400 MHz, CDCl3) δ 8.08 (td, J = 7.1, 1.5 Hz, 4H), 
7.57 (td, J = 7.3, 1.5 Hz, 2H), 7.45 (t, J = 7.8 Hz, 4H), 5.44 (d, J = 3.7 Hz, 1H), 5.17 (dd, J = 11.0, 
3.7 Hz, 1H), 4.99 (dd, J = 10.4, 7.6 Hz, 1H), 4.69 (d, J = 7.6 Hz, 1H), 4.31 – 4.20 (m, 1H), 3.74 – 
3.64 (m, 1H), 3.37 (td, J = 11.6, 4.2 Hz, 1H), 3.00 (ddd, J = 12.4, 10.4, 4.4 Hz, 1H), 2.34 (s, 6H), 
2.33 (s, 6H), 1.91 – 1.80 (m, 2H), 1.48 (qd, J = 12.2, 8.4 Hz, 2H), 1.32 (d, J = 6.2 Hz, 3H), 1.23 
(d, J = 6.3 Hz, 3H). 
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36b (160mg, 0.57mmol) was dissolved in dry DCM (5.7mL, 0.1M) under nitrogen and cooled in 
ice-bath. Cl3CCN (0.86mL, 15 equiv.) was added to the reaction, followed by DBU (26μL, 0.3 
equiv.). The reaction was warmed up slowly to room temperature. After stirring for 2h, the reaction 
was concentrated under reduced pressure. The crude was purified by flash column chromatography 
on silica gel deactivated with 0.5% Et3N in hexanes (EtOAc:hexanes, 50:50 v/v) to obtain α-36 
and β-36 (186mg, 77% combined yield) 
α-36 1H NMR (500 MHz, C6D6) δ 8.32 (s, 1H), 8.27 – 8.22 (m, 2H), 7.07 – 6.97 (m, 4H), 5.52 
(dd, J = 11.0, 3.5 Hz, 1H), 4.15 (dqd, J = 12.2, 6.2, 2.2 Hz, 1H), 3.43 (ddd, J = 12.3, 10.9, 3.9 Hz, 
1H), 2.15 (s, 6H), 1.53 (ddd, J = 13.2, 4.0, 2.3 Hz, 1H), 1.28 – 1.15 (m, 1H), 1.05 (d, J = 6.2 Hz, 
3H). 
α-36 13C NMR (176 MHz, C6D6) δ 165.6, 161.0, 133.1, 130.7, 130.2, 128.5, 128.4, 95.9, 70.3, 
68.0, 58.7, 40.7, 32.6, 21.1. 
β-36 1H NMR (500 MHz, C6D6) δ 8.54 (s, 1H), 8.23 – 8.15 (m, 2H), 7.08 – 6.96 (m, 3H), 6.22 
(d, J = 7.9 Hz, 1H), 5.63 (dd, J = 10.6, 8.0 Hz, 1H), 3.39 (dqd, J = 12.3, 6.1, 2.1 Hz, 1H), 2.72 
(ddd, J = 12.2, 10.5, 4.3 Hz, 1H), 2.10 (s, 6H), 1.26 (ddd, J = 13.1, 4.3, 2.1 Hz, 1H), 1.18 – 1.09 
(m, 1H), 1.07 (d, J = 6.2 Hz, 3H). 
β-36 13C NMR (176 MHz, C6D6) δ 165.5, 162.0, 132.8, 131.1, 130.0, 128.5, 128.4, 98.4, 70.8, 
70.7, 63.8, 40.7, 30.7, 21.1. 
 
Synthesis of Chiral Phosphoric Acid 21 
 
(R)-21 was prepared based on previously reported methods.21 
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1H NMR (500 MHz, CDCl3): δ 7.24 (m, 4H), 6.85 (d, J = 6.4 Hz, 4H), 6.19 (t, J = 8.1 Hz, 2H), 
3.16 (ddd, J = 17.1, 11.4, 6.5 Hz, 2H), 2.98 (dd, J = 16.2, 7.8 Hz, 2H), 2.38 (dd, J = 12.1, 6.4 Hz, 
2H), 2.21 (q, J = 11.4 Hz, 2H). 
13C NMR (126 MHz, CDCl3): δ 162.9 (dd, J = 246.7, 13.3 Hz), 146.4 (d, J = 2.3 Hz), 141.9, 140.8 
(d, J = 3.1 Hz), 140.6, 133.3, 130.4 (d, J = 1.8 Hz), 123.1, 112.4 (dd, J = 19.8, 6.2 Hz), 102.3 (t, J 
= 25.5 Hz), 60.1, 38.8, 30.6. 
19F NMR (471 MHz, CDCl3): δ -111.03. 
31P NMR (202 MHz, CDCl3): δ -7.55. 
HRMS (m/z): [M-H]- calcd. for C29H19F4O4P, 537.0879; found, 537.0935 
IR (thin film, cm-1): 2953, 1622, 1593, 1455, 1415, 1115, 985 
[α]D: +166.9 (c = 1.01 in CHCl3) 
 
Synthesis of Macrolactone 25 
 
Scheme 2.8. Synthesis of macrolactone 25 from oleandomycin.  
25a was prepared from oleandomycin based on previously reported procedures.22 25a (300mg, 
0.57mmol) was stirred in CH2Cl2 (0.1 M) with PhSH (0.24mL, 4 equiv.) and Et3N (0.32mL, 4 
equiv.) at room temperature. After 48h, reaction mixture was concentrated under reduced pressure. 
Crude was purified by flash column chromatography on silica gel (EtOAc:Hexanes, 30:70 to 50:50 
v/v) to obtain 177 mg of 25 as yellow foamy solid (63% yield).  
1H NMR (700 MHz, CDCl3): δ 7.37 (d, J = 7.7 Hz, 2H), 7.33 – 7.25 (m, 2H), 7.19 (t, J = 7.3 Hz, 
1H), 5.63 (q, J = 6.4 Hz, 1H), 4.07 (s, 1H), 3.66 – 3.53 (m, 3H), 3.39 (d, J = 13.1 Hz, 1H), 3.32 (d, 
J = 12.6 Hz, 2H), 3.10 (q, J = 6.6 Hz, 1H), 2.61 (dt, J = 14.1, 6.8 Hz, 1H), 2.37 (s, 1H), 2.02 (s, 
40 
 
1H), 2.01 – 1.89 (m, 3H), 1.72 – 1.62 (m, 2H), 1.52 (s, 1H), 1.26 (d, J = 6.6 Hz, 3H), 1.22 (d, J = 
6.7 Hz, 3H), 1.12 (t, J = 6.6 Hz, 6H), 1.03 (d, J = 6.9 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H). 
13C NMR (176 MHz, CDCl3): δ 215.8, 176.0, 136.6, 129.9, 129.1, 126.6, 83.0, 79.4, 77.8, 70.0, 
69.9, 44.3, 44.1, 41.8, 40.9, 40.3, 37.9, 36.2, 19.9, 18.7, 14.5, 9.2, 8.9, 7.9. 
HRMS (m/z): [M+Na]+ calcd. for C26H40O7, 519.2392; found, 519.2379 
TLC (EtOAc:Hexanes, 40:60 v/v): Rf = 0.2 
IR (thin film, cm-1): 3449, 2975, 2931, 2863, 1710, 1456, 1381, 1114 
[α]D: -20.1 (c = 1.01 in CHCl3) 
 
General Procedures for Glycosylation Reactions 
Glycosylation of Macrolide Catalyzed by TMS-OTf or BF3•OEt2: 
Macrolide (0.020mmol, 1.0 equiv.), sugar donor (0.024mmol, 1.2 equiv.) and 20mg of powdered 
4Å molecular sieve were stirred in 400μL of dry toluene (0.05 M) at room temperature under N2 
for 10 min. Reaction mixture was then cooled to -20oC. After stirring for another 10 min., TMS-
OTf or BF3•OEt2 (0.004mmol, 0.2 equiv.) in 20μL of dry toluene was added to the reaction. After 
17 to 24h, reaction was quenched with Et3N, filtered through a short pad of Celite with CH2Cl2 
washing and concentrated under reduced pressure. The crude mixture was purified by flash column 
chromatography (pipette column) on silica gel (EtOAc:Hexanes, gradient) to obtain a mixture of 
glycosides. Each individual glycoside was isolated by separation on semi-prep HPLC 
(EtOAc:Hexanes) and characterized.  
Glycosylation of Macrolide Catalyzed by Chiral Brønsted Acids: 
Macrolide (0.020mmol, 1.0 equiv.), sugar donor (0.024mmol, 1.2 equiv.), chiral Brønsted acid 
(0.004mmol, 0.2 equiv.) and 10mg of powdered 4Å molecular sieve were stirred in dry toluene 
(0.1 to 0.3 M) at room temperature. After 24 – 72h, reaction was quenched with Et3N, filtered 
through a short pad of Celite with CH2Cl2 washing and concentrated under reduced pressure. The 
crude mixture was purified by flash column chromatography (pipette column) on silica gel 
(EtOAc:Hexanes, gradient) to obtain a mixture of glycosides. Each individual glycoside was 
isolated by separation on semi-prep HPLC (EtOAc:Hexanes) and characterized.  
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Procedure for Deprotection of Macrolide Glycoside 
 
In a one dram vial, 4 (3.4mg, 4.2μmol) and Pd/C (0.9mg, 0.84μmol) were added, and the vial was 
sealed with rubber septum. The vial was evacuated and backfilled with N2 three times, followed 
by H2 for another three times. 200μL of EtOH was added to the vial, and the suspension was stirred 
with H2 balloon on top for 48h at room temperature. At the end of the reaction, the suspension was 
filtered through a thin pad of Cealite with EtOAc washing. Combined organic layer was 
concentrated under reduced pressure, and the crude mixture was purified by flash column 
chromatography (pipette column) on silica gel (CH2Cl2:MeOH, 15:1 v/v) to obtain the 
debenzylated glycoside 4a (2.1mg, 94% yield) as colorless oil. 
1H NMR (500 MHz, CDCl3): δ 5.13 (dd, J = 9.5, 3.0 Hz, 1H), 5.02 (d, J = 3.1 Hz, 1H), 3.92 (s, 
2H), 3.87 (d, J = 10.2 Hz, 1H), 3.83 – 3.74 (m, 1H), 3.69 – 3.51 (m, 3H), 3.08 (q, J = 7.3 Hz, 2H), 
2.84 – 2.67 (m, 2H), 2.67 – 2.56 (m, 1H), 2.42 – 2.23 (m, 1H), 1.93 (d, J = 5.8 Hz, 1H), 1.85 – 
1.58 (m, 3H), 1.51 (ddd, J = 13.9, 7.2, 4.0 Hz, 1H), 1.32 (d, J = 5.4 Hz, 3H), 1.29 (d, J = 7.2 Hz, 
3H), 1.11 (d, J = 6.9 Hz, 3H), 1.02 (m, 9H), 0.93 (t, J = 7.3 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 213.3, 178.5, 93.8, 79.0, 76.4, 76.1, 74.1, 72.4, 71.1, 68.8, 46.0, 
44.9, 43.7, 40.6, 37.5, 32.1, 29.5, 25.6, 18.2, 16.3, 15.4, 13.0, 10.8, 9.3, 8.9, 8.0, 6.4. 
HRMS (m/z): [M+Na]+ calcd. for C27H48O10, 555.3145; found, 555.3141. 
TLC (CH2Cl2:MeOH, 10:1 v/v): Rf = 0.4 
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Characterization of Glycoside Products 
 
1H NMR (700 MHz, C6D6): δ 7.29 (d, J = 7.4 Hz, 2H), 7.26 (t, J = 7.2 Hz, 3H), 7.18 – 7.03 (m, 
10H), 5.68 (dd, J = 9.8, 3.9 Hz, 1H), 4.89 – 4.79 (m, 3H), 4.75 (d, J = 3.1 Hz, 1H), 4.59 (d, J = 
11.9 Hz, 1H), 4.55 (d, J = 11.9 Hz, 1H), 4.50 (d, J = 11.2 Hz, 1H), 4.13 (s, 1H), 4.10 (t, J = 9.4 Hz, 
1H), 4.02 (dq, J = 12.3, 6.2 Hz, 1H), 3.92 (d, J = 4.0 Hz, 1H), 3.78 (d, J = 10.1 Hz, 1H), 3.68 (m, 
2H), 3.48 (dd, J = 9.9, 3.2 Hz, 1H), 3.06 (t, J = 9.2 Hz, 1H), 2.83 (q, J = 6.7 Hz, 1H), 2.77 (dt, J = 
13.5, 6.8 Hz, 1H), 2.71 – 2.63 (m, 1H), 1.81 – 1.74 (m, 2H), 1.65 (dt, J = 16.3, 7.3 Hz, 1H), 1.61 
– 1.52 (m, 2H), 1.43 (d, J = 6.8 Hz, 3H), 1.43 – 1.35 (m, 1H), 1.34 (d, J = 6.9 Hz, 3H), 1.24 (d, J 
= 6.2 Hz, 3H), 1.19 (ddt, J = 14.7, 11.8, 7.3 Hz, 1H), 1.10 (d, J = 6.7 Hz, 3H), 1.08 (d, J = 6.9 Hz, 
3H), 0.95 (d, J = 6.7 Hz, 3H), 0.79 (t, J = 7.3 Hz, 3H), 0.74 (d, J = 7.1 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 217.8, 176.7, 139.3, 139.1, 137.5, 129.0, 128.9, 128.6, 128.6, 128.4, 
128.3, 128.0, 127.8, 127.7, 100.6, 91.7, 84.6, 82.1, 80.6, 77.2, 75.6, 75.4, 75.4, 74.4, 71.1, 68.1, 
45.4, 45.0, 42.4, 41.1, 39.8, 38.8, 35.0, 26.2, 18.1, 18.0, 16.0, 16.0, 10.7, 9.4, 9.2, 8.8. 
HRMS (m/z): [M+NH4]
+ calcd. for C48H66O10, 820.5000; found, 820.4987 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.5 
IR (thin film, cm-1): 3500, 2971, 2927, 2971, 1725, 1701, 1454, 1069 
[α]D: -10.0 (c = 0.24 in CHCl3) 
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1H NMR (700 MHz, C6D6): δ 7.31 (d, J = 7.4 Hz, 2H), 7.29 (d, J = 7.4 Hz, 2H), 7.25 (d, J = 7.3 
Hz, 2H), 7.17 (d, J = 7.3 Hz), 7.15 – 7.12 (m), 7.11 – 7.04 (m, 3H), 5.19 – 5.13 (m, 1H), 4.93 (d, 
J = 11.3 Hz, 1H), 4.89 (d, J = 3.7 Hz, 1H), 4.84 (d, J = 11.3 Hz, 1H), 4.78 (d, J = 11.2 Hz, 1H), 
4.56 (d, J = 11.7 Hz, 1H), 4.52 (d, J = 2.9 Hz, 1H), 4.51 (d, J = 3.4 Hz, 1H), 4.31 (d, J = 3.4 Hz, 
1H), 4.17 (d, J = 10.3 Hz, 1H), 4.10 (dq, J = 12.4, 6.2 Hz, 1H), 4.05 (t, J = 9.3 Hz, 1H), 3.93 (s, 
1H), 3.79 (d, J = 9.5 Hz, 1H), 3.65 (s, 1H), 3.50 (dd, J = 9.7, 3.7 Hz, 1H), 3.10 (t, J = 9.2 Hz, 1H), 
2.90 – 2.74 (m, 2H), 2.60 (d, J = 6.4 Hz, 1H), 2.24 (s, 1H), 2.03 (q, J = 6.3 Hz, 1H), 1.60 (td, J = 
12.8, 11.1, 4.3 Hz, 1H), 1.55 (dt, J = 14.1, 7.1 Hz, 1H), 1.50 – 1.47 (m, 1H), 1.46 (d, J = 6.8 Hz, 
3H), 1.26 (d, J = 7.1 Hz, 3H), 1.25 (d, J = 6.3 Hz, 3H), 1.21 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.3 
Hz, 3H), 1.13 (m, 1H), 1.03 (ddt, J = 13.9, 7.3, 3.9 Hz, 1H), 0.98 (d, J = 7.1 Hz, 3H), 0.66 (t, J = 
7.3 Hz, 3H), 0.61 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, C6D6): δ 212.4, 178.6, 139.5, 139.0, 138.6, 128.7, 128.6, 128.5, 128.4, 
128.2, 128.0, 127.9, 127.7, 95.9, 83.8, 82.4, 80.5, 79.2, 76.0, 75.6, 75.3, 73.6, 71.2, 69.1, 44.9, 
43.4, 40.9, 39.9, 38.6, 37.6, 25.6, 18.3, 17.2, 15.5, 13.9, 10.6, 9.1, 8.3, 7.1. 
HRMS (m/z): [M+NH4]
+ calcd. for C48H66O10, 820.5000; found, 820.4985 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.5 
IR (thin film, cm-1): 3468, 2971, 2925, 1704, 1453, 1070 
[α]D: +31.7 (c = 0.49 in CHCl3) 
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1H NMR (700 MHz, CDCl3): δ 7.38 – 7.33 (m, 2H), 7.33 – 7.29 (m, 5H), 7.28 (m, 8H), 5.11 (dd, 
J = 9.6, 2.9 Hz, 1H), 4.91 (d, J = 11.3 Hz, 1H), 4.89 – 4.80 (m, 5H), 4.63 (d, J = 10.9 Hz, 1H), 4.50 
(d, J = 7.8 Hz, 1H), 3.96 (d, J = 4.4 Hz, 1H), 3.89 (d, J = 10.3 Hz, 1H), 3.83 (dd, J = 4.8, 1.6 Hz, 
1H), 3.69 – 3.64 (m, 2H), 3.44 – 3.38 (m, 2H), 3.26 (s, 1H), 3.20 (t, J = 9.2 Hz, 1H), 2.78 – 2.69 
(m, 2H), 2.66 – 2.59 (m, 1H), 2.33 – 2.25 (m, 1H), 1.86 – 1.77 (m, 2H), 1.75 – 1.69 (m, 1H), 1.62 
– 1.56 (m, 1H), 1.52 – 1.47 (m, 1H), 1.28 (d, J = 6.8 Hz, 3H), 1.27 (d, J = 6.2 Hz, 3H), 1.22 – 1.15 
(m, 1H), 1.05 (d, J = 6.9 Hz, 3H), 1.03 (d, J = 6.5 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H), 1.00 (d, J = 
7.2 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 213.6, 179.2, 138.6, 138.1, 137.4, 129.7, 128.9, 128.6, 128.5, 
128.4, 128.2, 128.0, 128.0, 127.7, 103.5, 84.8, 83.9, 81.0, 78.2, 76.3, 75.5, 75.4, 75.3, 71.7, 71.1, 
44.7, 43.8, 40.7, 39.1, 38.2, 38.0, 35.5, 25.6, 18.0, 17.5, 15.5, 13.1, 10.8, 9.3, 8.3, 6.3. 
HRMS (m/z): [M+NH4]
+ calcd. for C48H66O10, 820.5000; found, 820.4992 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.55 
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1H NMR (700 MHz, C6D6): δ 7.35 (d, J = 7.2 Hz, 2H), 7.31 (t, J = 6.4 Hz, 8H), 7.25 (dt, J = 12.5, 
6.8 Hz, 6H), 7.14 – 7.03 (m, 20H), 5.81 (t, J = 7.5 Hz, 1H), 5.72 (d, J = 3.6 Hz, 1H), 5.02 (d, J = 
11.4 Hz, 1H), 4.99 (d, J = 3.8 Hz, 1H), 4.93 (d, J = 11.2 Hz, 1H), 4.89 – 4.84 (m, 2H), 4.83 (d, J = 
11.4 Hz, 1H), 4.77 (dd, J = 11.4, 1.9 Hz, 3H), 4.72 (d, J = 10.6 Hz, 1H), 4.57 (s, 2H), 4.51 (dd, J 
= 11.1, 9.2 Hz, 2H), 4.36 (d, J = 10.5 Hz, 1H), 4.31 (d, J = 9.4 Hz, 1H), 4.18 (dd, J = 4.9, 2.8 Hz, 
1H), 4.17 – 4.14 (m, 1H), 4.08 (m, 3H), 3.82 (s, 1H), 3.56 (dd, J = 9.6, 3.8 Hz, 1H), 3.46 (dd, J = 
10.1, 3.6 Hz, 1H), 3.25 (ddt, J = 13.1, 6.2, 3.4 Hz, 1H), 3.09 (m, 2H), 2.85 (dq, J = 10.2, 6.7 Hz, 
1H), 2.68 (q, J = 6.3 Hz, 1H), 2.51 – 2.43 (m, 1H), 2.01 (qd, J = 6.6, 6.1, 1.6 Hz, 1H), 1.88 – 1.80 
(m, 1H), 1.59 (d, J = 6.7 Hz, 3H), 1.57 (m, 1H), 1.55 (d, J = 6.0 Hz, 3H), 1.46 (d, J = 6.2 Hz, 3H), 
1.27 (d, J = 6.7 Hz, 3H), 1.26 – 1.23 (m, 1H), 1.22 (d, J = 7.0 Hz, 3H), 1.19 (d, J = 6.2 Hz, 3H), 
1.18 – 1.15 (m, 1H), 1.15 – 1.08 (m, 1H), 0.95 (d, J = 7.1 Hz, 3H), 0.64 (d, J = 7.2 Hz, 3H), 0.47 
(t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, C6D6): δ 211.0, 177.0, 139.9, 139.5, 139.4, 139.2, 139.1, 138.6, 128.7, 
128.7, 128.5, 128.5, 128.5, 128.4, 128.3, 128.0, 127.8, 127.7, 127.7, 127.6, 127.6, 127.5, 100.8, 
93.7, 85.0, 83.7, 83.6, 82.5, 82.1, 81.8, 80.3, 80.2, 78.8, 75.6, 75.6, 75.4, 75.1, 74.9, 73.4, 69.1, 
69.1, 44.9, 44.6, 41.4, 38.9, 38.1, 28.5, 26.0, 24.6, 18.3, 18.2, 17.0, 15.9, 15.6, 13.7, 13.6, 11.9, 
10.1, 10.0, 9.8, 8.9, 8.8, 7.8, 7.4, 6.9. 
HRMS (m/z): [M+NH4]
+ calcd. for C75H94O14, 1236.6987; found, 1239.6962 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.6 
IR (thin film, cm-1): 2921, 2854, 1713, 1454, 1070 
[α]D: +40.5 (c = 0.07 in CHCl3) 
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1H NMR (500 MHz, C6D6): δ 7.39 (d, J = 7.3 Hz, 3H), 7.34 – 7.18 (m, 8H), 7.14 – 6.96 (m, 4H), 
5.65 (dd, J = 9.9, 3.8 Hz, 1H), 4.96 (d, J = 11.3 Hz, 1H), 4.85 (d, J = 3.5 Hz, 1H), 4.64 (dd, J = 
11.8, 4.3 Hz, 2H), 4.57 (d, J = 11.9 Hz, 1H), 4.49 (t, J = 11.6 Hz, 2H), 4.20 (dd, J = 10.4, 3.4 Hz, 
1H), 4.14 (d, J = 2.4 Hz, 1H), 4.03 – 3.91 (m, 2H), 3.86 – 3.79 (m, 2H), 3.70 (d, J = 9.8 Hz, 1H), 
3.66 (s, 1H), 3.34 (s, 1H), 2.91 – 2.75 (m, 2H), 2.70 – 2.60 (m, 1H), 1.83 – 1.72 (m, 1H), 1.68 – 
1.62 (m, 1H), 1.62 – 1.57 (m, 1H), 1.55 (td, J = 7.3, 2.5 Hz, 1H), 1.47 (d, J = 6.8 Hz, 3H), 1.34 (d, 
J = 6.9 Hz, 3H), 1.25 – 1.18 (m, 1H), 1.15 (d, J = 6.5 Hz, 3H), 1.10 (d, J = 6.8 Hz, 3H), 1.07 (d, J 
= 6.7 Hz, 3H), 0.97 (d, J = 6.7 Hz, 3H), 0.94 – 0.89 (m, 1H), 0.79 (t, J = 7.4 Hz, 3H), 0.74 (d, J = 
7.1 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 217.3, 176.8, 139.4, 139.1, 137.7, 130.3, 130.2, 129.1, 128.7, 
128.5, 128.4, 128.4, 128.3, 128.1, 128.0, 101.3, 90.6, 79.1, 78.6, 77.3, 76.7, 75.5, 75.3, 74.8, 73.0, 
71.0, 67.7, 45.2, 45.0, 42.3, 41.1, 40.1, 38.6, 35.2, 26.2, 18.0, 16.8, 16.0, 15.9, 14.4, 10.7, 9.4, 9.2, 
8.6. 
HRMS (m/z): [M+Na]+ calcd. for C48H66O10, 825.4554; found, 825.4535 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.5  
IR (thin film, cm-1): 3494, 2961, 2919, 2873, 2849, 1725, 1705, 1453 
[α]D: +8.8 (c = 0.07 in CHCl3)
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1H NMR (700 MHz, CDCl3): δ 7.38 – 7.27 (m, 21H), 5.13 (d, J = 3.8 Hz, 2H), 4.97 (d, J = 11.5 
Hz, 1H), 4.82 (d, J = 11.7 Hz, 1H), 4.77 – 4.68 (m, 3H), 4.65 (d, J = 11.5 Hz, 1H), 4.10 (dd, J = 
9.9, 3.7 Hz, 1H), 3.89 (m, 2H), 3.85 – 3.84 (m, 1H), 3.83 – 3.81 (m, 1H), 3.79 (d, J = 10.4 Hz, 
1H), 3.69 (s, 1H), 3.65 (d, J = 9.7 Hz, 1H), 3.41 (s, 1H), 2.82 – 2.69 (m, 2H), 2.64 – 2.53 (m, 1H), 
2.32 (m, 1H), 1.90 (q, J = 6.3 Hz, 1H), 1.82 (tt, J = 14.8, 7.3 Hz, 1H), 1.73 (dt, J = 15.7, 6.9 Hz, 
1H), 1.67 – 1.61 (m, 1H), 1.52 (ddt, J = 14.6, 11.8, 7.5 Hz, 1H), 1.31 (d, J = 6.7 Hz, 3H), 1.24 (m, 
1H), 1.18 (d, J = 6.4 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H), 1.00 – 0.97 (m, 
6H), 0.93 (t, J = 7.3 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H). 
13C NMR (176 MHz, CDCl3): δ 213.5, 178.7, 138.7, 138.6, 128.5, 128.5, 128.4, 128.4, 127.8, 
127.8, 127.8, 127.7, 127.7, 94.2, 79.5, 79.0, 76.3, 75.9, 74.8, 73.5, 73.5, 71.1, 68.2, 44.4, 43.6, 
40.7, 39.2, 37.8, 37.5, 29.9, 25.6, 22.8, 16.9, 16.7, 15.2, 14.3, 13.0, 10.8, 9.3, 8.0, 6.4. 
HRMS (m/z): [M+Na]+ calcd. for C48H66O10, 825.4554; found, 825.4534 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.5 
IR (thin film, cm-1): 3508, 2924, 2851, 1704, 1454, 1095, 1044 
[α]D: +19.0 (c = 0.05 in CHCl3)
48 
 
 
1H NMR (500 MHz, C6D6): δ 7.48 (d, J = 7.3 Hz, 2H), 7.31 (d, J = 7.0 Hz, 3H), 7.27 (d, J = 7.2 
Hz, 2H), 7.23 – 7.17 (m, 5H), 7.15 – 6.97 (m, 7H), 5.09 (dd, J = 9.6, 3.1 Hz, 1H), 4.94 (d, J = 11.3 
Hz, 1H), 4.85 (d, J = 12.0 Hz, 2H), 4.48 (d, J = 11.5 Hz, 1H), 4.42 (s, 2H), 4.39 (d, J = 4.4 Hz, 
1H), 4.32 (d, J = 7.7 Hz, 1H), 4.27 (d, J = 4.6 Hz, 2H), 4.01 (dd, J = 9.7, 7.8 Hz, 1H), 3.95 (d, J = 
3.7 Hz, 1H), 3.91 – 3.80 (m, 2H), 3.25 (dd, J = 9.8, 2.8 Hz, 1H), 3.13 (d, J = 2.4 Hz, 1H), 3.03 – 
2.90 (m, 1H), 2.91 – 2.78 (m, 2H), 2.68 – 2.53 (m, 2H), 2.00 (q, J = 6.8 Hz, 1H), 1.63 – 1.52 (m, 
2H), 1.49 (d, J = 6.7 Hz, 3H), 1.47 – 1.42 (m, 1H), 1.37 (d, J = 6.3 Hz, 3H), 1.31 (d, J = 6.7 Hz, 
3H), 1.21 (d, J = 6.9 Hz, 3H), 1.13 (dd, J = 13.7, 3.7 Hz, 1H), 1.10 (d, J = 6.4 Hz, 3H), 1.06 (d, J 
= 7.2 Hz, 3H), 0.99 (ddt, J = 15.0, 7.6, 3.1 Hz, 1H), 0.66 (t, J = 7.3 Hz, 3H), 0.59 (d, J = 6.9 Hz, 
3H). 
13C NMR (176 MHz, C6D6): δ 211.8, 179.4, 139.2, 138.8, 138.3, 129.1, 128.8, 128.5, 128.4, 
128.4, 128.3, 128.1, 128.00, 127.9, 127.8, 104.9, 85.8, 83.8, 78.5, 78.5, 77.0, 76.3, 75.7, 75.2, 72.8, 
71.3, 70.9, 45.2, 44.1, 41.0, 39.2, 38.5, 38.5, 35.8, 25.5, 17.8, 17.0, 15.7, 13.6, 10.7, 9.1, 8.6, 6.7. 
HRMS (m/z): [M+NH4]
+ calcd. for C48H66O10, 820.5000; found, 820.4984 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.5 
IR (thin film, cm-1): 3464, 2971, 2927, 2877, 1701, 1598, 1454, 1064 
[α]D: -13.1 (c = 0.31 in CHCl3) 
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1H NMR (500 MHz, C6D6): δ 7.42 – 7.24 (m, 5H), 7.19 - 7.04 (m, 6H), 6.95 (m, 4H), 5.99 (q, J 
= 6.6 Hz, 1H), 4.89 – 4.75 (m, 3H), 4.68 (d, J = 3.3 Hz, 1H), 4.62 (d, J = 12.1 Hz, 1H), 4.55 (d, J 
= 12.1 Hz, 1H), 4.48 (d, J = 11.2 Hz, 1H), 4.20 (s, 1H), 4.06 (t, J = 9.4 Hz, 1H), 3.98 (dq, J = 10.3, 
6.3 Hz, 1H), 3.80 (d, J = 4.3 Hz, 1H), 3.67 (d, J = 9.7 Hz, 1H), 3.63 (d, J = 10.1 Hz, 1H), 3.52 – 
3.44 (m, 3H), 3.27 (d, J = 13.5 Hz, 1H), 3.12 (d, J = 13.5 Hz, 1H), 3.06 – 2.97 (m, 2H), 2.67 (dq, 
J = 9.8, 6.5 Hz, 1H), 2.15 (dd, J = 14.5, 10.6 Hz, 1H), 2.06 (d, J = 13.8 Hz, 1H), 1.48 (m, 1H), 1.40 
(d, J = 6.7 Hz, 3H), 1.38 – 1.28 (m, 7H), 1.21 (dd, J = 6.4, 4.3 Hz, 6H), 1.00 (d, J = 6.7 Hz, 3H), 
0.67 (d, J = 7.1 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 217.4, 175.5, 139.2, 139.0, 137.7, 137.4, 129.9, 129.2, 129.2, 
129.1, 128.9, 128.8, 128.6, 128.4, 128.4, 127.7, 127.7, 126.3, 100.9, 92.3, 84.6, 84.4, 82.0, 80.5, 
80.0, 75.6, 75.4, 74.2, 70.4, 69.4, 67.9, 44.7, 44.5, 43.1, 42.3, 40.1, 39.2, 36.9, 21.0, 18.8, 18.0, 
15.4, 9.9, 9.7, 8.7. 
HRMS (m/z): [M+Na]+ calcd. for C53H68O11S, 935.4380; found, 935.4362 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.4 
IR (thin film, cm-1): 3439, 2926, 1720, 1454, 1328, 1069 
[α]D: +9.1 (c = 0.07 in CHCl3) 
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1H NMR (500 MHz, C6D6): δ 7.39 – 7.28 (m, 7H), 7.23 (d, J = 7.1 Hz, 2H), 7.09 (q, J = 7.1 Hz, 
3H), 7.01 (t, J = 7.6 Hz, 2H), 6.92 (t, J = 7.4 Hz, 1H), 5.96 (q, J = 6.7 Hz, 1H), 4.92 (t, J = 11.4 
Hz, 2H), 4.82 – 4.58 (m, 3H), 4.40 (d, J = 11.3 Hz, 1H), 4.30 (d, J = 7.9 Hz, 1H), 4.16 (s, 1H), 3.72 
(d, J = 9.5 Hz, 1H), 3.67 (m, 1H), 3.64 (d, J = 10.1 Hz, 1H), 3.48 (t, J = 9.1 Hz, 1H), 3.36 – 3.24 
(m, 3H), 3.17 (d, J = 13.5 Hz, 1H), 3.10 – 2.97 (m, 2H), 2.86 (t, J = 9.2 Hz, 1H), 2.84 – 2.74 (m, 
2H), 2.25 – 2.03 (m, 2H), 1.77 (t, J = 6.9 Hz, 1H), 1.53 – 1.42 (m, 5H), 1.39 (d, J = 6.7 Hz, 3H), 
1.35 (d, J = 6.9 Hz, 3H), 1.20 (d, J = 6.8 Hz, 3H), 1.12 (d, J = 6.1 Hz, 3H), 1.03 (d, J = 6.6 Hz, 
3H), 0.69 (d, J = 7.1 Hz, 3H).  
13C NMR (176 MHz, C6D6): δ 217.4, 174.7, 139.5, 139.0, 138.9, 137.6, 129.8, 129.2, 128.6, 
128.6, 128.6, 128.4, 128.3, 127.9, 127.7, 127.7, 126.4, 104.5, 88.3, 84.7, 84.5, 83.4, 82.6, 80.7, 
75.5, 75.2, 75.1, 71.6, 70.5, 69.7, 45.4, 44.3, 42.1, 41.6, 40.4, 38.3, 37.6, 20.8, 18.8, 17.7, 14.4, 
9.6, 9.6, 8.8. 
HRMS (m/z): [M+Na]+ calcd. for C53H68O11S, 935.4380; found, 935.4368 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.45 
IR (thin film, cm-1): 3485, 2973, 2925, 2855, 1725, 1454, 1380, 1117, 1067 
[α]D: +2.5 (c = 0.29 in CHCl3) 
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1H NMR (700 MHz, C6D6): δ 7.40 – 7.36 (m, 2H), 7.35 – 7.31 (m, 2H), 7.29 – 7.24 (m, 4H), 7.23 
– 7.17 (m, 4H), 7.14 – 7.03 (m, 5H), 6.99 (dd, J = 8.4, 7.1 Hz, 2H), 6.96 – 6.87 (m, 1H), 5.86 (q, 
J = 6.4 Hz, 1H), 4.98 (d, J = 11.4 Hz, 1H), 4.95 (d, J = 3.7 Hz, 1H), 4.89 (d, J = 11.2 Hz, 1H), 4.82 
(d, J = 11.3 Hz, 1H), 4.60 (d, J = 11.3 Hz, 1H), 4.57 – 4.49 (m, 2H), 4.21 (dq, J = 9.5, 6.1 Hz, 1H), 
4.12 (dd, J = 9.9, 8.9 Hz, 1H), 4.09 (s, 1H), 3.79 (dd, J = 9.9, 3.6 Hz, 1H), 3.68 (d, J = 9.3 Hz, 1H), 
3.51 (s, 1H), 3.46 (dd, J = 9.9, 3.7 Hz, 1H), 3.40 (d, J = 2.6 Hz, 1H), 3.28 (d, J = 13.3 Hz, 1H), 
3.12 (t, J = 9.3 Hz, 1H), 3.08 (d, J = 13.3 Hz, 1H), 2.98 (q, J = 7.0 Hz, 1H), 2.71 (d, J = 3.8 Hz, 
1H), 2.65 (dq, J = 9.8, 6.7 Hz, 1H), 2.14 (m, 1H), 2.00 (dd, J = 14.8, 2.8 Hz, 1H), 1.84 (dd, J = 8.3, 
6.0 Hz, 1H), 1.62 – 1.55 (m, 1H), 1.46 – 1.40 (m, 3H), 1.39 (d, J = 6.7 Hz, 3H), 1.36 (d, J = 6.2 
Hz, 3H), 1.30 (d, J = 6.8 Hz, 3H), 1.20 (d, J = 7.1 Hz, 3H), 1.17 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 
6.6 Hz, 3H), 0.63 (d, J = 7.1 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 216.0, 175.5, 139.6, 139.0, 138.6, 137.6, 130.0, 129.2, 128.8, 
128.6, 128.5, 128.4, 128.4, 128.3, 127.7, 127.7, 127.7, 127.6, 126.4, 99.9, 90.1, 84.1, 83.7, 82.0, 
81.1, 78.3, 75.5, 75.4, 74.3, 70.4, 69.6, 68.9, 44.8, 44.0, 42.1, 41.8, 40.7, 37.5, 21.2, 18.7, 18.3, 
14.5, 9.3, 8.8, 8.8. 
HRMS (m/z): [M+NH4]
+ calcd. for C53H68O11S, 930.4826; found, 930.4796 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.2 
IR (thin film, cm-1): 3406, 2918, 2853, 1718, 1597, 1454, 1369, 1069 
[α]D: +15.0 (c = 0.24 in CHCl3)
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1H NMR (700 MHz, C6D6): δ 7.45 (d, J = 7.5 Hz, 2H), 7.38 (d, J = 7.5 Hz, 2H), 7.31 – 7.23 (m, 
3H), 7.19 – 7.12 (m, 4H), 7.09 (d, J = 6.5 Hz, 5H), 7.05 (s, 1H), 6.99 (t, J = 7.4 Hz, 2H), 6.90 (t, J 
= 7.2 Hz, 1H), 5.80 (q, J = 6.5 Hz, 1H), 5.08 (d, J = 11.7 Hz, 1H), 4.91 (d, J = 11.2 Hz, 1H), 4.86 
(d, J = 11.5 Hz, 1H), 4.81 (d, J = 11.7 Hz, 2H), 4.68 (d, J = 7.6 Hz, 1H), 4.49 (d, J = 11.4 Hz, 1H), 
4.02 (s, 1H), 3.89 (s, 1H), 3.79 (d, J = 9.6 Hz, 1H), 3.66 (t, J = 9.0 Hz, 1H), 3.59 – 3.52 (m, 3H), 
3.40 (d, J = 13.3 Hz, 1H), 3.37 – 3.32 (m, 1H), 3.26 (d, J = 13.2 Hz, 1H), 3.21 – 3.13 (m, 2H), 2.99 
– 2.94 (m, 1H), 2.55 (p, J = 6.4 Hz, 1H), 2.16 – 2.03 (m, 2H), 1.94 – 1.89 (m, 1H), 1.73 – 1.68 (m, 
1H), 1.50 – 1.45 (m, 1H), 1.44 (d, J = 6.6 Hz, 3H), 1.27 (d, J = 6.0 Hz, 3H), 1.19 (t, J = 7.8 Hz, 
6H), 0.95 (d, J = 6.3 Hz, 3H), 0.61 (d, J = 7.0 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 214.7, 175.7, 139.5, 139.2, 139.1, 137.8, 130.2, 130.2, 129.2, 
128.6, 128.5, 128.5, 128.4, 128.2, 128.1, 128.1, 128.0, 127.9, 127.8, 127.6, 126.5, 102.3, 86.2, 
85.5, 84.2, 83.5, 82.8, 77.3, 75.5, 75.1, 71.4, 70.3, 69.5, 44.4, 44.0, 42.1, 41.2, 37.8, 32.4, 29.6, 
20.6, 18.6, 18.3, 14.8, 14.4, 9.1, 8.8, 8.7. 
HRMS (m/z): [M+NH4]
+ calcd. for C53H68O11S, 930.4826; found, 930.4757 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.3 
IR (thin film, cm-1): 3382, 3240, 2957, 2912, 2851, 1694, 1617, 1453, 1069 
[α]D: -2.5 (c = 0.25 in CHCl3) 
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1H NMR (700 MHz, C6D6): δ 7.52 (dd, J = 8.3, 1.0 Hz, 3H), 7.40 – 7.28 (m, 6H), 7.13 (t, J = 7.5 
Hz, 3H), 7.11 – 7.03 (m, 7H), 6.95 (t, J = 7.4 Hz, 1H), 5.27 (d, J = 3.4 Hz, 1H), 5.26 – 5.22 (m, 
1H), 5.04 (d, J = 11.3 Hz, 1H), 4.93 (dd, J = 20.5, 11.3 Hz, 2H), 4.68 (d, J = 11.6 Hz, 1H), 4.64 (d, 
J = 11.4 Hz, 2H), 4.54 (dq, J = 12.0, 5.9 Hz, 1H), 4.40 (d, J = 9.2 Hz, 1H), 4.35 – 4.27 (m, 1H), 
3.90 (m, 2H), 3.60 (dd, J = 10.0, 3.4 Hz, 1H), 3.49 – 3.36 (m, 2H), 3.27 – 3.14 (m, 2H), 2.59 (q, J 
= 7.5, 6.9 Hz, 1H), 2.54 – 2.46 (m, 1H), 2.01 (s, 1H), 1.96 (dd, J = 13.7, 3.7 Hz, 1H), 1.83 – 1.68 
(m, 2H), 1.50 (d, J = 6.1 Hz, 3H), 1.43 (d, J = 7.2 Hz, 3H), 1.25 (d, J = 7.1 Hz, 3H), 1.17 (d, J = 
6.8 Hz, 3H), 1.05 (d, J = 7.2 Hz, 3H), 0.48 (d, J = 7.0 Hz, 3H), 0.39 (d, J = 6.6 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 175.1, 139.8, 139.4, 138.9, 138.6, 129.9, 129.3, 128.6, 128.5, 
128.5, 128.4, 128.3, 128.0, 127.8, 127.7, 127.6, 127.5, 126.3, 107.4, 98.2, 84.9, 82.3, 81.8, 76.6, 
75.6, 75.3, 74.3, 73.0, 72.9, 68.4, 44.1, 43.1, 42.2, 39.6, 37.9, 34.9, 32.4, 27.7, 23.2, 18.8, 16.0, 
14.5, 14.4, 13.6, 9.9, 9.4, 7.6. 
HRMS (m/z): [M+Na-H2O]
+ calcd. for C53H68O11S, 912.4720; found, 912.4690 
TLC (EtOAc:Hexanes, 20:80 v/v): Rf = 0.3 
IR (thin film, cm-1): 3463, 2923, 2851, 1734, 1454, 1377, 1071 
[α]D: +4.0 (c = 0.12 in CHCl3) 
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1H NMR (700 MHz, C6D6): δ 7.54 (d, J = 7.3 Hz, 2H), 7.43 (d, J = 7.4 Hz, 2H), 7.30 (d, J = 7.4 
Hz, 2H), 7.24 (d, J = 7.3 Hz, 2H), 7.20 – 7.13 (m, 4H), 7.12 – 7.02 (m, 7H), 6.96 (t, J = 7.4 Hz, 
1H), 5.31 (d, J = 7.9 Hz, 1H), 5.17 (m, 2H), 4.95 (d, J = 11.4 Hz, 1H), 4.82 (dd, J = 27.1, 11.5 Hz, 
2H), 4.71 (d, J = 11.4 Hz, 1H), 4.57 (dd, J = 10.7, 1.8 Hz, 1H), 4.48 (d, J = 11.6 Hz, 1H), 3.98 – 
3.83 (m, 2H), 3.70 (t, J = 9.0 Hz, 1H), 3.65 – 3.54 (m, 2H), 3.51 – 3.38 (m, 2H), 3.26 – 3.13 (m, 
2H), 2.80 – 2.71 (m, 1H), 2.51 – 2.40 (m, 1H), 2.05 – 1.94 (m, 2H), 1.85 – 1.75 (m, 1H), 1.77 – 
1.69 (m, 1H), 1.54 – 1.45 (m, 1H), 1.43 (d, J = 7.3 Hz, 3H), 1.31 (d, J = 6.2 Hz, 3H), 1.22 (d, J = 
6.8 Hz, 3H), 1.16 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 7.2 Hz, 3H), 0.46 (d, J = 2.7 Hz, 3H), 0.45 (d, J 
= 3.1 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 177., 139.9, 139.5, 139.4, 138.7, 129.9, 129.3, 128.5, 128.5, 128.5, 
128.4, 128.3, 128.1, 128.0, 127.7, 127.6, 127.6, 127.5, 126.3, 107.2, 101.1, 85.3, 84.1, 83.6, 80.8, 
75.7, 74.9, 74.8, 73.9, 73.4, 73.4, 73.0, 71.6, 43.3, 43.0, 40.0, 39.5, 37.6, 34.9, 27.7, 18.2, 16.2, 
14.4, 13.3, 10.8, 10.0, 7.6. 
HRMS (m/z): [M+Na-H2O]
+ calcd. for C53H68O11S, 912.4720; found, 912.4703 
TLC (EtOAc:Hexanes, 20:80 v/v): Rf = 0.4 
IR (thin film, cm-1): 2919, 2851, 1720, 1379, 1068 
[α]D: -+15.4  (c = 0.07 in CHCl3) 
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1H NMR (500 MHz, C6D6): δ 7.36 (t, J = 7.7 Hz, 5H), 7.34 – 7.27 (m, 4H), 7.26 – 7.17 (m, 4H), 
7.14 – 7.05 (m, 3H), 7.03 – 6.86 (m, 4H), 6.01 (q, J = 6.5 Hz, 1H), 4.93 (d, J = 11.3 Hz, 1H), 4.76 
(d, J = 3.4 Hz, 1H), 4.67 – 4.51 (m, 5H), 4.48 (d, J = 11.3 Hz, 1H), 4.24 – 4.16 (m, 4H), 3.91 (dd, 
J = 10.4, 2.8 Hz, 1H), 3.84 (d, J = 4.4 Hz, 1H), 3.78 (q, J = 6.6 Hz, 1H), 3.68 (d, J = 9.7 Hz, 1H), 
3.64 (d, J = 10.1 Hz, 1H), 3.44 (t, J = 2.9 Hz, 2H), 3.33 (d, J = 2.4 Hz, 1H), 3.27 (d, J = 13.5 Hz, 
1H), 3.13 (d, J = 13.5 Hz, 1H), 3.03 (q, J = 6.8 Hz, 1H), 2.73 (dq, J = 10.3, 6.9 Hz, 1H), 2.14 (dd, 
J = 14.8, 10.6 Hz, 1H), 2.05 (d, J = 14.6 Hz, 1H), 1.75 (q, J = 7.8 Hz, 1H), 1.53 – 1.43 (m, 1H), 
1.43 (d, J = 6.8 Hz, 3H), 1.36 (d, J = 7.0 Hz, 5H), 1.30 (d, J = 5.7 Hz, 3H), 1.21 (d, J = 6.7 Hz, 
3H), 1.14 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.7 Hz, 3H), 0.68 (d, J = 7.1 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 217.4, 175.4, 139.4, 139.1, 137.7, 137.7, 129.8, 129.2, 129.2, 
128.8, 128.7, 128.5, 128.5, 128.4, 128.4, 128.3, 127.9, 127.8, 127.8, 127.7, 126.3, 101.8, 91.3, 
84.4, 80.2, 79.1, 78.5, 76.6, 75.2, 74.6, 72.8, 70.4, 69.3, 67.5, 44.8, 44.5, 43.1, 42.3, 40.1, 39.1, 
37.0, 21.0, 18.9, 16.8, 15.4, 9.9, 9.7, 8.8. 
HRMS (m/z): [M+Na]+ calcd. for C53H68O11S, 935.4380; found, 935.4353 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.4 
IR (thin film, cm-1): 3399, 2920, 2851, 1723, 1453, 1380, 1099 
[α]D: +12.8 (c = 0.09 in CHCl3) 
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1H NMR (700 MHz, C6D6): δ 7.36 (d, J = 7.5 Hz, 2H), 7.34 – 7.24 (m, 6H), 7.21 – 7.17 (m, 4H), 
7.12 (dt, J = 15.3, 7.4 Hz, 4H), 7.08 – 6.89 (m, 4H), 5.96 (q, J = 6.5 Hz, 1H), 4.89 (d, J = 11.4 Hz, 
1H), 4.86 (d, J = 11.7 Hz, 1H), 4.73 (d, J = 11.3 Hz, 1H), 4.61 (d, J = 12.0 Hz, 1H), 4.52 (d, J = 
12.4 Hz, 2H), 4.30 (d, J = 7.7 Hz, 1H), 4.16 (s, 1H), 3.98 – 3.89 (m, 1H), 3.75 (s, 1H), 3.72 (d, J = 
9.9 Hz, 2H), 3.32 (s, 1H), 3.27 (d, J = 13.6 Hz, 1H), 3.23 (dd, J = 9.8, 2.6 Hz, 1H), 3.13 (d, J = 
13.5 Hz, 1H), 3.10 (d, J = 2.1 Hz, 1H), 3.03 (m, 2H), 2.84 (q, J = 6.3 Hz, 1H), 2.78 (dt, J = 13.5, 
6.8 Hz, 1H), 2.17 – 2.10 (m, 1H), 2.07 (d, J = 14.8 Hz, 1H), 1.76 (q, J = 6.7 Hz, 1H), 1.48 (s, 3H), 
1.46 (m, 2H), 1.43 (d, J = 6.7 Hz, 3H), 1.32 (d, J = 6.8 Hz, 3H), 1.20 (d, J = 6.8 Hz, 3H), 1.06 (d, 
J = 6.3 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 0.66 (d, J = 7.1 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 217.6, 175.0, 139.3, 139.2, 139.1, 137.7, 129.8, 129.2, 128.7, 
128.5, 128.5, 128.3, 127.8, 127.8, 127.7, 126.3, 104.7, 87.8, 84.5, 82.7, 80.6, 80.2, 76.7, 75.5, 75.0, 
73.2, 70.8, 70.5, 69.6, 45.4, 44.3, 42.1, 41.9, 40.3, 38.4, 37.6, 20.9, 18.8, 16.6, 14.5, 9.7, 9.6, 8.8. 
HRMS (m/z): [M+NH4]
+ calcd. for C53H68O11S, 930.4826; found, 930.4801 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.25 
IR (thin film, cm-1): 3447, 2919, 2855, 1720, 1454, 1378, 1064 
[α]D: -2.3 (c = 0.69 in CHCl3) 
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1H NMR (500 MHz, C6D6): δ 7.39 (dd, J = 7.5, 5.9 Hz, 4H), 7.36 – 7.29 (m, 3H), 7.26 – 7.18 (m, 
6H), 7.14 – 7.07 (m, 2H), 7.02 – 6.88 (m, 5H), 5.88 (q, J = 6.6 Hz, 1H), 5.05 (d, J = 3.8 Hz, 1H), 
4.96 (d, J = 11.4 Hz, 1H), 4.75 – 4.43 (m, 5H), 4.18 (dd, J = 10.2, 3.8 Hz, 1H), 4.13 – 4.05 (m, 
1H), 4.00 (s, 1H), 3.96 (dd, J = 10.2, 2.8 Hz, 1H), 3.83 – 3.76 (m, 1H), 3.72 (d, J = 9.8 Hz, 1H), 
3.54 (s, 1H), 3.40 (s, 1H), 3.38 (d, J = 2.6 Hz, 1H), 3.25 (d, J = 13.2 Hz, 1H), 3.07 (d, J = 13.1 Hz, 
1H), 2.99 – 2.89 (m, 2H), 2.74 (dq, J = 10.6, 6.6 Hz, 1H), 2.14 (dd, J = 14.7, 10.4 Hz, 1H), 1.98 
(dd, J = 14.8, 3.1 Hz, 1H), 1.93 – 1.83 (m, 1H), 1.64 – 1.55 (m, 1H), 1.45 (d, J = 6.7 Hz, 3H), 1.43 
(m, 1H), 1.30 (d, J = 6.4 Hz, 3H), 1.27 (d, J = 7.1 Hz, 3H), 1.25 (d, J = 6.8 Hz, 3H), 1.18 (d, J = 
6.7 Hz, 3H), 0.98 (d, J = 6.7 Hz, 3H), 0.66 (d, J = 7.1 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 216.3, 175.4, 139.4, 139.3, 139.0, 129.9, 129.2, 128.8, 128.7, 
128.5, 128.4, 128.3, 127.4, 127.4, 127.1, 126.4, 100.6, 89.0, 83.7, 79.7, 78.7, 78.2, 77.0, 75.2, 74.5, 
72.9, 70.4, 69.6, 68.6, 44.6, 44.0, 42.1, 41.5, 40.7, 37.5, 20.7, 18.7, 17.0, 14.8, 9.3, 8.7. 
HRMS (m/z): [M+Na]+ calcd. for C53H68O11S, 935.4380; found, 935.4337 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.2 
IR (thin film, cm-1): 3472, 2920, 2880, 2852, 1707, 1455, 1106 
[α]D: +38.0 (c = 0.07 in CHCl3) 
58 
 
 
1H NMR (700 MHz, C6D6): δ 7.46 (d, J = 7.5 Hz, 2H), 7.38 (t, J = 7.4 Hz, 4H), 7.30 (d, J = 7.5 
Hz, 2H), 7.21 – 7.18 (m, 5H), 7.10 (m, 4H), 7.01 (t, J = 7.7 Hz, 2H), 6.91 (t, J = 7.4 Hz, 1H), 5.74 
(q, J = 6.2 Hz, 1H), 4.98 (d, J = 11.3 Hz, 1H), 4.91 (t, J = 12.7 Hz, 2H), 4.57 – 4.47 (m, 4H), 4.26 
(s, 1H), 4.05 (dd. J = 9.6, 7.9 Hz, 1H), 3.99 (s, 1H), 3.96 (s, 1H), 3.90 (d, J = 9.8 Hz, 1H), 3.80 
(dd, J = 9.6, 4.1 Hz, 1H), 3.63 (s, 1H), 3.39 (d, J = 13.2 Hz, 1H), 3.34 (dd, J = 9.6, 2.6 Hz, 1H), 
3.24 (d, J = 13.2 Hz, 1H), 3.20 – 3.15 (m, 1H), 3.07 (q, J = 6.1 Hz, 1H), 2.91 (q, J = 6.9 Hz, 1H), 
2.60 (dt, J = 13.2, 6.7 Hz, 1H), 2.49 (s, 1H), 2.05 – 1.90 (m, 4H), 1.47 – 1.41 (m, 1H), 1.33 (d, J = 
6.5 Hz, 3H), 1.30 (d, J = 6.7 Hz, 3H), 1.20 (d, J = 7.1 Hz, 3H), 1.18 (d, J = 6.8 Hz, 3H), 1.17 (d, J 
= 6.3 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H), 0.61 (d, J = 7.1 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 213.8, 176.1, 139.4, 139.2, 139.1, 137.9, 130.1, 129.2, 128.7, 
128.5, 128.4, 128.4, 128.3, 128.1, 128.0, 127.8, 127.8, 127.7, 126.4, 103.7, 87.7, 83.8, 83.4, 79.6, 
77.7, 77.2, 75.5, 75.2, 72.9, 70.6, 70.4, 69.7, 44.7, 43.2, 42.1, 41.8, 40.4, 38.3, 37.0, 20.1, 18.6, 
17.2, 14.8, 8.8, 8.6. 
HRMS (m/z): [M+NH4]
+ calcd. for C53H68O11S, 930.4826; found, 930.4716 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.2 
IR (thin film, cm-1): 3525, 2925, 1705, 1453, 1362, 1067 
[α]D: -15.4 (c = 0.08 in CHCl3) 
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1H NMR (700 MHz, C6D6): δ 7.52 (d, J = 7.3 Hz, 2H), 7.41 (dd, J = 16.9, 7.4 Hz, 4H), 7.32 (d, J 
= 7.4 Hz, 2H), 7.21 (t, J = 7.6 Hz, 2H), 7.15 – 7.02 (m, 9H), 6.95 (t, J = 7.4 Hz, 1H), 5.34 – 5.26 
(m, 1H), 5.24 (d, J = 3.5 Hz, 1H), 5.04 (d, J = 11.2 Hz, 1H), 4.71 (t, J = 11.2 Hz, 2H), 4.63 (d, J = 
11.8 Hz, 1H), 4.53 (dd, J = 20.0, 11.3 Hz, 2H), 4.47 – 4.41 (m, 2H), 4.30 (dd, J = 10.4, 3.5 Hz, 
1H), 4.17 (dd, J = 10.4, 2.7 Hz, 1H), 3.92 (dd, J = 10.6, 8.3 Hz, 1H), 3.87 (d, J = 10.5 Hz, 1H), 
3.52 (s, 1H), 3.48 (d, J = 13.3 Hz, 1H), 3.42 (d, J = 13.3 Hz, 1H), 3.22 (p, J = 7.2 Hz, 1H), 2.61 – 
2.51 (m, 2H), 2.01 (s, 1H), 1.98 (dd, J = 13.7, 3.7 Hz, 1H), 1.82 – 1.68 (m, 2H), 1.46 (d, J = 6.3 
Hz, 3H), 1.43 (m, 1H), 1.38 (d, J = 7.1 Hz, 3H), 1.19 (d, J = 6.8 Hz, 6H), 1.10 (d, J = 7.2 Hz, 3H), 
0.50 (d, J = 7.0 Hz, 3H), 0.38 (d, J = 6.6 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 175.0, 139.8, 139.6, 139.4, 138.7, 129.9, 129.3, 128.6, 128.5, 
128.4, 128.4, 128.4, 128.3, 128.1, 128.0, 127.8, 127.7, 127.6, 127.6, 126.3, 107.5, 98.8, 81.1, 79.7, 
79.2, 77.7, 75.5, 74.6, 74.4, 73.1, 73.1, 73.1, 72.8, 68.0, 44.2, 43.0, 42.4, 39.8, 38.0, 35.0, 27.7, 
17.4, 15.9, 14.5, 13.7, 9.4, 9.0, 7.6. 
HRMS (m/z): [M+Na-H2O]
+ calcd. for C53H68O11S, 912.4720; found, 912.4676 
TLC (EtOAc:Hexanes, 20:80 v/v): Rf = 0.3 
IR (thin film, cm-1): 2923, 2853, 1726, 1455, 1377, 1100 
[α]D: +9.0 (c = 0.08 in CHCl3) 
  
60 
 
 
1H NMR (500 MHz, C6D6): δ 7.54 (dd, J = 8.3, 1.1 Hz, 2H), 7.46 (d, J = 7.1 Hz, 2H), 7.35 (t, J = 
7.5 Hz, 4H), 7.22 – 7.17 (m, 4H), 7.16 – 7.08 (m, 4H), 7.10 – 7.01 (m, 3H), 7.00 – 6.90 (m, 1H), 
5.23 – 5.11 (m, 3H), 4.99 (d, J = 11.7 Hz, 1H), 4.80 (d, J = 11.4 Hz, 1H), 4.71 (d, J = 11.9 Hz, 1H), 
4.59 – 4.47 (m, 3H), 4.27 (s, 1H), 4.08 (dd, J = 9.7, 7.8 Hz, 1H), 3.94 – 3.84 (m, 2H), 3.53 – 3.40 
(m, 3H), 3.27 (q, J = 6.2 Hz, 1H), 3.25 – 3.18 (m, 1H), 3.19 (d, J = 2.6 Hz, 1H), 2.76 (qd, J = 7.2, 
1.7 Hz, 1H), 2.47 (dtd, J = 14.0, 7.0, 1.8 Hz, 1H), 2.04 – 1.91 (m, 2H), 1.78 – 1.64 (m, 2H), 1.46 
(d, J = 7.3 Hz, 3H), 1.23 (d, J = 6.4 Hz, 3H), 1.20 – 1.15 (m, 6H), 1.13 (d, J = 7.2 Hz, 3H), 0.48 
(d, J = 7.0 Hz, 3H), 0.41 (d, J = 6.4 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 177.2, 140.0, 139.7, 139.7, 138.8, 129.9, 129.2, 128.6, 128.4, 
128.4, 128.4, 128.4, 128.3, 128.1, 128.0, 127.8, 127.7, 127.6, 127.4, 126.2, 107.2, 101.7, 83.3, 
80.8, 80.7, 78.0, 75.3, 75.2, 73.8, 73.7, 73.4, 73.4, 73.0, 70.7, 43.5, 42.9, 40.2, 39.3, 37.5, 34.9, 
34.3, 32.4, 27.7, 27.3, 23.2, 17.2, 16.2, 14.6, 14.4, 13.3, 11.0, 10.1, 7.7. 
HRMS (m/z): [M+Na-H2O]
+ calcd. for C53H68O11S, 912.4720; found, 912.4699 
TLC (EtOAc:Hexanes, 20:80 v/v): Rf = 0.3 
IR (thin film, cm-1): 2920, 2851, 1718, 1461, 1378, 1086 
[α]D: -4.4 (c = 0.28 in CHCl3) 
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1H NMR (500 MHz, C6D6): δ 7.43 – 7.26 (m, 8H), 7.24 – 7.18 (m, 5H), 7.14 – 6.86 (m, 7H), 5.92 
(q, J = 6.7 Hz, 1H), 4.98 (d, J = 11.3 Hz, 1H), 4.84 (d, J = 3.5 Hz, 1H), 4.73 (d, J = 12.0 Hz, 1H), 
4.59 (d, J = 12.1 Hz, 1H), 4.49 (dd, J = 19.3, 11.3 Hz, 2H), 4.34 (d, J = 11.5 Hz, 1H), 4.21 (s, 1H), 
4.08 (dd, J = 10.2, 3.6 Hz, 1H), 3.96 (q, J = 7.2 Hz, 1H), 3.83 (dd, J = 10.3, 2.6 Hz, 1H), 3.73 (d, 
J = 10.0 Hz, 1H), 3.67 – 3.54 (m, 3H), 3.44 (s, 1H), 3.37 – 3.28 (m, 2H), 3.19 (d, J = 13.6 Hz, 1H), 
3.06 (q, J = 6.5 Hz, 1H), 2.86 – 2.71 (m, 1H), 2.24 (dd, J = 14.7, 10.6 Hz, 1H), 2.00 (d, J = 14.6 
Hz, 1H), 1.88 – 1.74 (m, 1H), 1.51 (d, J = 6.8 Hz, 3H), 1.46 (s, 3H), 1.44 (m, 1H), 1.22 (d, J = 6.8 
Hz, 3H), 1.19 (d, J = 6.4 Hz, 6H), 0.96 (d, J = 6.6 Hz, 3H), 0.64 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, C6D6): δ 216.2, 175.2, 139.1, 139.0, 138.9, 138.5, 129.5, 129.1, 128.8, 
128.8, 128.3, 128.3, 128.2, 128.2, 128.1, 128.1, 127.9, 127.7, 127.6, 127.3, 127.1, 126.0, 125.6, 
100.8, 89.5, 83.9, 80.6, 78.1, 77.9, 77.4, 74.9, 74.1, 73.7, 72.7, 72.3, 71.5, 69.9, 68.9, 68.5, 67.2, 
45.1, 44.4, 42.6, 41.7, 40.0, 38.9, 20.5, 18.3, 16.9, 16.2, 15.2, 12.6, 9.1, 9.1, 8.5. 
HRMS (m/z): [M+NH4]
+ calcd. for C53H68O11S, 930.4826; found, 930.4797 
TLC (EtOAc:Hexanes, 40:60 v/v): Rf = 0.36 
IR (thin film, cm-1): 3351, 2924, 2850, 1723, 1454, 1377, 1097 
[α]D: -27.8 (c = 0.11 in CHCl3)
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1H NMR (500 MHz, C6D6): δ 7.39 (d, J = 7.3 Hz, 2H), 7.35 (d, J = 7.1 Hz, 2H), 7.31 (d, J = 8.5 
Hz, 2H), 7.24 (d, J = 7.2 Hz, 2H), 7.19 - 7.13 (m, 6H), 7.09 (t, J = 7.4 Hz, 3H), 7.00 (t, J = 7.6 Hz, 
2H), 6.92 (t, J = 7.4 Hz, 1H), 5.94 (q, J = 6.6 Hz, 1H), 4.94 – 4.78 (m, 3H), 4.49 (d, J = 11.5 Hz, 
1H), 4.41 (d, J = 7.7 Hz, 1H), 4.41 – 4.29 (m, 2H), 4.16 (s, 1H), 4.03 – 3.93 (m, 2H), 3.71 (d, J = 
11.3 Hz, 2H), 3.31 (s, 1H), 3.23 – 2.95 (m, 7H), 2.79 (dq, J = 9.9, 6.5 Hz, 1H), 2.12 – 1.91 (m, 
2H), 1.83 (q, J = 7.2 Hz, 1H), 1.58 (d, J = 6.8 Hz, 3H), 1.49 – 1.39 (m, 2H), 1.35 (d, J = 6.4 Hz, 
3H), 1.26 (d, J = 6.9 Hz, 3H), 1.20 (d, J = 2.5 Hz, 3H), 1.18 (d, J = 3.0 Hz, 3H), 0.98 (d, J = 6.6 
Hz, 3H), 0.67 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, C6D6): δ 217.2, 175.6, 139.3, 138.9, 138.5, 137.7, 129.9, 129.2, 128.7, 
128.6, 128.5, 128.5, 128.4, 128.2, 128.0, 127.8, 126.4, 103.9, 86.5, 84.2, 84.0, 80.0, 79.8, 77.0, 
76.1, 75.3, 73.0, 70.8, 70.4, 69.6, 44.5, 44.3, 42.7, 42.2, 40.3, 38.5, 37.3, 20.8, 18.7, 17.0, 16.0, 
9.6, 9.1, 8.8. 
HRMS (m/z): [M+NH4]
+ calcd. for C53H68O11S, 930.4826; found, 930.4806 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.3 
IR (thin film, cm-1): 3479, 2972, 2921, 2854, 1727, 1453, 1378, 1069 
[α]D: -6.2 (c = 0.13 in CHCl3) 
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1H NMR (700 MHz, C6D6): δ 7.43 – 7.32 (m, 6H), 7.21 (dt, J = 19.7, 7.7 Hz, 5H), 7.14 – 7.10 
(m, 4H), 7.10 – 7.03 (m, 2H), 7.00 (t, J = 7.8 Hz, 2H), 6.89 (t, J = 7.4 Hz, 1H), 5.64 (q, J = 6.5 Hz, 
1H), 4.99 (d, J = 11.4 Hz, 1H), 4.97 (d, J = 3.6 Hz, 1H), 4.75 – 4.64 (m, 2H), 4.62 – 4.47 (m, 3H), 
4.20 (dd, J = 10.2, 3.7 Hz, 1H), 4.05 (d, J = 9.0 Hz, 1H), 4.00 (d, J = 3.6 Hz, 1H), 3.97 – 3.89 (m, 
3H), 3.86 (d, J = 10.4 Hz, 1H), 3.69 – 3.61 (m, 2H), 3.45 (d, J = 13.2 Hz, 1H), 3.40 – 3.34 (m, 1H), 
3.22 (d, J = 13.3 Hz, 1H), 2.92 (q, J = 5.9 Hz, 1H), 2.75 (dq, J = 10.2, 6.8 Hz, 1H), 2.24 – 2.16 (m, 
1H), 2.03 – 1.94 (m, 2H), 1.78 (dd, J = 14.5, 6.5 Hz, 1H), 1.50 – 1.41 (m, 1H), 1.38 (d, J = 6.7 Hz, 
3H), 1.26 (d, J = 7.0 Hz, 3H), 1.21 (d, J = 6.7 Hz, 3H), 1.17 (d, J = 6.5 Hz, 3H), 1.12 (d, J = 7.0 
Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H), 0.68 (d, J = 7.0 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 211.0, 177.1, 139.4, 139.3, 138.3, 137.8, 130.2, 129.4, 129.0, 
128.7, 128.7, 128.6, 128.4, 128.4, 127.8, 126.5, 100.4, 89.7, 82.5, 79.7, 78.4, 78.3, 77.4, 75.2, 74.8, 
73.2, 70.5, 69.7, 68.0, 44.9, 43.2, 42.3, 38.9, 35.9, 18.8, 18.6, 17.1, 15.3, 8.9, 8.6, 8.0. 
HRMS (m/z): [M+Na]+ calcd. for C53H68O11S, 935.4380; found, 935.4365 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.36 
IR (thin film, cm-1): 3334, 2923, 2852, 1716, 453, 1178, 1047 
[α]D: -34.4 (c = 0.19 in CHCl3) 
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1H NMR (700 MHz, C6D6): δ 7.58 (d, J = 7.6 Hz, 2H), 7.35 (d, J = 7.5 Hz, 2H), 7.31 (d, J = 7.4 
Hz, 4H), 7.28 – 7.18 (m, 4H), 7.13 (t, J = 7.4 Hz, 4H), 7.06 (dd, J = 16.3, 8.9 Hz, 2H), 7.00 (t, J = 
7.6 Hz, 2H), 6.92 (t, J = 7.4 Hz, 1H), 5.92 (q, J = 6.6 Hz, 1H), 5.09 (d, J = 10.5 Hz, 1H), 4.90 (d, 
J = 12.0 Hz, 1H), 4.81 (d, J = 10.5 Hz, 1H), 4.64 (d, J = 11.9 Hz, 1H), 4.53 (dd, J = 15.1, 12.1 Hz, 
2H), 4.36 (d, J = 7.7 Hz, 1H), 4.28 (s, 1H), 4.15 (s, 1H), 4.05 – 4.02 (m, 1H), 3.99 (d, J = 10.2 Hz, 
1H), 3.64 (d, J = 9.5 Hz, 1H), 3.54 (s, 1H), 3.48 (s, 1H), 3.20 (dd, J = 10.0, 2.3 Hz, 1H), 3.15 (d, J 
= 13.5 Hz, 1H), 3.10 – 3.02 (m, 2H), 2.98 (q, J = 7.2, 6.8 Hz, 1H), 2.87 (q, J = 6.2 Hz, 1H), 2.84 – 
2.76 (m, 1H), 2.17 – 2.07 (m, 1H), 2.00 (d, J = 14.5 Hz, 1H), 1.78 (d, J = 7.0 Hz, 1H), 1.60 (d, J = 
6.7 Hz, 3H), 1.51 – 1.40 (m, 2H), 1.34 (d, J = 6.5 Hz, 3H), 1.30 (d, J = 7.1 Hz, 3H), 1.19 (d, J = 
6.7 Hz, 3H), 1.13 (d, J = 6.2 Hz, 3H), 0.96 (d, J = 6.4 Hz, 3H), 0.62 (d, J = 7.1 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 216.3, 175.9, 139.2, 139.1, 137.5, 130.1, 129.2, 128.8, 128.7, 
128.6, 128.5, 128.4, 128.3, 127.8, 127.8, 126.5, 106.5, 89.7, 84.1, 82.6, 80.0, 79.7, 76.6, 76.0, 75.0, 
73.4, 71.2, 70.3, 69.0, 45.0, 44.6, 42.2, 41.9, 40.3, 40.0, 36.7, 20.4, 18.8, 16.6, 15.1, 9.6, 8.9. 
HRMS (m/z): [M+NH4]
+ calcd. for C53H68O11S, 930.4826; found, 930.4774 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.2 
IR (thin film, cm-1): 3441, 2920, 2825, 1723, 1454, 1378, 1084 
[α]D: -7.0 (c = 0.11 in CHCl3) 
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1H NMR (700 MHz, C6D6): δ 7.52 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 7.7 Hz, 2H), 7.37 (dd, J = 
15.7, 7.7 Hz, 4H), 7.23 – 7.18 (m, 5H), 7.15 – 7.03 (m, 6H), 6.95 (t, J = 7.0 Hz, 1H), 5.90 (d, J = 
3.5 Hz, 1H), 5.26 (q, J = 6.6 Hz, 1H), 5.09 (d, J = 11.3 Hz, 1H), 4.76 (d, J = 11.9 Hz, 1H), 4.66 (d, 
J = 11.2 Hz, 1H), 4.63 – 4.51 (m, 3H), 4.46 (d, J = 10.5 Hz, 1H), 4.32 (dd, J = 10.4, 3.4 Hz, 1H), 
4.13 – 4.05 (m, 2H), 3.97 (d, J = 10.4 Hz, 1H), 3.90 – 3.84 (m, 1H), 3.53 – 3.39 (m, 2H), 3.18 (p, 
J = 7.4 Hz, 1H), 2.76 (q, J = 7.2 Hz, 1H), 2.45 (p, J = 8.1, 7.5 Hz, 1H), 2.02 – 1.94 (m, 2H), 1.86 
– 1.74 (m, 2H), 1.51 – 1.40 (m, 4H), 1.33 (d, J = 6.4 Hz, 3H), 1.20 – 1.14 (m, 6H), 1.12 (d, J = 7.1 
Hz, 3H), 0.44 (d, J = 6.8 Hz, 3H), 0.38 (d, J = 6.9 Hz, 3H). 
13C NMR (176 MHz, C6D6): δ 176.7, 139.7, 139.7, 139.5, 138.6, 129.9, 129.3, 128.6, 128.5, 
128.4, 128.4, 128.3, 127.7, 127.7, 127.5, 126.3, 107.3, 96.6, 81.0, 79.6, 79.1, 77.4, 75.2, 74.4, 73.3, 
73.3, 73.2, 73.0, 67.5, 43.6, 43.1, 40.5, 39.6, 38.0, 34.9, 27.7, 17.1, 16.1, 14.4, 13.5, 10.4, 10.2, 
7.7. 
HRMS (m/z): [M+Na-H2O]
+ calcd. for C53H68O11S, 912.4720; found, 912.4700 
TLC (EtOAc:Hexanes, 20:80 v/v): Rf = 0.36 
IR (thin film, cm-1): 3477, 2959, 2923, 2852, 1725, 1454, 1374, 1098 
[α]D: -36.7 (c = 0.17 in CHCl3) 
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1H NMR (700 MHz, CDCl3) δ 8.05 (d, J = 6.9 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.44 (t, J = 7.7 
Hz, 2H), 5.15 (m, 2H), 4.70 (d, J = 7.6 Hz, 1H), 3.90 (s, 1H), 3.86 – 3.81 (m, 2H), 3.76 – 3.66 
(m, 2H), 3.47 (d, J = 10.1 Hz, 1H), 2.87 (m, 1H), 2.81 (q, J = 6.9 Hz, 1H), 2.76 – 2.69 (m, 1H), 
2.57 (dt, J = 10.0, 6.4 Hz, 1H), 2.27 (s, 6H), 1.88 – 1.76 (m, 1H), 1.75 – 1.39 (m, 4H), 1.34 (d, J 
= 6.1 Hz, 3H), 1.09 (t, J = 6.1 Hz, 6H), 1.06 (m, 2H), 1.03 (dd, J = 6.9, 1.5 Hz, 6H), 0.99 (d, J = 
6.8 Hz, 3H), 0.96 – 0.85 (m, 2H), 0.84 (t, J = 7.2 Hz, 6H). 
13C NMR (176 MHz, C6D6) δ 210.6, 176.1, 129.9, 132.5, 128.3, 75.5, 71.6, 103.5, 76.3, 86.4, 
70.7, 69.7, 40.8, 45.1, 63.7, 40.4, 40.4, 37.2, 40.6, 35.6, 40.5, 29.9, 15.0, 8.7, 30.0, 17.8, 7.7, 
14.7, 20.5, 10.4, 8.8 
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1H NMR (700 MHz, CDCl3) δ 8.08 (d, J = 6.9 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.44 (t, J = 7.7 
Hz, 2H), 5.12 – 5.02 (m, 2H), 4.65 (d, J = 7.6 Hz, 1H), 3.88 (d, J = 4.5 Hz, 1H), 3.80 (d, J = 4.8 
Hz, 1H), 3.64 (dd, J = 15.1, 8.6 Hz, 2H), 3.58 (d, J = 10.5 Hz, 1H), 2.86 (m, 1H), 2.71 (q, J = 6.9 
Hz, 1H), 2.61 (dt, J = 11.1, 6.0 Hz, 1H), 2.53 (dq, J = 10.3, 6.7 Hz, 1H), 2.32 (d, J = 25.9 Hz, 
1H), 2.26 (s, 6H), 1.81 (d, J = 13.1 Hz, 1H), 1.80 – 1.70 (m, 1H), 1.71 – 1.64 (m, 1H), 1.65 – 
1.52 (m, 2H), 1.52 – 1.41 (m, 2H), 1.33 (dd, J = 15.3, 6.5 Hz, 1H), 1.29 (d, J = 6.1 Hz, 3H), 1.27 
– 1.19 (m, 2H), 1.08 (d, J = 6.4 Hz, 3H), 1.04 (d, J = 7.0 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H), 0.91 
(d, J = 3.4 Hz, 3H), 0.90 (d, J = 3.0 Hz, 2H), 0.87 (t, J = 7.4 Hz, 3H), 0.80 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 212.5, 165.9, 133.0, 130.1, 128.4, 103.5, 86.3, 78.1, 76.1, 72.0, 
71.0, 69.9, 64.0, 44.3, 43.4, 40.9, 40.7, 38.2, 37.5, 34.7, 30.9, 29.9, 25.5, 21.3, 17.4, 14.7, 13.6, 
10.8, 9.3, 8.1, 6.5. 
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Structural Elucidation of Glycoside Products 
The structure of each isolated glycoside was characterized and assigned based on 1D and 2D NMR 
experiments. Each proton signal on 1H NMR was assigned by analyzing cross-peaks on COSY, 
HSQC, and HMBC spectra. Figure 2.10 shows (a) easily identifiable starting points for NMR 
assignments, and (b) propagation of frequently observed COSY or HMBC correlations for each 
isolated spin systems.  
 
Figure 2.10. General guidelines for NMR signal assignments for glycoside products. 
The stereochemical configuration of glycosidic linkage (α or β) was assigned based on the 3J 
coupling constant between anomeric proton H1’ and its vicinal proton H2’. For α-anomer, H1’ and 
H2’ are in gauche conformation; for β-anomer, H1’ and H2’ are in anti conformation. According to 
Karplus equation, the 3J coupling constant between H1’ and H2’ in α-anomer should be smaller (~  
3 to 4 Hz) compared to the 3J coupling constant between H1’ and H2’ in β-anomer (~7.5 to 8.0 Hz).  
 
Figure 2.11. Assignments for anomeric configuration of glycosidic linkage.  
The site of glycosylation on macrolide was assigned based on the observation of HMBC cross-
peak between anomeric carbon and proton geminal to hydroxyl group or cross-peak between 
anomeric proton and carbon with hydroxyl group.  
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Figure 2.12. Determining site of glycosylation based on HMBC correlations.  
Table 2.6 summarizes 3J coupling constants and key HMBC correlations used to assign the 
stereochemical configuration of glycosidic linkages and sites of glycosylation for each glycoside: 
Compound 3J (H1’-H2’) HMBC Correlations 
3 3.1 Hz H1’ (δ 4.74) - C3 (δ 91.8) 
H3 (δ 3.77) - C1’ (δ 100.6) 
4 3.7 Hz H1’ (δ 4.92) - C5 (δ 82.5) 
H5 (δ 3.94) - C1’ (δ 95.9) 
5 3.8 Hz 
3.6 Hz 
H1’ (δ 4.99) - C5 (δ 80.3) 
H1’ (δ 5.71) - C11 (δ 83.7) 
H11 (δ 4.30) - C1’ (δ 100.9) 
α-23 3.5 Hz  H1’ (δ 4.86) - C3 (δ 89.8) 
H3 (δ 3.80) - C1’ (δ 100.8) 
α-24 3.8 Hz H5 (δ 3.85) - C1’ (δ 94.2) 
β-24 7.7 Hz  H1’ (δ 4.32) - C5 (δ 85.8) 
H5 (δ 3.95) - C1’ (δ 104.9) 
α-27 3.3 Hz H1’ (δ 4.67) - C3 (δ 92.4) 
H3 (δ 3.62) - C1’ (δ 101.0) 
β-27 7.9 Hz H1’ (δ 4.31) - C3 (δ 88.3) 
H3 (δ 3.64) - C1’ (δ 104.4) 
α-28 3.6 Hz  H1’ (δ 4.95) - C5 (δ 90.1) 
H5 (δ 3.52) - C1’ (δ 99.9) 
β-28 7.8 Hz  H1’ (δ 4.68) - C5 (δ 86.2) 
α-29 3.4 Hz  H3 (δ 4.39) - C1’ (δ 98.2) 
H5 (δ 3.92) - C9 (δ 107.5) 
H11 (δ 3.36) - C9 (δ 107.5) 
β-29 7.9 Hz H3 (δ 4.55) - C1’ (δ 101.1) 
H5 (δ 3.88) - C9 (δ 107.3) 
α-30 3.4 Hz H1’ (δ 4.76) - C3 (δ 91.3) 
H3 (δ 3.63) - C1’ (δ 101.7) 
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Compound 3J (H1’-H2’) HMBC Correlations 
β-30 7.7 Hz H1’ (δ 4.29) - C3 (δ 87.5) 
H3 (δ 3.71) - C1’ (δ 104.4) 
α-31 3.8 Hz H1’ (δ 5.05) - C5 (δ 89.1) 
H5 (δ 3.53) - C1’ (δ 100.4) 
β-31 7.9 Hz H1’ (δ 4.51) - C5 (δ 87.7) 
α-32 3.5 Hz H1’ (δ 5.24) - C3 (δ 74.5) 
H3 (δ 4.43) - C1’ (δ 98.8) 
H5 (δ 3.90) - C9 (δ 107.5) 
H11 (δ 3.93) - C9 (δ 107.5) 
β-32 7.8 Hz H1’ (δ 5.17) - C3 (δ 73.9) 
H3 (δ 4.56) - C1’ (δ 101.7) 
H5 (δ 3.91) - C9 (δ 107.3) 
H11 (δ 3.88) - C9 (δ 107.3) 
α-33 3.5 Hz H1’ (δ 4.84) - C3 (δ 89.6) 
H3 (δ 3.73) - C1’ (δ 100.8) 
β-33 7.7 Hz H1’ (δ 4.41) - C3 (δ 86.5) 
H3 (δ 3.99) - C1’ (δ 103.8) 
α-34 3.7 Hz H1’ (δ 4.97) - C5 (δ 89.6) 
H5 (δ 4.01) - C1’ (δ 100.5) 
β-34 7.7 Hz H1’ (δ 4.35) - C5 (δ 89.7) 
H5 (δ 3.54) - C1’ (δ 107.4) 
α-35 3.5 Hz H3 (δ 4.45) - C1’ (δ 96.9) 
H5 (δ 3.96) - C9 (δ 107.2) 
H11 (δ 3.87) - C9 (δ 107.2) 
Table 2.6. Summary of coupling constant and key HMBC correlations used to assign the anomeric 
configuration and site of glycosylation.   
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CHAPTER 3 
Direct Conversion of BINOL-Based to H8-BINOL-Based Chiral Brønsted Acids Through 
Single-Step Hydrogenation 
(This chapter was partially published in: Tay, J. H.; Arguelles, J. A.; Nagorny, P. Org. Lett. 
2015, 17, 3774.) 
 
3.1 Introduction 
The design of new catalyst scaffolds and shortened synthetic routes are undeniably the 
major forces that drive the growing applications of chiral Brønsted acids as organocatalysts in 
various asymmetric transformations. In 2004, Akiyama1 and Terada2 independently published 
seminal works hightlighting the utility of BINOL-based CPA catalysts in catalyzing asymmetric 
Mannich-type reactions.  Since then, the 1,1’-bi-2-naphthol or BINOL scaffold 43 has become a 
ubiquitous element in the design of phosphoric acid catalysts and has served as an inspiration for 
the new design of catalyst scaffolds. Its axial chirality is perhaps the most important feature that 
enables the development of asymmetric reactions using the BINOL-based catalyst. In addition, 
BINOL scaffold is highly tunable, conformationally rigid and C2 symmetric, making it a versatile 
building block for catalysts even beyond chiral Brønsted acid.  
One of the most commonly used alternatives to the BINOL-scaffold in chiral Brønsted acid 
catalysis is the H8-BINOL scaffold 44. H8-BINOL retains the same C2 symmetry as BINOL but 
it has a partially saturated naphthol-derived backbone. This distinction leads to differences in 
solubility, acidity, geometry and the bite angle between chiral acids built on BINOL and H8-
BINOL scaffolds. Although both scaffolds are structurally similar, the preparation of their 
corresponding CPA requires two distinct synthetic sequences, each necessitating 5 to 7 steps 
(Scheme 3.1). To synthesize the H8-BINOL equivalent of a BINOL-based CPA, BINOL 43 is 
hydrogenated to H8-BINOL 44 in the first step. In other words, starting from BINOL 43 and H8-
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BINOL 44, 10 more synthetic steps are needed to prepare two structurally similar CPAs. We 
envision that the step-count can be greatly reduced if there is a way to convert BINOL-based CPA 
to H8-BINOL based CPA in a single step.  
 
Scheme 3.1. Overview of synthetic route for BINOL-based and H8-BINOL-based Chiral Brønsted 
acids.  
 
3.2 Results and Discussion 
BINOL 43 is normally reduced to H8-BINOL 44 through a hydrogenation reaction in the 
presence of palladium on carbon3 (Pd/C) or a platinum oxide4 (Pt2O) catalyst. There was no 
reaction when BINOL-based CPA (S)-9 was subjected to the hydrogenation reaction with 1 atm 
hydrogen gas and Pd/C in EtOAc (Table 3.1, entry 1). However, when we switched the 
hydrogenation catalyst to Pt2O, we observed a 26% conversion to the desired H8-BINOL-based 
CPA (S)-13 based on 1H NMR analysis (entry 2). No hydrogenation was observed when solvents 
such as acetone, dichloromethane, benzene or dimethylformamide were used (entries 3 – 6). 
However, the hydrogenation reaction proceeded with quantitative yield in protic solvents such as 
acetic acid and a mixture of methanol with dichloromethane (entries 7 and 8). More importantly, 
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we did not observe any reduction of the phosphate functionality or racemization of the CPA 
catalyst under this reaction condition.  
 
Table 3.1. Solvent screen for selective hydrogenation of BINOL-based CPA.  
 
To probe the scope of the method, we investigated BINOL-derived CPA substrates with 
different substituent groups at the 3,3’-position (Table 3.2). BINOL-derived CPA without 3,3’-
substitution was converted to the corresponding H8-BINOL-base CPA under the optimization 
condition with >98% yield. The hydrogenation of CPAs with electron-withdrawing groups, such 
as 3,5-bis-trifluoromethylphenyl-substituted acid, 3,5-bis-pentafluorosulfanylphenyl substituted 
acid and 3,5-bis-fluorophenyl-substituted acid, also proceeded smoothly with a quantitative yield. 
However, when 3,5-bis-chlorophenyl-substituted acid was subjected to the hydrogenation 
condition, we observed a mixture of products corresponding to dichlorination followed by 
reductions of the resulting phenyl rings.  
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Table 3.2. Substrate scope of selective hydrogenation of BINOL-based CPAs catalyzed by Pt2O. 
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Next, the study continued with the hydrogenation of CPAs with alkyl-substitued-phenyl 
rings. CPAs with 3,3’-phenyl substituted with bulky tert-butyl and iso-propyl groups at the meta-
positions were selectively hydrogenated to the corresponding H8-BINOL-based CPAs (49 and 50) 
in excellent yields. Similar CPAs with 2,4,6-tricyclohexyl-substituted phenyl and 2,4,6-
triisopropy-substitued phenyl also underwent the selective reduction without any problems. 
However, overreduction of the 3,3’-phenyl was observed when it was substituted with a less bulky 
methyl group at the meta-position.  To test the scalability of the method, hydrogenation of CPA 
(S)-9 was repeated on a 1.0-gram scale. The reaction proceeded selectively to produce (S)-13 with 
quantitative yield. 
BINOL 43 or H8-BINOL 44 can also be appended with acidic functionalities other than 
phosphoric acid, such as N-trifyl phosphoramide or the disulfonimide group. We were curious how 
our method would perform in the presence of those functional groups. When compounds (R)-15 
and (R)-18 were subjected to hydrogenation with Pt2O, we observed the same chemoselectivity 
and conversion to (R)-54 and (R)-55 with excellent yield (Scheme 3.2). Nonetheless, no 
conversion was observed when the same condition was applied to the hydrogenation of N-triflyl 
thiophosphoramide (R)-56. Presumably the reaction did not proceed because of catalyst poisoning 
by the phosphorus sulfur.  
 
Scheme 3.2. Hydrogenation of BINOL-derived compounds with functionalities other than 
phosphoric acid. 
78 
 
3.3 Conclusion 
In summary, this new method provids a new efficient strategy to synthesize H8-BINOL-
based chiral Brønsted acids through a direct reduction of their corresponding BINOL-derived 
analogs. The condition was general for the selective hydrogenation of BINOL-based chiral acids 
substituted with an electron-withdrawing group and bulky aliphatic substituents. In addition, the 
scope of the reaction also extended to the reduction of BINOL-derived compounds with functional 
groups such as N-trifyl-phosphoramide and disulfonimide. Using our method, five new H8-
BINOL based chiral Brønsted acids (13, 46, 49,50 and 55) were synthesized. We believe that the 
outlined strategy can facilitate the rapid construction of a catalyst library of chiral Brønsted acids 
and improve the accessibility of H8-BINOL-based Brønsted acids for asymmetric reactions.  
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3.4 Experimental Information 
General Methods 
All reagents and solvents were purchased from Sigma-Aldrich, Fisher Scientific, Corvinus 
Chemicals and were used as received without further purification unless specified. Platinum (IV) 
oxide was purchased from Sigma-Aldrich with surface area >75m2/g or similar catalysts from 
Strem. Chiral acids used in these studies were purchased from Sigma Aldrich or synthesized 
according to known literature procedures. Heating was achieved by use of a silicone bath with 
heating controlled by electronic contact thermometer. Deionized water was used in the preparation 
of all aqueous solutions and for all aqueous extractions. Solvents used for extraction and 
chromatography were ACS or HPLC grade. Purification of reactions mixtures was performed by 
flash chromatography using SiliCycle SiliaFlash P60 (230-400 mesh).  
 1H NMR spectra were recorded on Varian vnmrs 700 (700 MHz), Varian vnmrs 500 (500 
MHz), Varian INOVA 500 (500 MHz) or Varian MR400 (400 MHz) spectrometers and chemical 
shifts (δ) are reported in parts per million (ppm) with solvent resonance as the internal standard 
(CDCl3 at δ 7.26). Data are reported as (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet; coupling constant(s) in Hz; integration). Proton-decoupled 13C NMR spectra were 
recorded on Varian vnmrs 700 (700 MHz), Varian vnmrs 500 (500 MHz), Varian INOVA 500 
(500 MHz) or Varian MR400 (400 MHz) spectrometers and chemical shifts (δ) are reported in 
ppm with solvent resonance as the internal standard (CDCl3 at δ 77.16). High resolution mass 
spectra (HRMS) were recorded on Micromass AutoSpec Ultima or VG (Micromass) 70-250-S 
Magnetic sector mass spectrometers in the University of Michigan mass spectrometry laboratory. 
Infrared (IR) spectra were recorded as thin film on a Perkin Elmer Spectrum BX FT-IR 
spectrometer. Absorption peaks were reported in wavenumbers (cm-1).  Optical rotations were 
measured in a solvent of choice on a JASCO P-2000 or Autopol III digital polarimeter at 589 nm 
(D-line) and reported as follows [α]D24 (c g/100 mL, solvent). 
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General Procedures for Selective Hydrogenation of BINOL-based Chiral Brønsted Acids 
 
In a two drams vial, Brønsted acid and 10%(w/w) of PtO2 (>75m
2/g) were added with the 
corresponding solvent mixture, and the vial was sealed with rubber septum. The vial was evacuated 
and backfilled with N2 three times, followed by H2 for another three times. The suspension was 
stirred with H2 balloon on top overnight (16 – 18 h) at room temperature. At the end of the reaction, 
the suspension was filtered through a thin pad of Cealite on top of silica gel with dichloromethane 
washing. Combined organic layer was concentrated in vacuo to yield the corresponding H8-
Brønsted acid with >98% purity.  
For large scale reaction carried out in acetic acid, the filtrate was washed with 6N HCl (aq) and 
the aqueous layer was extracted three times with dichloromethane. Combined organic layer was 
dried over Na2SO4 and concentrated in vacuo to yield the corresponding H8-Brønsted acid. 
1) H2 balloon used for the reaction was “double-bagged”. Concentration of the reaction was 
maintained accordingly so that no precipitate crashed out of the solution throughout the 
reaction to ensure the reaction would go to completion. Stirring should not be too vigorous, 
otherwise, catalyst or substrate would stick to the wall of the vial above the solvent level. 
For large scale reaction, a thicker needle should be used to ensure better delivery of H2 gas 
and round bottom flask is preferred. In general, the change of the reaction mixture from 
dark grey suspension to clear suspension is a good indication of reaction completion. 
Otherwise, reaction could be easily monitored by MS-ESI with negative ion detection. 
2) The prior exposure of BINOL-based CPAs to silica gel seems to introduce impurities that 
deactivate the catalyst. Most likely, such catalyst deactivation is due to the presence of Na+ 
and Ca2+ phosphates. Therefore, washing the inactive batches of acids with 6 M HCl is 
recommended for such cases. 
3) Some variation in the catalytic activity of platinum (IV) oxide was noticed, and in such 
instances longer reaction times were required to achieve complete reductions. In addition, 
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the catalyst slowly deactivates upon prolonged exposure to the acids. For the cases when 
incomplete conversion is observed, we recommend working up the reaction, washing the 
mixture of partially hydrogenated CPAs with 6M HCl and subjecting it to another cycle of 
hydrogenation with a new portion of catalyst. 
 
Determination of the Enantiopurity of Chiral Brønsted Acids after Hydrogenation 
To demonstrate that hydrogenation does not result in racemization, enantiopurity of acids (S)-45 
and (S)-13 obtained from hydrogenation catalyzed by Pt2O was determined. The optical rotation 
of CPAs may strongly depend on the protonation state of the acid (due to the presence of metal 
phosphate impurities). Therefore, the determination of ee’s of (S)-45 and (S)-13 was accomplished 
by reduction of acids to the corresponding H8-BINOL derivatives with LAH and measuring their 
enantiopurity by chiral HPLC as described below:  
 
Scheme 3.3. Reduction of the phosphate functionality of (S)-45 using LAH.  
(S)-45 (20.0 mg, 0.056 mmol) was dissolved in anhydrous THF (0.04M) and cooled in ice bath. 
10.6 mg of LiAlH4 (5 equiv.) was added to the reaction and the mixture was stirred and warmed 
up to rt overnight.  The reaction was quenched by slowing adding 6N HCl in ice bath (exotherm!!) 
and extracted with diethyl ether. Combined organic layers was washed with brine, dried over 
Na2SO4, filtered through glass wool plug and concentrated in vacuo to afford diol (S)-44 in 
quantitative yield.   The enantiopurity of (S)-44 was determined by HPLC analysis to be >99% ee:  
Chiralcel OD-H column (4.6 mm ϕ x 250 mm L), 95:5 hexanes:isopropanol, 1.0 ml/min flow rate, 
λ = 218 nm, tR(R) = 7.12 min, tR(S) = 8.52 min. 
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Figure 3.1. HPLC traces of (a) racemic 44 and (b) 44 obtained from reduction of (S)-45.  
 
 
Scheme 3.4. Two-steps reduction of the phosphate functionality of (S)-13. 
(S)-13 (10.0 mg, 0.013 mmol) was dissolved in DCE (0.06 M) and treated with oxalyl chloride (5 
equiv.) and catalytic amount of DMF.   The reaction was heated at 75oC and stirred overnight. 
After the reaction was done, the mixture was concentrated  in vacuo and the crude was purified by 
flash chromatography on SiO2 (30% EtOAc in hexanes) to afford phosphoryl chloride (S)-13a. 
(S)-13a was then subjected to reduction by LiAlH4 according to above mentioned procedures. The 
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corresponding diol (S)-13b was obtained after purification by prep TLC (Rf  = 0.51, 10% EtOAc 
in hexanes). The enantiopurity of (S)-13b was determined by HPLC analysis to be >99% ee:  
Chiralcel OD-H column (4.6 mm ϕ x 250 mm L), 100% hexanes, 1.0 ml/min flow rate, λ = 218 
nm, tR(R) = 4.99 min, tR(S) = 5.98 min. 
 
Figure 3.2. HPLC traces of (a) racemic 13b and (b) 13b obtained from reduction of (S)-13. 
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Characterization of H8-BINOL-based Brønsted Acids 
 
1H NMR (500 MHz, CDCl3) δ 7.97 (s, 4H), 7.91 (s, 2H), 7.16 (s, 
2H), 2.94 (m, 4H), 2.75 (ddd, J = 16.1, 8.7, 4.4 Hz, 2H), 2.48 – 2.36 
(m, 2H), 1.90 (m, 6H), 1.76 – 1.63 (m, 2H) 
13C NMR (126 MHz, CDCl3) δ 153.39, 153.24, 153.09, 144.28, 
144.21, 140.36, 139.89, 135.63, 130.55, 130.23, 128.18, 128.01, 
122.22, 29.27, 28.13, 22.60, 22.46 
19F NMR (377 MHz, CDCl3) δ 81.70 (t, J = 151.3 Hz, 1F), δ 62.61 
(d, J = 150.3 Hz, 4F) 
31P NMR (162 MHz, CDCl3) δ 2.71 
HRMS (ESI neg.) m/z calcd for C32H25F20O4PS4 [M-H]
- 1010.9981, 
found 1010.9976 
IR (thin film, cm-1) 2940, 1445, 1258, 1100, 840. 
 
 
 
Characterizations of product match with previously reported data.5 
 
 
 
Characterizations of product match with previously reported data.6 
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1H NMR (500 MHz, CDCl3) δ 7.97 (s, 4H), 7.91 (s, 2H), 7.16 (s, 
2H), 2.94 (m, 4H), 2.75 (ddd, J = 16.1, 8.7, 4.4 Hz, 2H), 2.48 – 2.36 
(m, 2H), 1.90 (m, 6H), 1.76 – 1.63 (m, 2H) 
13C NMR (126 MHz, CDCl3) δ 153.39, 153.24, 153.09, 144.28, 
144.21, 140.36, 139.89, 135.63, 130.55, 130.23, 128.18, 128.01, 
122.22, 29.27, 28.13, 22.60, 22.46 
19F NMR (377 MHz, CDCl3) δ 81.70 (t, J = 151.3 Hz, 1F), δ 62.61 
(d, J = 150.3 Hz, 4F) 
31P NMR (162 MHz, CDCl3) δ 2.71 
HRMS (ESI neg.) m/z calcd for C32H25F20O4PS4 [M-H]
- 1010.9981, 
found 1010.9976 
IR (thin film, cm-1) 2940, 1445, 1258, 1100, 840. 
 
 
 
Characterizations of product match with previously reported data.6 
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1H NMR (500 MHz, CD2Cl2) δ 7.31 (m, 6H), 7.14 (s, 2H), 2.91 (m, 
4H), 2.75 (ddd, J = 12.6, 8.5, 4.6 Hz, 2H), 2.40 (dt, J = 16.8, 5.4 Hz, 
2H), 1.89 (m, 6H), 1.78 – 1.63 (m, 2H), 1.23 (s, 36H) 
13C NMR (176 MHz, CD2Cl2) δ 150.88, 143.82, 137.53, 137.10, 
135.47, 133.28, 131.90, 127.74, 124.42, 121.55, 35.25, 31.79, 
29.75, 28.33, 23.33, 23.27 
31P NMR (162 MHz, CD2Cl2) δ 0.27 
HRMS (ESI neg.) m/z calcd for C48H61O4P [M-H]
- 731.4235, found 
731.4221 
IR (thin film, cm-1) 2952, 1595, 1408, 1362, 1248, 1018, 918, 873. 
 
 
1H NMR (500 MHz, CDCl3) δ 7.18 (s, 4H), 7.13 (s, 2H), 6.94 (s, 
2H), 2.92 – 2.75 (m, 4H), 2.70 (ddd, J = 12.4, 8.5, 4.4 Hz, 2H), 2.41 
– 2.33 (m, 2H), 1.84 (s, 6H), 1.69 – 1.56 (m, 2H), 1.26 (s, 4H), 1.13 
(dd, J = 6.3, 4.6 Hz, 24H) 
13C NMR (126 MHz, CDCl3) δ 148.57, 143.30, 137.29, 137.10, 
134.88, 132.39, 131.21, 129.17, 128.36, 127.38, 125.48, 123.30, 
34.16, 29.37, 27.97, 24.27, 23.92, 22.89, 22.79 
31P NMR (202 MHz, CDCl3) δ -0.96 
HRMS (ESI neg.) m/z calcd for C44H53O4P [M-H]
- 675.3609, found 
675.3606 
IR (thin film, cm-1) 2957, 1597, 1448, 1276, 1220, 1020, 966, 922, 
871. 
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Characterizations of product match with previously reported data.7 
 
 
 
Characterizations of product match with previously reported data.8 
 
 
Characterizations of product match with previously reported data.9 
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1H NMR (700 MHz, CDCl3) δ 7.87 (s, 2H), 7.80 (s, 2H), 7.74 (s, 
2H), 7.14 (s, 2H), 2.99 – 2.88 (m, 4H), 2.45 – 2.27 (m, 4H), 1.89 
(m, 2H), 1.87 – 1.76 (m, 6H) 
13C NMR (176 MHz, CDCl3) δ 144.94, 141.11, 138.82, 138.79, 
135.89, 133.89, 130.70, 128.48, 124.15, 122.60, 121.78, 30.32, 
28.02, 22.64, 22.03 
19F NMR (377 MHz, CDCl3) δ -62.70 (d, J = 11.7 Hz) 
HRMS (ESI neg.) m/z calcd for C36H25F12NO4S2 [M-H]
- 826.0961, 
found 826.0956 
IR (thin film, cm-1) 2936, 1553, 1368, 1276, 1178, 1127, 896, 846. 
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CHAPTER 4 
Method for Determining Enantiopurity of Chiral Phosphoric Acids Based on 31P NMR and 
the Use of Chiral Amines as Discriminating Agents 
(This chapter was partially published in: Tay, J. H.; Nagorny, P. Synlett 2016, 27, 551.) 
 
4.1 Introduction 
Motivated by the goal of improving the preparation of chiral Brønsted acids, we developed 
a new method to synthesize H8-BINOL-based chiral acids derived from a single step 
hydrogenation of BINOL-derived chiral acids.1 The hydrogenation was performed in the presence 
of platinum (IV) oxide, which prompted us to examine if the chiral Brønsted acids underwent 
racemization under such reaction conditions. As we searched for a method to determine the 
enantiomeric excess of the CPA generated in the study, we learned that there is no straightforward 
method for accessing the enantiopurity of CPAs, and that there is very limited information about 
the racemization barrier for BINOL- and H8-BINOL-based CPAs.  
Generally, HPLC analysis is one of the most reliable techniques for determining the 
enantiopurity of chiral compounds. Nonetheless, HPLC analysis requires the use of a specialized 
equipment that is expensive and often not readily available in every lab. Furthermore, the analysis 
is highly substrate specific, and the development of HPLC assays is time consuming because of 
the large number of parameters for optimization (i.e. column type, eluent composition, flow rate, 
etc.). Alternatively, enantiopurity of CPA can be calculated based on the optical rotation 
measurement if the reference value is available. Unfortunately, very few specific optical rotation 
measurements of CPA compounds have been reported in the literature. Moreover, optical rotation 
analysis can be unreliable if the sample of CPA contains phosphate salt impurities. The major 
drawbacks of these analysis inspired us to develop a simple and reliable method for evaluating the 
enantiopurity of CPAs. 
90 
 
4.2 Experimental Designs 
A brief survey of the literature revealed that phosphorus (V)2 and phosphorus (III)3 
compounds are used as chiral complexing agents to determine the enantiopurity of various 
alkaloids, amines, alcohols, amino acids and carboxylic acids based on1H NMR analysis. For 
example, CPA and chiral amine could form diastereomeric ion pairs which typically have distinct 
physical properties such as solubility, melting point and spectral characteristics. However, the 
reserve analysis was not known. In other words, there was no report on the determination of the 
enantiopurity of chiral phosphorus compounds in the presence of a chiral discrimination agent. 
Based on literature precedents, we hypothesized that a chiral amine would undergo irreversible 
protonation by CPA and form a mixture of diastereomeric ammonium phosphates (Scheme 4.1). 
The key to the analysis relied on the integration of the diastereomeric 31P NMR signal produced 
by the ion pairs. 31P NMR spectrum is simple, contains less signals, and was therefore ideal for the 
analysis. 
 
Scheme 4.1. Proposed method for analysis of enantiopurity of chiral phosphoric acids in the 
presence of a chiral amine as NMR discriminating agent.  
 
4.3 Results and Discussion 
After a series of screenings, commercially available amino alcohol 57 was identified as a 
suitable chiral discriminating agent. When a racemic mixture of CPA 17 was combined with 1.5 
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equivalents of 57 in deuterated chloroform, we observed two nonequivalent 31P NMR signals 
(Figure 4.1). More importantly, the diastereomeric 31P signals were observed with good resolution 
(Δδ = 2.69ppm), which allowed the accurate integration of those signals.  
 
Figure 4.1. Resolution of 31P signals of CPA 13 in the presence of chiral amine 57.  
The method was applicable to the analysis of most CPAs tested (Table 4.1), except for 
CPA 7 and 8. In those cases, chiral amine 58 was identified as an alternative chiral discriminating 
agent for the same analysis (entries 6 – 8). Addtitionally, the method tolerated measurement at 
different concentrations without compromising the accuracy of the analysis (entries 4 – 7).  
 
Table 4.1. Resolution of 31P signals of various CPAs in the presence of a chiral amine as NMR 
discriminating agent. 
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Figure 4.2. Structures of discriminating agents 57, 58 and CPAs.  
 
With regard to substrate scope, a mixture of 57 and H8-BINOL-derived CPAs 12 or 46 
also exhibited well resolved diastereomeric 31P peaks (Table 4.1, entries 9 and 10). The method 
was also found to be applicable to analysis of N-trifly phosphoramide 15, even though a lower 
resolution was observed (entry 11). To determine the accuracy of the method, we constructed a 
calibration curve that compared the actual enantiopurity of CPA samples and the ee measured by 
integration of 31P NMR signals (Figure 4.3). An excellent linear correlation was observed for the 
measurements (R2 = 0.999) and the average absolute error was found to be less than 1.1%. We 
concluded that the method is reliable and accurate. 
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Figure 4.3. (a) 31P NMR spectra of non-racemic mixture of CPA 17 in the presence of chiral 
discriminating agent 57. (b) Calibration curve showing linear correlation between %ee determined 
by 31P NMR and %ee based on gravimetric analysis.  
 
Next, we utilized the method to evaluate the enantiopurify of CPA after the hydrogenation 
reaction in the presence of Pt2O. Previously, we had to reduce the phosphate group of the H8-
BINOL-based CPA product using LiAlH4, and measure the ee of the resulting diol using HPLC 
analysis. Now, the new method based on 31P NMR analysis and the use chiral amine as 
discriminating agent provided a significantly faster and simpler way of assessing the enantiopurity 
of the CPA product. Consistent with our prior result, the analysis based on 31P NMR indicated that 
(R)-12 synthesized from hydrogenation of (R)-17 was enantiopure (Scheme 4.2). In other words, 
(R)-17 did not epimerize under the hydrogenation conditions in the presence of Pt2O. 
 
Scheme 4.2. Application of 31P NMR in combination of chiral discriminating agent to determine 
the enantiopurity of CPA after hydrogenation catalyzed by Pt2O. 
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To further demonstrate the applied use of the new method, we utilized the method to 
investigate the thermal racemization of CPA. BINOL and BINOL-derived phosphate methyl ester 
had been reported to racemize when being heated, with half-life, t1/2 = 60 min and 100 min 
respectively at 220oC.4 However, no information was known about the thermal stability of BINOL- 
and H8-BINOL-derived phosphoric acids. Enantiopure (R)-17 and its H8-BINOL-derived analog 
(R)-12 were subjected to heating at high temperatures, and their enantiopurities were measured 
afterward using the 31P NMR method.  
After (R)-17 was subjected to heating at 200oC in dichlorobenzene, we measured a 4% loss 
in ee after the reaction ran for 24 h. (R)-17 underwent even faster epimerization at 220oC, with 
enantiopurity measured at 84% ee after 18 h. Further elevation of the temperature to 250oC led to 
decomposition of (R)-17. On the other hand, enantiopure (R)-12 was isolated after being heated 
at 220oC for 18 h. The results indicated therefore that H8-BINOL-derived CPA with saturated H8-
BINOL backbone is configurationally more stable compared to its unsaturated analog under 
thermal stress. 
 
Table 4.2. Application of 31P NMR analysis to the study of BINOL-based and H8-BINOL-based 
CPA epimerization under thermal stress.  
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4.4 Conclusion 
In summary, we developed a simple, quick and reliable method to determine the 
enantiopurity of chiral phosphoric acids using commercially available chiral amine as a 
discriminating agent and 31P NMR analysis. The method is general and excellent resolution was 
observed for a series of CPAs tested. Using the method, we also studied the enantio-stability of 
CPA under hydrogenation and thermal conditions. We found that BINOL-and H8-BINOL-derived 
CPAs do not epimerize under hydrogenation condition in the presence of Pt2O. However, H8-
BINOL-drived CPAs are configurationally more stable than its BINOL-based analog when they 
are subjected to thermal stress.
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4.5 Experimental Information 
General Methods 
All reagents and solvents were purchased from Sigma-Aldrich, Fisher Scientific, Corvinus 
Chemicals and were used as received without further purification unless specified. Heating was 
achieved by use of a sand bath with heating controlled by electronic contact thermometer. 
Deionized water was used in the preparation of all aqueous solutions and for all aqueous 
extractions. Solvents used for extraction and chromatography were ACS or HPLC grade. 
Purification of reactions mixtures was performed by flash chromatography using SiliCycle 
SiliaFlash P60 (230-400 mesh).  
1H NMR spectra were recorded on Varian vnmrs 700 (700 MHz), Varian vnmrs 500 (500 MHz), 
Varian INOVA 500 (500 MHz) or Varian MR400 (400 MHz) spectrometers and chemical shifts 
(δ) are reported in parts per million (ppm) with solvent resonance as the internal standard (CDCl3 
at δ 7.26). 31P NMR spectra were recorded on Varian vnmrs 700 (283 Mhz) and referenced to 
residue CHCl3 
1H signal at δ 7.26 by absolute referencing.  
 
General Procedures for Enantiopurity Determination based on NMR Discrimination 
10 mg of nonracemic chiral phosphoric acid* was mixed with 1.5 equivalent of discriminating 
agent in 0.6 mL of CDCl3 in NMR tubes. 
31P spectrum of the mixture was measure and the ee% 
was calculated based on the following formula: 
𝑒𝑒% =  
(𝑎𝑟𝑒𝑎 𝑜𝑓 𝑚𝑎𝑗𝑜𝑟 𝑝𝑒𝑎𝑘) − (𝑎𝑟𝑒𝑎 𝑜𝑓 𝑚𝑖𝑛𝑜𝑟 𝑝𝑒𝑎𝑘)
𝑎𝑟𝑒𝑎 𝑜𝑓 𝑚𝑎𝑗𝑜𝑟 𝑝𝑒𝑎𝑘 + 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑚𝑖𝑛𝑜𝑟 𝑝𝑒𝑎𝑘
∗ 100% 
*CPA was dissolved in DCM, washed with 6N HCl (aq) and dried over Na2SO4 prior to analysis.  
 
General Procedures for Thermal Racemization Studies 
10 mg of CPA was dissolved in either 0.5 mL of 1,2-dichlorobenene or 0.5 gr of biphenyl. The 
mixture was heated in a sealed 1 dr vial using sand bath. When the experiment was done, 1,2-
dichlorobenzene was removed by blow-drying under a stream of N2, while biphenyl was removed 
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by flash chromatograph on SiO2 (100% hexanes then 1:1 hexanes/EtOAc). The resulting crude 
CPA was mixed with 1.5 equivalent of discriminating agent in CDCl3 and 
31P NMR spectrum was 
taken to determine the enantiopurity of CPA. 
 
Calibration Curve for 31P NMR Analysis of 17 in the Presence of Discriminating Agent 57 
Nonracemic mixtures of 17 at various %ee were accurately prepared by mixing standard solutions 
of (R)- and (S)-17 in CDCl3. 
Entry Expected %ee %ee by 31P-NMR Error % 
1 0.0 0.0 0.0 
2 5.0 4.7 0.3 
3 10.0 13.6 3.6 
4 20.0 20.5 0.5 
5 30.0 31.6 1.6 
6 50.0 52.7 2.7 
7 70.0 70.9 0.9 
8 80.0 80.2 0.2 
9 90.0 90.5 0.5 
10 95.0 96.1 1.1 
11 100.0 100.0 0.0 
  Average 1.0 
 
Table 4.3. Comparison between %ee based on gravimetric analysis and %ee based on 31P NMR 
analysis. 
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Figure 4.4. Calibration curve showing linear correlation between %ee determined by 31P NMR 
and %ee based on gravimetric analysis. 
 
 
31P NMR Spectra of CPAs in the Presence of Chiral Discriminating Agent 
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CHAPTER 5 
An Efficient One-pot Protocol for the Synthesis of Natural Product Glycosides Based on 
the Use of Boronic Acid as Transient Protecting Group 
 
5.1 Introduction 
Organoboron compounds play a significant role in the development of carbohydrate 
chemistry.1 In 1953, Soboczenski reported the preparation of various cyclic boronate compounds 
through condensation of phenylboronic acid with diols and monosaccharides such as sorbitol and 
mannitol.2 Since then, the complexation of organoboron compounds and carbohydrates has been 
the subject of rigorous studies and the phenomenon has been utilized in various applications such 
as chromatographic science, analytical sensing, biological imaging, drug delivery and chemical 
synthesis.  
Boronic acid is especially useful as a protecting group for diol moiety. In 1978, Fréchet 
demonstrated the potential of polystyrylboronic acid resin as a solid support to selectively 
synthesize acylated monosaccharide derivatives (Scheme 5.1 (a)).3 The boronic acid on the resin 
acted as a both protecting group for cis diols on carbohydrate substrates and the linker that 
connected substrates to the solid support. The same strategy was later adopted by Boons to 
synthesize dissacharide compounds on solid support (Scheme 5.1 (b)).4  
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Scheme 5.1. Utilization of polystyrylboronic acid as a solid support in (a) acylation and (b) 
glycosylation of monosaccharides.  
 
Beyond synthesis of simple carbohydrate derivatives, boronic acid has not been widely 
used in the glycosylation of natural products. One of the few examples was reported by Harmatha 
in 1994.5 In his synthesis of 20-hydroxyecdysone glycoside, phenylboronic acid was used to 
selectively protect vicinal-diol on the D-ring side chain. After acylation of the C2-hydroxy group 
on the A-ring, glycosylation with glycosyl bromide and silver silicate resulted in the formation of 
a 1:1 mixture of C3-glycoside and C25-glycoside. To further demonstrate the utility of boronic 
acid in the synthesis of natural product glycoside, we aimed to develop a strategy toward the 
selective glycosylation of bacterial macrolactones and cardiotonic steroids that is operationally 
simple and efficient with regard to pot economy. We envisioned that the protection, deprotection 
and glycosylation of a natural product could be incorporated in a one-pot protocol through the 
judicious selection of reaction conditions.  
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Scheme 5.2. Synthesis of 20-hydroxyecdysone glycosides involving the use of phenylboronic acid 
as the protecting group for vicinal diol.  
 
5.2 One-pot Glycosylation of Antibiotic-derived Macrolactones 
During our optimization for regioselective glycosylation of 6-dEB6, we observed that the 
C11-hydroxyl group on the macrolactone was the least accessible for glycosylation. Since the C3- 
and C5-hydroxy groups were in a 1,3-syn relationship, we surmised that they could be selectively 
masked as boronate ester enabling glycosylation to occur at the C11-position. Indeed, the diol was 
successfully protected in situ by using phenylboronic acid in the presence of a 4Å molecular sieve 
as the dehydrating agent (Scheme 5.3). Subsequent glycosylation with trichloroacetimidate donor 
2 and TMSOTF in the same pot, followed by a peroxide work-up, afforded the C11-glycoside 59 
with good yield. 
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Scheme 5.3. One-pot synthesis of C11-glycoside 59 from 6-dEB (1). 
 
In addition, the one-pot protocol was applied to the synthesis of C11-glycoside 60 from 
oleandomycin-derived macrolactone 25 (Scheme 5.4). Due to the presence of thioether, which 
could be oxidized during the peroxide work-up, methyl boronic acid was used instead. The methyl 
boronic ester was cleaved at the end of the reaction upon multiple azeotrope treatments with 
methanol. 
 
Scheme 5.4. One-pot synthesis of C11-glycoside 60 from macrolactone 25. 
 
5.3 Introduction to Cardiotonic Steroids  
Cardiotonic steroids are an interesting class of small molecules which exhibit a diverse 
range of biological activities.  Many members of the class have been extensively studied for their 
therapeutic values in treating heart related diseases, such as congestive heart failure and cardiac 
arrhythmia.7  More recently, their actions on the cellular sodium-potassium ATPase pump have a 
been explored in the context of cancer treatment.8 Nonetheless, the actual implementation of 
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cardiotonic steroids as therapeutic agents is still limited and challenging due to their toxic 
properties.9 To circumvent the problem, numerous efforts have been focused on making analogues 
of cardiotonic steroids through total or semi-synthesis to identify compounds with improved 
therapeutic windows.10   
Most cardiotonic steroids consist of a core structure of fuse rings, a lactone moiety at the 
C17 position and a sugar moiety connected through the C3-hydroxy group (Figure 5.1). SAR 
studies show that all the three major components of a cardiotonic steroid plays significant roles in 
determining its biological activities.11 Given the rich structural diversity of natural and unnatural 
sugar, we believe that manipulation of the sugar moiety at the C3 position provides one of the most 
efficient routes to generate a library of cardiotonic steroid analogues. 
 
Figure 5.1. Structure of ouabain, a cardiotonic steroid.  
 
 While there is a plethora of methods developed for the formation of glycosidic linkages, 
the glycosylation of polyoxygenated natural products such as the steroidal core is not trivial, 
mainly because of regioselectivity issues. In 2017, Nagorny reported the total synthesis of 
cannogenol (a cardiotonic steroid) and its rhamnoside.12 In an attempt to accomplish selective 
installation of rhamnose sugar at the C3-alcohol, a triol intermediate was subjected to 
glycosylation with rhamnose-derived trichloroacetimidate donor and TMSOTf as activator. 
(Scheme 5.5) Nonetheless, the reaction led to the formation of about 1:1 mixture of two 
regioisomeric glycosides.  
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Scheme 5.5. Example of unselective glycosylation of steroidal compound.  
 
In most synthesis of cardiac glycosides, a multistep protection/deprotection sequence is 
commonly used to ensure selective delivery of a sugar unit at the desired C3 hydroxy group.10 For 
example, in the total synthesis of ouabain developed by Deslongchamps, the rhamnose sugar was 
installed onto the aglycone of ouabain (ouabagenin) through a six steps sequence.13 (Scheme 5.6) 
Five steps out of the sequence involved protecting group manipulation, and the overall yield for 
the whole sequence ended up being 35%. Clearly, a more efficient protocol for the installation of 
glycone onto steroidal core is warranted.  
 
 
Scheme 5.6. Synthesis of ouabain from ouabagenin developed by Deslongchamps.  
 
110 
 
To streamline the synthesis of new cardiotonic steroids with different sugar moiety, we set 
out to develop a pot-efficient protocol for the coupling between the steroidal core and the sugar 
based on the use of boronic acid as the transient protecting group. 
 
5.4 One-pot Glycosylation of Strophanthidol 
We first tested our protocol using strophanthidol (61) as the substrate. Strophanthidol has 
two pairs of hydroxy groups in a 1,3-relationship: C3/C5 alcohols and C5/C19 alcohols. We 
hypothesized that methyl boronic acid would preferably form cyclic ester with the C5 and C19 
hydroxy groups because the primary alcohol at the C19 position is sterically more accessible. 
Indeed, after we mixed strophanthidol (61) with methyl boronic acid in the presence of the 4Å 
molecular sieves in dichloromethane, we were able to obtain a single compound containing methyl 
boronic ester moiety with quantitative mass recovery (Scheme 5.7). We subsequently subjected 
the isolated boronic ester intermediate to a glycosylation condition with a benzyl protected fucose 
trichloroacetimidate donor 26 and TMS-OTf as the activator. Upon work up with MeOH to remove 
the methyl boronic acid masking group, we observed exclusive formation of C3-glycoside 62, 
albeit with moderate yield and low diastereoselectivity. The result however supports our initial 
hypothesis that the formation of cyclic boronate at the C5 and C19 hydroxy groups of 
strophanthidol is favored exclusively.  
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Scheme 5.7. Initial studies on boronic acid protection of strophanthidol (61) and subsequent 
glycosylation.  
 
Next, we moved on to optimize the conditions for the glycosylation step.  To address the 
problem of low diastereoselectivity, we switched the protecting group on the glycosyl donor from 
a benzyl to a benzoate group to take advantage of the anchimeric effect. After the first step for the 
formation of boronated protected strophanthidol, glycosyl donor 63 and the catalyst were added to 
the same reaction pot to initiate glycosylation (Table 5.1). We tested several general conditions for 
the activation of the trichloroacetimidate donor, and we found most Lewis acid activators were 
inefficient in promoting the glycosylation reaction (entries 1 – 3).  However, when TfOH was used 
as the activator we were able to obtain a significantly better conversion and isolated yield (entry 
4). We also noticed that the isolated yield increased by two-fold, from 37% to 76%, when portions 
of the glycosyl donor were added to the reaction at 30 minute intervals (entry 5). Through further 
optimization, we were able to obtain the C3-rhamnoside of strophanthidol 64 with good yield and 
exclusive formation of the α-glycosidic linkage (entry 6). 
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Table 5.1. Optimization for one-pot glycosylation of strophanthidol (1) with a benzoyl-protected 
donor 63. 
 
To further enhance the efficiency of our protocol, we incorporated a deprotection condition 
that could remove both methyl boronic ester and the benzoate protecting group on the sugar at the 
end of the reaction. After the glycosylation was complete, the reaction was diluted with MeOH, 
bubbled with NH3 gas and stirred at room temperature overnight (Table 5.2). After flash 
chromatography on silica gel, we were able to isolate the totally unprotected rhamnoside of 
strophanthidol 69 with good yield (entry 1). Using the one-pot protocol, we also synthesized 
strophanthidol glycoside with unprotected L-fucose (70) and D-fucose (71) at the C3 position with 
good yield. When we applied the same strategy to couple glucose and mannose to strophanthidol, 
we noticed a significant formation of an ortho ester by-product. Previously, Kihlberg and coworker 
have reported the use of a fluorine substituted benzoate group as the protecting group on the sugar 
donor to minimize the formation of ortho ester during glycosylation.14 Indeed, when we used 2-
fluoro-benzoate protected glucose and mannose trichloroacetimidate donor (67 and 68) in our 
reaction, the formation of ortho ester was suppressed. We were able to synthesize the 
corresponding D-glucoside (72) and D-mannoside (73) of strophanthidol with good yield.  In all, 
our one-pot protocol has allowed us to efficiently synthesize five glycosides of strophanthidol, 
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three of which are new glycosides (70, 71 and 73) that have not been reported in the literature to 
date. 
 
Table 5.2. The substrate scope for one-pot glycosylation of strophanthidol (61).  
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5.5 One-pot Glycosylation of Anhydro-ouabagenin 
 Next, we applied the one-pot protocol to the glycosylation of another cardiotonic steroid, 
anhydro-ouabagenin (74). As before, we observed the formation of a single boronate compound 
by 1H NMR when 74 was mixed with methyl boronic acid in the presence of the 4Ǻ molecular 
sieve (Scheme 5.8 (a)). However, when the isolated boronate compound was subjected to 
glycosylation with donor 63 and TfOH as the activator, the reaction resulted in a mixture of C3-
glycoside 75 and C19-glycoside 76. We believed the boronate intermediate underwent 
isomerization under the acidic conditions and consequently led to unselective glycosylation at the 
C3 and C19 positions (Scheme 5.8 (b)). Similar intramolecular migration of a boronate group was 
previously reported by Taylor.15 
 
Scheme 5.8. (a) One-pot glycosylation of anhydro-ouabagenin (74) with trichloroacetimidate 
donor and TfOH as the activator. (b) Proposed isomerization of a boronate compound derived from 
anhydro-ouabagenin (74).  
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To circumvent the problem of unselective glycosylation, we explored other glycosylation 
methods that might minimize undesired isomerization of the boronate intermediate. We postulated 
that the isomerization could be minimized if a milder or neutral glycosylation condition with 
glycosyl halide were employed.  Upon further screening, we identified glycosylation with glycosyl 
bromide 77 and Ag2CO3 as the optimum condition to generate C3-glycoside 75 with good yield 
and much improved regioselectivity (Scheme 5.9).  
 
Scheme 5.9. One-pot glycosylation of anhydro-ouabagenin (74) with glycosyl bromide donor 77 
and Ag2CO3 as activator. 
 
5.6 Conclusion 
In summary, the one-pot protocol provided an operationally simple and efficient route to 
synthesize glycosides from poly-oxygenated natural products. Simple boronic acids were proven 
to be highly effective transient protecting groups for complex natural products containing 1,3-diol 
moiety. The one-pot protocol allowed us to selectively generate glycosides from antibiotic-derived 
macrolactones and cardiotonic steroid cores that are otherwise difficult to access.   
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5.7 Experimental Information 
General Methods 
All reagents and solvents were purchased from Sigma-Aldrich, Fisher Scientific, and were 
used as received without further purification unless specified. 4Å molecular sieve was activated 
prior to use by heating under reduced pressure. Cooling was achieved by use of cryocool machine 
or ice bath. Deionized water was used in the preparation of all aqueous solutions and for all 
aqueous extractions. Solvents used for extraction and chromatography were ACS or HPLC grade. 
Purification of reactions mixtures was performed by flash chromatography using SiliCycle 
SiliaFlash P60 (230-400 mesh).  
 1H NMR spectra were recorded on Varian vnmrs 700 (700 MHz), Varian vnmrs 500 (500 
MHz), Varian INOVA 500 (500 MHz) or Varian MR400 (400 MHz) spectrometers and chemical 
shifts (δ) are reported in parts per million (ppm) with solvent resonance as the internal standard 
(CDCl3 at δ 7.26, CD3OD at δ 3.31, C6D6 at δ 7.16). Data are reported as (br = broad, s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet; coupling constant(s) in Hz; integration). Proton-
decoupled 13C NMR spectra were recorded on Varian vnmrs 700 (700 MHz), Varian vnmrs 500 
(500 MHz), Varian INOVA 500 (500 MHz) or Varian MR400 (400 MHz) spectrometers and 
chemical shifts (δ) are reported in ppm with solvent resonance as the internal standard (CDCl3 at 
δ 77.16, CD3OD at 49.0, C6D6 at 128.06). High resolution mass spectra (HRMS) were recorded 
on Micromass AutoSpec Ultima or VG (Micromass) 70-250-S Magnetic sector mass 
spectrometers in the University of Michigan mass spectrometry laboratory. Infrared (IR) spectra 
were recorded as thin film on a Thermo-Nicolet IS-50 spectrometer. Absorption peaks were 
reported in wavenumbers (cm-1).  Optical rotations were measured in a solvent of choice on a 
JASCO P-2000 or Autopol III digital polarimeter at 589 nm (D-line). 
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Synthesis of Glycoside 59 
 
6-dEB (5mg, 0.010mmol), PhB(OH)2 (1.2mg, 1 equiv.) and 10mg of powdered 4Å molecular sieve 
were stirred in 100μL of dry toluene at room temperature. After 3h, sugar donor 2 (17.4mg, 3 
equiv.) in 100μL of dry toluene was added to the reaction, and the mixture was cooled to -20oC. 
TMS-OTf (0.36μL, 0.2 equiv.) in 20μL of dry toluene was added to the reaction. After 17h, the 
reaction was quenched with Et3N, warmed up to room temperature and diluted with EtOAc. 30% 
H2O2, sat. NaHCO3 and water were added to the solution, and the suspension was stirred at room 
temperature. After 2h, the reaction was extracted with CH2Cl2 twice. Combined organic was dried 
over Na2SO4, filtered through glass wool and concentrated under reduced pressure. The crude 
mixture was purified by flash column chromatography (pipette column) on silica gel 
(EtOAc:Hexanes, 20:80 to 35:65 v/v) to obtain 59 (5mg, 62% yield) as colorless oil and starting 
material 6-dEB (1.5mg, 38% recovery). The diastereomeric glycosides were isolated by semi-prep 
HPLC (18mL/min, EtOAc:Hexanes, 25:75 v/v) and characterized.  
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1H NMR (500 MHz, C6D6): δ 7.41 (d, J = 7.4 Hz, 2H), 7.32 (d, J = 7.4 Hz, 2H), 7.26 (d, J = 7.2 
Hz, 2H), 7.11 – 7.01 (m, 3H), 5.83 (t, J = 7.3 Hz, 1H), 5.63 (d, J = 3.4 Hz, 1H), 5.01 (d, J = 11.5 
Hz, 1H), 4.98 (d, J = 10.7 Hz, 1H), 4.86 (d, J = 11.2 Hz, 1H), 4.80 (t, J = 11.5 Hz, 2H), 4.53 (d, J 
= 11.2 Hz, 1H), 4.15 (m, 2H), 4.05 (dq, J = 12.0, 6.0 Hz, 1H), 3.99 (d, J = 10.4 Hz, 1H), 3.67 (m, 
1H), 3.52 (dd, J = 10.1, 3.4 Hz, 1H), 3.09 (m, 2H), 2.96 (s, 1H), 2.73 (dq, J = 13.4, 6.7 Hz, 1H), 
2.64 (q, J = 6.5 Hz, 1H), 1.87 – 1.77 (m, 1H), 1.70 (m, 1H), 1.65 (m, 1H), 1.54 (d, J = 6.0 Hz, 3H), 
1.49 (d, J = 6.7 Hz, 3H), 1.32 (d, J = 6.2 Hz, 3H), 1.26 (d, J = 6.6 Hz, 3H), 1.20 (m, 2H), 1.03 (d, 
J = 6.8 Hz, 3H), 1.00 – 0.93 (m, 1H), 0.81 (d, J = 7.1 Hz, 3H), 0.62 (d, J = 7.1 Hz, 3H), 0.48 (t, J 
= 7.3 Hz, 3H). 
13C NMR (126 MHz, C6D6): δ 211.0, 176.8, 139.9, 139.3, 139.3, 128.7, 128.5, 128.4, 128.2, 128.0, 
127.8, 127.6, 127.5, 100.8, 85.0, 83.6, 82.0, 81.9, 79.0, 76.4, 75.6, 75.4, 75.4, 75.0, 69.1, 44.8, 
44.2, 41.4, 39.3, 38.5, 38.0, 35.3, 26.1, 18.3, 16.7, 15.4, 13.9, 10.0, 9.9, 7.8, 7.4. 
HRMS (m/z): [M+NH4]
+ calcd. for C48H66O10, 820.5000; found, 820.4979 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.3  
IR (thin film, cm-1): 3438, 2967, 2919, 2855, 1710, 1453, 1070 
[α]D: -3.2 (c = 0.10 in CHCl3) 
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1H NMR (700 MHz, C6D6): δ 7.46 (d, J = 7.5 Hz, 2H), 7.27 (d, J = 7.5 Hz, 2H), 7.19 (t, J = 7.6 
Hz, 4H), 7.15 – 7.02 (m, 5H), 5.76 (dd, J = 8.3, 6.1 Hz, 1H), 5.07 (d, J = 11.4 Hz, 1H), 4.86 (d, J 
= 11.4 Hz, 1H), 4.76 (d, J = 11.4 Hz, 1H), 4.72 (d, J = 11.4 Hz, 1H), 4.67 (d, J = 11.4 Hz, 1H), 
4.50 (d, J = 9.1 Hz, 1H), 4.40 (d, J = 7.3 Hz, 1H), 4.39 (d, 1H), 3.91 (d, J = 10.1 Hz, 1H), 3.78 – 
3.71 (m, 1H), 3.55 (dd, J = 9.2, 7.4 Hz, 1H), 3.48 (t, J = 9.0 Hz, 1H), 3.35 (dq, J = 9.6, 6.1 Hz, 1H), 
3.29 (ddt, J = 12.3, 9.3, 6.0 Hz, 1H), 3.14 (t, J = 9.1 Hz, 1H), 2.76 – 2.67 (m, 2H), 2.65 (s, 1H), 
1.89 (q, J = 6.7 Hz, 1H), 1.80 – 1.76 (m, 1H), 1.74 (m, 1H), 1.64 – 1.58 (m, 1H), 1.57 – 1.52 (m, 
1H), 1.40 (d, J = 6.8 Hz, 3H), 1.36 (d, J = 6.1 Hz, 3H), 1.33 (m, 1H), 1.28 (d, J = 6.7 Hz, 3H), 1.17 
(d, J = 6.3 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.04 (td, J = 13.6, 3.5 Hz, 1H), 0.87 (d, J = 7.1 Hz, 
3H), 0.84 (t, J = 7.4 Hz, 3H), 0.79 (d, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, C6D6): δ 214.1, 174.8, 139.8, 139.4, 139.3, 128.5, 128.5, 128.4, 128.4, 128.3, 
127.8, 127.7, 127.7, 127.5, 99.4, 84.8, 83.6, 83.2, 78.3, 76.1, 75.8, 75.5, 75.2, 75.1, 74.9, 71.6, 
44.0, 43.9, 41.0, 39.6, 39.0, 38.7, 35.5, 26.7, 18.2, 17.2, 15.1, 14.3, 10.7, 10.2, 8.0, 7.5. 
HRMS (m/z): [M+NH4]
+ calcd. for C48H66O10, 820.5000; found, 820.4989 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.4 
IR (thin film, cm-1): 3489, 2971, 2928, 2880, 1733, 1702, 1453, 1071 
[α]D: -42.3 (c = 0.23 in CHCl3) 
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Synthesis of Glycoside 60 
 
25 (10mg, 0.020mmol), MeB(OH)2 (1.2mg, 1 equiv.) and 20mg of powdered 4Å molecular sieve 
were stirred in 200μL of dry toluene at room temperature. After 5h, sugar donor 22 (35mg, 3 equiv.) 
in 150μL of dry toluene was added to the reaction, and the mixture was cooled to -20oC. TMS-
OTf (1.8μL, 0.5 equiv.) in 50μL of dry toluene was added to the reaction. After 17h, the reaction 
was quenched with Et3N, warmed up to room temperature and stirred with MeOH for 30 minutes. 
Next, the reaction was filtered through a short pad of Celite with CH2Cl2 washing and concentrated 
under reduced pressure. The crude mixture was purified by flash column chromatography (pipette 
column) on silica gel (EtOAc:Hexanes, 20:80 to 60:40 v/v) to obtain 60 (8.7mg, 48% yield) as 
yellow oil and starting material 25 (4.6mg, 46% recovery). 
1H NMR (700 MHz, CDCl3): δ 7.43 – 7.27 (m, 17H), 7.23 (t, J = 7.2 Hz, 2H), 7.15 (t, J = 7.3 Hz, 
1H), 5.50 (d, J = 6.1 Hz, 1H), 5.06 (d, J = 3.2 Hz, 1H), 4.96 (d, J = 11.6 Hz, 1H), 4.85 (t, J = 12.0 
Hz, 2H), 4.77 (d, J = 11.7 Hz, 1H), 4.69 (d, J = 11.1 Hz, 1H), 4.67 (s, 1H), 4.61 (d, J = 11.4 Hz, 
1H), 4.39 (d, J = 6.8 Hz, 1H), 4.03 (dd, J = 9.8, 2.9 Hz, 1H), 3.97 – 3.90 (m, 1H), 3.89 (d, J = 10.5 
Hz, 1H), 3.82 (q, J = 6.5 Hz, 1H), 3.77 – 3.71 (m, 1H), 3.65 (s, 1H), 3.36 – 3.25 (m, 3H), 2.51 – 
2.44 (m, 1H), 2.38 – 2.29 (m, 1H), 1.97 – 1.91 (m, 1H), 1.81 – 1.68 (m, 3H), 1.29 (d, J = 6.7 Hz, 
3H), 1.07 (d, J = 5.1 Hz, 3H), 1.02 (d, J = 7.1 Hz, 3H), 0.98 (d, J = 6.5 Hz, 3H), 0.91 (d, J = 4.4 
Hz, 3H), 0.65 (d, J = 7.1 Hz, 3H). 
13C NMR (176 MHz, CDCl3): δ 213.2, 176.0, 139.1, 138.9, 138.8, 137.6, 130.0, 129.00, 128.6, 
128.5, 128.5, 128.3, 128.2, 128.2, 127.7, 127.6, 127.6, 127.5, 126.2, 99.3, 82.7, 79.8, 79.5, 79.4, 
78.0, 76.8, 76.2, 75.1, 74.5, 72.9, 71.3, 67.8, 44.9, 44.7, 44.5, 42.8, 40.5, 39.3, 33.8, 18.7, 17.5, 
16.9, 15.4, 9.3, 8.4, 8.0. 
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HRMS (m/z): [M+Na]+ calcd. for C53H68O11S, 935.4380; found, 935.4363 
TLC (EtOAc:Hexanes, 30:70 v/v): Rf = 0.2  
IR (thin film, cm-1): 3411, 2973, 2919, 2852, 1721, 1453, 1379, 1096 
[α]D: +8.6 (c = 0.93 in CHCl3) 
 
Synthesis of Strophanthidol 
 
Scheme 5.10. Synthesis of strophanthidol (61) from strophanthidin.  
Strophanthidin (500mg, 1.24mmol) was dissolved in EtOH (0.15M) and cooled in ice-bath. NaBH4 
(95mg, 2.0 equiv.) was added, and the reaction was warmed up to room After stirring at room 
temperature for 2h, the reaction was cooled in ice-bath, diluted with 50mL of EtOAc, and quenched 
slowly with 50mL of saturated NH4Cl (aq). The biphasic mixture was stirred vigorously overnight. 
Next, the organic layer was separated and concentrated under reduced pressure. The crude mixture 
was purified by flash column chromatography on silica gel (MeOH:CH2Cl2 15:1 to 10:1 v/v) to 
obtain strophanthidol 61 (430mg, 85% yield) as white solid. 
1H NMR (700 MHz, CDCl3): δ 5.87 (s, 1H), 5.75 (s, 1H), 4.97 (d, J = 18.2 Hz, 1H), 4.80 (d, J = 
17.9 Hz, 1H), 4.70 (d, J = 7.5 Hz, 1H), 4.37 (d, J = 11.2 Hz, 1H), 4.20 (d, J = 4.1 Hz, 1H), 4.07 (d, 
J = 4.6 Hz, 1H), 3.47 (dd, J = 11.4, 7.5 Hz, 1H), 2.76 (dd, J = 9.8, 5.5 Hz, 1H), 2.55 (td, J = 14.7, 
4.1 Hz, 1H), 2.15 (dt, J = 13.6, 10.0 Hz, 1H), 2.09 (dd, J = 15.0, 3.1 Hz, 1H), 2.05 – 1.98 (m, 1H), 
1.97 – 1.91 (m, 3H), 1.86 (dtd, J = 14.4, 9.3, 5.4 Hz, 1H), 1.79 – 1.63 (m, 4H), 1.64 – 1.45 (m, 
5H), 1.41 – 1.31 (m, 2H), 1.25 – 1.17 (m, 2H), 0.85 (s, 3H). 
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13C NMR (176 MHz, CDCl3): δ 174.8, 174.7, 117.9, 85.5, 78.2, 73.7, 67.9, 65.7, 50.7, 49.6, 42.3, 
40.6, 40.2, 39.0, 36.9, 35.5, 32.7, 27.7, 26.9, 24.0, 21.4, 19.2, 15.9. 
HRMS (m/z): [M+Na]+ calcd. for C23H34O6, 429.2247; found, 429.2248 
IR (thin film, cm-1): 3323, 2939, 1779, 1731, 1619, 1450, 1025 
[α]D: +30.6 (c = 1.0 in CHCl3) 
 
Synthesis of Strophanthidol Boronate and Glycoside 62 
 
Strophanthidol 61 (8mg, 0.020mmol), MeB(OH)2 (1.3mg, 1.1 equiv.) and 30mg of powered 4Å 
molecular sieve were stirred in 100μL of dry dichloromethane at room temperature. After 2h, the 
reaction was filtered through Celite and concentrated under reduced pressure to obtain boronate 
intermediate 61a (>98% mass recovery). 
1H NMR (700 MHz, CDCl3): δ 5.88 (s, 1H), 4.96 (d, J = 18.0 Hz, 1H), 4.79 (d, J = 18.1 Hz, 1H), 
4.28 (d, J = 11.7 Hz, 1H), 4.06 – 3.98 (m, 1H), 3.59 (d, J = 8.3 Hz, 1H), 3.45 (d, J = 11.6 Hz, 1H), 
2.77 (dd, J = 9.7, 5.5 Hz, 1H), 2.20 – 2.15 (m, 1H), 2.10 – 2.02 (m, 4H), 1.95 (dd, J = 13.9, 3.6 
Hz, 1H), 1.88 (dtd, J = 14.6, 9.4, 5.4 Hz, 1H), 1.79 – 1.60 (m, 10H), 1.59 – 1.52 (m, 2H), 1.45 – 
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1.34 (m, 3H), 1.22 (dtd, J = 26.4, 13.6, 12.5, 5.8 Hz, 1H), 1.10 (qd, J = 13.9, 13.4, 3.8 Hz, 1H), 
0.86 (s, 3H). 
13C NMR (176 MHz, CDCl3): δ 174.6, 174.3, 118.0, 85.3, 76.2, 73.6, 66.7, 65.3, 50.6, 49.6, 41.0, 
40.2, 38.6, 38.1, 36.9, 36.8, 32.9, 27.6, 27.0, 23.8, 21.4, 19.8, 15.9. 
10B NMR (75 MHz, CDCl3): δ 32.6 (br) 
IR (thin film, cm-1): 3470, 2938, 1780, 1737, 1620 
[α]D: +21.8 (c = 1.0 in CHCl3) 
61a and trichloroacetimidate donor 26 (23.2mg, 2.0 equiv.) was dissolved in 400μL dry 
dichloromethane and cooled to -20oC. TMSOTf (0.18 μL, 0.05 equiv.) in 20μL dry 
dichloromethane was added to the reaction. After stirring for 16h, the reaction quenched with Et3N 
at room temperature and filtered through a short pad of Celite. The crude mixture was azeotroped 
with MeOH multiple times and then purified by flash column chromatography on silica gel 
(EtOAc:Hexanes, 70:30 v/v) to obtain glycoside 62 as a mixture of two diastereomers (9.4mg, 57% 
yield). The diastereomeric glycosides were separated by semi-prep HPLC (18mL/min, 
EtOAc:Hexanes, 70:30 v/v) and characterized. 
 
1H NMR (700 MHz, CDCl3): δ 7.38 – 7.27 (m, 15H), 5.87 (s, 1H), 5.01 – 4.93 (m, 2H), 4.87 – 
4.81 (m, 2H), 4.79 (dd, J = 18.1, 1.8 Hz, 1H), 4.77 – 4.71 (m, 2H), 4.70 (d, J = 11.8 Hz, 1H), 4.67 
(s, 1H), 4.38 (d, J = 7.7 Hz, 1H), 4.30 (d, J = 11.4 Hz, 1H), 4.24 (d, J = 10.2 Hz, 1H), 4.22 (s, 1H), 
3.81 (dd, J = 9.7, 7.7 Hz, 1H), 3.57 (d, J = 2.9 Hz, 1H), 3.53 (dd, J = 9.7, 2.9 Hz, 1H), 3.50 – 3.43 
(m, 1H), 3.42 (t, J = 10.8 Hz, 1H), 2.76 (dd, J = 9.7, 5.4 Hz, 1H), 2.54 (td, J = 14.8, 3.8 Hz, 1H), 
2.19 – 2.10 (m, 2H), 2.07 – 1.96 (m, 2H), 1.95 – 1.82 (m, 3H), 1.76 – 1.71 (m, 1H), 1.70 – 1.62 
(m, 2H), 1.60 – 1.44 (m, 6H), 1.39 – 1.24 (m, 6H), 1.20 (dd, J = 13.7, 4.5 Hz, 1H), 1.16 (d, J = 6.4 
Hz, 3H), 0.85 (s, 3H). 
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13C NMR (176 MHz, CDCl3): δ 174.5, 174.3, 138.5, 138.4, 138.3, 128.7, 128.6, 128.5, 128.4, 
128.3, 127.8, 127.7, 118.0, 101.4, 85.7, 83.1, 79.1, 76.8, 75.9, 75.7, 74.9, 74.8, 73.5, 73.2, 70.9, 
64.8, 50.7, 49.5, 42.6, 40.6, 40.2, 39.1, 36.2, 35.1, 32.8, 29.9, 26.8, 24.2, 23.9, 21.3, 19.1, 17.0, 
15.8. 
HRMS (m/z): [M+Na]+ calcd. for C50H62O10, 845.4235; found, 845.4232 
IR (thin film, cm-1): 3441, 2935, 1780, 1742, 1620, 1453, 1063 
[α]D: +21.3 (c = 0.31 in CHCl3) 
 
1H NMR (700 MHz, CDCl3): δ 7.41 – 7.27 (m, 15H), 5.88 (s, 1H), 5.21 (s, 1H), 4.99 – 4.94 (m, 
2H), 4.83 – 4.77 (m, 3H), 4.77 – 4.71 (m, 2H), 4.65 (dd, J = 17.9, 11.8 Hz, 3H), 4.36 (d, J = 11.3 
Hz, 1H), 4.02 (t, J = 2.8 Hz, 1H), 4.00 (dd, J = 10.0, 3.9 Hz, 1H), 3.91 – 3.83 (m, 2H), 3.65 (d, J 
= 1.4 Hz, 1H), 3.42 (d, J = 9.7 Hz, 1H), 2.77 (dd, J = 9.7, 5.5 Hz, 1H), 2.54 (td, J = 14.5, 4.4 Hz, 
1H), 2.19 – 1.92 (m, 6H), 1.87 (dtd, J = 14.6, 9.4, 5.5 Hz, 1H), 1.73 – 1.44 (m, 8H), 1.34 (m, 2H), 
1.31 – 1.17 (m, 4H), 1.09 (d, J = 6.5 Hz, 3H), 0.86 (s, 3H). 
13C NMR (176 MHz, CDCl3): δ 174.5, 174.2, 138.6, 138.6, 138.4, 128.6, 128.4, 128.4, 127.9, 
127.8, 127.7, 127.7, 118.1, 96.4, 85.7, 79.4, 77.4, 77.1, 76.7, 75.6, 75.0, 74.0, 73.5, 73.1, 72.5, 
67.2, 65.0, 50.7, 49.4, 42.4, 40.6, 40.3, 39.0, 35.3, 34.2, 32.8, 29.9, 26.8, 26.2, 24.2, 21.3, 19.4, 
16.8, 15.8. 
HRMS (m/z): [M+Na]+ calcd. for C50H62O10, 845.4235; found, 845.4230 
IR (thin film, cm-1): 3436, 2924, 1742, 1620, 1453 
[α]D: -27.1 (c = 0.11 in CHCl3) 
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Synthesis of Glycoside 64 
 
Strophanthidol 61 (16.3mg, 0.040mmol), MeB(OH)2 (2.6mg, 1.1 equiv.) and 60mg of powered 
4Å molecular sieve were stirred in 200μL of dry dichloromethane at room temperature. After 2h, 
0.5 equiv. of sugar donor 63 in 1.8mL of dry dichloromethane was added to the reaction, and the 
mixture was cooled in ice-bath. TfOH (1.1μL, 0.3 equiv.) in 20μL of dry dichloromethane was 
added to the reaction. At 1h interval, 0.5 equiv. of sugar donor in 200μL of dry dichloromethane 
was added to reaction (repeated 3 times). After the last portion of sugar portion was added, the 
reaction was stirred in ice bath for 1 h before being warmed up to room temperature and quenched 
with Et3N. Next, the reaction was filtered through a short pad of silica get/Celite and concentrated 
under reduced pressure. The crude mixture was azeotroped with MeOH multiple times and then 
purified by flash column chromatography on silica gel (EtOAc:Hexanes, 60:40 to 70:30 v/v) to 
obtain 64 (27.9mg, 81% yield) as white foamy solid.  
1H NMR (500 MHz, CDCl3): δ 8.12 – 8.06 (m, 2H), 8.04 – 7.97 (m, 2H), 7.87 – 7.78 (m, 2H), 
7.65 – 7.59 (m, 1H), 7.56 – 7.46 (m, 3H), 7.46 – 7.36 (m, 3H), 7.27 – 7.24 (m, 2H), 5.88 (s, 1H), 
5.71 (dd, J = 5.5, 2.4 Hz, 2H), 5.66 – 5.60 (m, 1H), 5.16 (d, J = 1.9 Hz, 1H), 4.98 (dd, J = 18.1, 
1.8 Hz, 1H), 4.81 (dd, J = 18.1, 1.7 Hz, 1H), 4.40 (d, J = 11.4 Hz, 1H), 4.30 – 4.19 (m, 4H), 3.50 
(t, J = 10.6 Hz, 1H), 2.78 (dd, J = 9.6, 5.4 Hz, 1H), 2.60 (td, J = 14.9, 3.8 Hz, 1H), 2.20 (dd, J = 
15.4, 3.3 Hz, 1H), 2.18 – 1.95 (m, 5H), 1.88 (dtd, J = 14.3, 9.2, 5.4 Hz, 1H), 1.79 (s, 1H), 1.76 – 
1.68 (m, 3H), 1.64 (h, J = 4.3 Hz, 3H), 1.54 (tq, J = 11.9, 3.3 Hz, 3H), 1.36 (d, 3H), 1.35 – 1.31 
(m, 1H), 1.28 – 1.15 (m, 1H), 0.87 (s, 3H). 
13C NMR (176 MHz, CDCl3): δ 174.6, 174.4, 165.9, 165.7, 165.5, 133.8, 133.6, 133.3, 130.0, 
129.9, 129.8, 129.2, 129.1, 129.1, 128.8, 128.6, 128.4, 117.9, 97.8, 85.5, 77.4, 77.3, 76.9, 73.6, 
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71.3, 71.1, 70.0, 68.1, 64.9, 50.7, 49.5, 42.7, 40.5, 40.2, 39.2, 35.8, 34.6, 32.7, 29.8, 26.8, 25.5, 
24.1, 21.3, 19.2, 17.8, 15.9. 
HRMS (m/z): [M+Na]+ calcd. for C50H56O13, 887.3592; found, 887.3594 
IR (thin film, cm-1): 3485, 2935, 1780, 1729, 1601, 1451 
[α]D: +9.3 (c = 0.57 in CHCl3) 
 
Synthesis of Trichloroacetimidate Donor 67 and 68 
 
Scheme 5.11. Synthesis of 2-fluoro-benzoyl protected glucose-derived trichloroacetimidate 
donor 67.  
 
D-Glucose (300mg, 1.67mmol) and DMAP (102mg, 0.5 equiv.) were dissolved in dry pyridine 
and cooled in ice-bath. 2-fluorobenzoyl chloride (1.4mL, 7.0 equiv.) was added to the reaction 
dropwise. After stirring at room temperature overnight, the reaction was quenched with 2mL of 
MeOH and stirred for 1h. Next, the reaction was diluted with 50mL of DCM and washed with 2N 
HCl (two times), sat. NaHCO3 (two times), and brine solution. The organic layer was dried over 
Na2SO3, filtered and concentrated under reduced pressure. The crude mixture was used in next 
step without further purification. 
The crude from previous step was dissolved in 5mL of DCM and 33% HBr in AcOH was added 
to the reaction dropwise. After stirring at room temperature for 5h, the reaction was quenched 
slowly with sat NaHCO3 (aq). Next, the mixture was diluted with DCM, and washed with sat 
NaHCO3 (aq), followed by brine solution. The organic layer was dried over Na2SO3, filtered and 
concentrated under reduced pressure. The crude mixture was used in next step without further 
purification. 
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The crude from previous step was dissolved in acetone/H2O/DCM (10mL:1mL:2mL) before 
Ag2CO3 (800mg) was added to the reaction. After stirring at room temperature for overnight, the 
reaction was filtered through Celite and concentrated under reduced pressure. The crude mixture 
was purified by flash column chromatography on silica gel (EtOAc:hexanes, 30:70 to 40:60 v/v) 
to obtain hemiacetal 67a. 
67a (300mg, 0.45mmol) was dissolved in 3mL of DCM (0.15M) and cooled in ice-bath. 
Trichloroacetonitrile (0.9mL, 20 equiv.) was added to the reaction, followed by DBU (34μL, 0.5 
equiv.). After stirring at room temperature for 2h, the reaction was concentrated under reduced 
pressure. The crude mixture was purified by flash column chromatography on silica gel 
(EtOAc:hexanes, 15:85 v/v) to obtain α-trichloroacetimidate donor 67 (250mg, 68% yield) as 
white foamy solid.  
1H NMR (700 MHz, CDCl3): δ 8.67 (s, 1H), 7.96 (t, J = 7.5 Hz, 1H), 7.89 (t, J = 7.5 Hz, 1H), 
7.83 (t, J = 7.4 Hz, 1H), 7.77 (t, J = 7.5 Hz, 1H), 7.54 – 7.48 (m, 3H), 7.44 (q, J = 7.1 Hz, 1H), 
7.21 (t, J = 7.5 Hz, 1H), 7.18 – 7.09 (m, 4H), 7.08 (t, J = 9.5 Hz, 2H), 7.02 (t, J = 9.5 Hz, 1H), 
6.24 (t, J = 9.9 Hz, 1H), 5.80 (t, J = 9.9 Hz, 1H), 5.60 (dd, J = 10.2, 3.7 Hz, 1H), 4.67 – 4.60 (m, 
2H), 4.57 (dd, J = 12.7, 4.9 Hz, 1H). 
13C NMR (176 MHz, CDCl3): δ 163.9, 163.9, 163.2, 163.2, 163.2, 163.1, 163.0, 163.0, 162.9, 
162.9, 162.8, 162.8, 161.7, 161.5, 161.3, 161.3, 160.7, 135.4, 135.4, 135.2, 135.2, 134.9, 134.9, 
134.9, 134.8, 132.4, 132.3, 132.1, 131.9, 124.3, 124.2, 124.2, 124.2, 124.2, 124.1, 124.1, 124.1, 
118.3, 118.2, 118.0, 118.0, 117.7, 117.7, 117.3, 117.2, 117.2, 117.1, 117.1, 117.1, 116.9, 93.1, 
90.8, 70.8, 70.6, 70.4, 68.9, 62.7. (complex multiplet in δ 164 – 117 due to C-F couplings.) 
HRMS (m/z): [M+Na]+ calcd. for C36H24Cl3F4NO10, 834.0294; found, 834.0301 
IR (thin film, cm-1): 1729, 1677, 1612, 1584, 1489, 1456, 1290, 1243 
[α]D: +66.5 (c = 1.0 in CHCl3) 
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Scheme 5.12. Synthesis of 2-fluoro-benzoyl protected mannose-derived trichloroacetimidate 
donor 68.  
 
Trichloroacetimidate donor 68 was synthesized from D-Mannose following the same synthetic 
sequence for 67.  
1H NMR (700 MHz, CDCl3): δ 8.87 (s, 1H), 7.99 (q, J = 7.8 Hz, 2H), 7.82 (q, J = 7.9 Hz, 2H), 
7.59 – 7.56 (m, 1H), 7.54 – 7.46 (m, 2H), 7.44 (qd, J = 7.0, 6.5, 2.8 Hz, 1H), 7.19 (t, J = 7.6 Hz, 
1H), 7.16 – 7.11 (m, 3H), 7.11 – 7.05 (m, 3H), 7.01 (dd, J = 10.6, 8.4 Hz, 1H), 6.57 (s, 1H), 6.21 
(t, J = 9.7 Hz, 1H), 5.97 – 5.95 (m, 2H), 4.69 – 4.65 (m, 1H), 4.62 – 4.56 (m, 2H). 
13C NMR (176 MHz, CDCl3): δ 163.8, 163.8, 163.2, 163.2, 163.1, 163.1, 163.1, 163.0, 162.8, 
161.7, 161.6, 161.6, 161.3, 159.9, 135.4, 135.3, 135.1, 135.1, 134.8, 134.7, 132.5, 132.5, 132.2, 
132.1, 124.2, 124.2, 124.2, 124.1, 124.1, 124.0, 124.0, 118.4, 118.3, 117.9, 117.8, 117.7, 117.6, 
117.6, 117.5, 117.3, 117.2, 117.2, 117.1, 117.1, 117.1, 117.0, 94.6, 90.7, 71.5, 70.1, 69.0, 66.4, 
62.8. (complex multiplet in δ 164 – 117 due to C-F couplings.) 
HRMS (m/z): [M+Na]+ calcd. for C36H24Cl3F4NO10, 834.0294; found, 834.0303 
IR (thin film, cm-1): 1725, 1678, 1612, 1585, 1488, 1456, 1289, 1243 
[α]D: -34.3 (c = 1.0 in CHCl3) 
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General Procedure for One-pot Glycosylation of Strophanthidol 
 
Strophanthidol 61 (16.3mg, 0.040mmol), MeB(OH)2 (2.6mg, 1.1 equiv.) and 60mg of powered 
4Å molecular sieve were stirred in 200μL of dry dichloromethane at room temperature. After 2h, 
0.5 equiv. of trichloroacetimidate donor in 1.8mL of dry dichloromethane was added to the 
reaction, and the mixture was cooled in ice-bath. TfOH (1.1μL, 0.3 equiv.) in 20μL of dry 
dichloromethane was added to the reaction. At 1h interval, 0.5 equiv. of trichloroacetimidate donor 
in 200μL of dry dichloromethane was added to reaction (repeated 3 times). After the last portion 
of trichloroacetimidate donor was added, the reaction was stirred in ice bath for 1 h before being 
warmed up to room temperature. Next, the reaction was diluted with 3 mL of MeOH and NH3 gas 
was bubbled through the reaction for 30 min. After stirring at room temperature for 18 h, the 
reaction mixture was filtered through a short pad of silica gel/Celite and concentrated under 
reduced pressure. The crude mixture was purified by flash column chromatography (on pipette 
column) on silica gel (starting with MeOH:CH2Cl2, 5:95 v/v + 0.5% of AcOH, followed by a 
gradient of MeOH:CH2Cl2, 10:90 to 20:80 v/v ) to obtain glycoside 69 – 73.   
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Characterization of Strophanthidol Glycoside 69 – 73 
 
 
1H NMR (500 MHz, CD3OD): δ 5.90 (s, 1H), 5.03 (dd, J = 18.4, 1.8 Hz, 1H), 4.92 (dd, J = 18.4, 
1.8 Hz, 1H), 4.85 (d, J = 1.8 Hz, 1H), 4.19 – 4.11 (m, 2H), 3.79 (dd, J = 3.4, 1.7 Hz, 1H), 3.69 – 
3.59 (m, 3H), 3.40 (t, J = 9.5 Hz, 1H), 2.86 – 2.83 (m, 1H), 2.26 – 2.09 (m, 5H), 2.03 – 1.94 (m, 
1H), 1.94 – 1.85 (m, 2H), 1.84 – 1.65 (m, 6H), 1.58 – 1.38 (m, 9H), 1.29 (s, 1H) 1.26 (d, J = 6.2 
Hz, 3H), 1.25 – 1.19 (m, 1H), 0.89 (s, 3H). 
13C NMR (176 MHz, CD3OD): δ 178.3, 177.2, 117.8, 100.9, 86.4, 77.4, 75.6, 75.3, 73.8, 72.5, 
72.4, 70.7, 65.2, 51.9, 50.8, 44.1, 41.5, 41.1, 40.0, 36.2, 35.9, 33.0, 27.9, 26.4, 25.0, 22.8, 20.4, 
18.0, 16.3. 
HRMS (m/z): [M+Na]+ calcd. for C29H44O10, 575.2826; found, 575.2828 
IR (thin film, cm-1): 3342, 2938, 1732, 1449, 1021 
[α]D: -3.68 (c = 1.0 in CHCl3) 
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1H NMR (500 MHz, CD3OD): δ 5.90 (s, 1H), 5.03 (dd, J = 18.4, 1.8 Hz, 1H), 4.91 (dd, J = 18.4, 
1.7 Hz, 1H), 4.36 – 4.27 (m, 1H), 4.21 (s, 1H), 4.18 (d, J = 11.4 Hz, 1H), 3.69 – 3.62 (m, 1H), 3.60 
(d, J = 1.6 Hz, 1H), 3.58 (d, J = 11.4 Hz, 1H), 3.48 – 3.44 (m, 2H), 2.85 – 2.82 (m, 1H), 2.34 – 
2.22 (m, 2H), 2.21 – 2.08 (m, 2H), 2.03 – 1.82 (m, 5H), 1.77 – 1.58 (m, 6H), 1.56 – 1.35 (m, 7H), 
1.26 (d, J = 6.4 Hz, 3H), 1.24 – 1.18 (m, 2H), 0.88 (s, 3H). 
13C NMR (176 MHz, CD3OD): δ 178.3, 177.2, 117.9, 102.4, 86.4, 77.3, 75.6, 75.3, 75.2, 73.0, 
72.3, 72.1, 65.4, 51.9, 50.8, 44.1, 41.4, 41.1, 40.0, 37.4, 36.5, 33.0, 27.9, 25.1, 24.1, 22.7, 20.1, 
16.7, 16.3. 
HRMS (m/z): [M+Na]+ calcd. for C29H44O10, 575.2826; found, 575.2828 
IR (thin film, cm-1): 3348, 2940, 1733, 1666, 1624, 1448, 1022 
[α]D: +14.5 (c = 1.0 in CHCl3) 
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1H NMR (500 MHz, CD3OD): δ 5.90 (s, 1H), 5.03 (dd, J = 18.4, 1.8 Hz, 1H), 4.91 (dd, J = 18.4, 
1.7 Hz, 1H), 4.36 – 4.28 (m, 1H), 4.20 (d, J = 11.3 Hz, 1H), 4.17 (s, 1H), 3.64 (m, 1H), 3.61 – 3.54 
(m, 2H), 3.49 – 3.44 (m, 2H), 2.85 – 2.81 (m, 1H), 2.32 (td, J = 14.5, 3.8 Hz, 1H), 2.22 – 2.09 (m, 
4H), 2.03 – 1.81 (m, 4H), 1.80 – 1.61 (m, 6H), 1.58 – 1.34 (m, 7H), 1.26 (d, J = 6.5 Hz, 3H), 1.24 
– 1.16 (m, 2H), 0.88 (s, 3H). 
13C NMR (176 MHz, CD3OD): δ 178.3, 177.2, 117.9, 102.6, 86.4, 77.3, 75.8, 75.3, 75.3, 73.1, 
72.3, 72.1, 65.6, 51.9, 50.8, 43.8, 41.4, 41.1, 40.0, 36.8, 35.3, 33.1, 27.9, 26.5, 25.2, 22.6, 20.5, 
16.8, 16.3. 
HRMS (m/z): [M+Na]+ calcd. for C29H44O10, 575.2826; found, 575.2829 
IR (thin film, cm-1): 3354, 2940, 1733, 1666, 1624, 1449, 1024 
[α]D: +12.6 (c = 1.0 in CHCl3) 
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1H NMR (500 MHz, CD3OD): δ 5.90 (s, 1H), 5.03 (dd, J = 18.5, 1.8 Hz, 1H), 4.95 – 4.87 (dd, J 
= 18.5, 1.7 Hz, 1H), 4.40 (d, J = 7.9 Hz, 1H), 4.23 (s, 1H), 4.20 (d, J = 11.4 Hz, 1H), 3.86 (dd, J = 
11.9, 1.7 Hz, 1H), 3.69 – 3.63 (m, 1H), 3.58 (d, J = 11.4 Hz, 1H), 3.29 – 3.26 (m, 2H), 3.18 (dd, J 
= 9.2, 7.9 Hz, 1H), 2.85 – 2.82 (m, 1H), 2.32 (td, J = 14.5, 4.0 Hz, 1H), 2.22 – 2.09 (m, 3H), 2.05 
– 1.81 (m, 4H), 1.81 – 1.59 (m, 6H), 1.57 – 1.32 (m, 7H), 1.32 – 1.20 (m, 2H), 0.88 (s, 3H). 
13C NMR (176 MHz, CD3OD): δ 178.3, 177.2, 117.9, 102.0, 86.4, 78.2, 78.2, 77.3, 75.7, 75.3, 
75.1, 71.6, 65.6, 62.7, 51.9, 50.8, 43.8, 41.4, 41.0, 39.9, 36.9, 35.2, 33.1, 27.9, 26.5, 25.2, 22.6, 
20.5, 16.3. 
HRMS (m/z): [M+Na]+ calcd. for C29H44O11, 591.2776; found, 591.2791 
IR (thin film, cm-1): 3341, 2941, 1734, 1668, 1450, 1019 
[α]D: +10.1 (c = 1.0 in CHCl3) 
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1H NMR (500 MHz, CD3OD): δ 5.88 (s, 1H), 5.01 (dd, J = 18.5, 1.8 Hz, 1H), 4.94 – 4.86 (m, 
2H), 4.24 (s, 1H), 4.14 (d, J = 11.4 Hz, 1H), 3.86 – 3.78 (m, 2H), 3.72 – 3.55 (m, 5H), 2.82 – 2.80 
(m, J = 9.0 Hz, 1H), 2.34 (dd, J = 15.3, 3.5 Hz, 1H), 2.22 – 2.02 (m, 3H), 2.00 – 1.79 (m, 5H), 
1.77 – 1.59 (m, 5H), 1.57 – 1.34 (m, 8H), 1.31 – 1.15 (m, 2H), 0.87 (s, 3H). 
13C NMR (176 MHz, CD3OD): δ 178.3, 177.2, 117.9, 98.5, 86.4, 77.5, 75.4, 75.3, 72.8, 72.7, 
72.4, 68.6, 65.2, 63.0, 51.9, 50.8, 44.3, 41.5, 41.0, 40.0, 37.7, 36.1, 33.0, 27.9, 25.0, 23.0, 22.8, 
20.0, 16.3. 
HRMS (m/z): [M+Na]+ calcd. for C29H44O11, 591.2776; found, 591.2780 
IR (thin film, cm-1): 3358, 2939, 1733, 1667, 1617, 1452, 1027 
[α]D: +46.9 (c = 0.98 in CHCl3) 
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Synthesis of Anhydro-ouabagenin 74 
 
Scheme 5.13. Synthesis of anhydro-ouabagenin (74).  
74a was prepared according to previously reported method.16 74a (184mg, 0.39mmol) in 15mL of 
0.05 N HCl (EtOH solution) was heated to reflux for 30 minutes. After being cooled to room 
temperature, the reaction was neutralized by addition of solid NaHCO3. Next, the reaction was 
filtered through a filter paper, and the filtrate was concentrated under reduced pressure. The crude 
mixture was purified by flash column chromatography on silica gel (gradient of DCM:MeOH from 
90:10 to 75:25 v/v) to obtain anhydro-ouabagenin 74 (50mg, 30% yield) as white solid.  
1H NMR (500 MHz, CD3OD): δ 5.92 (s, 1H), 4.99 (dd, J = 18.4, 1.8 Hz, 1H), 4.89 (dd, J = 18.4, 
1.8 Hz, 1H), 4.71 (t, J = 8.1 Hz, 1H), 4.22 – 4.12 (m, 2H), 3.92 (td, J = 11.5, 4.2 Hz, 1H), 3.69 (d, 
J = 11.7 Hz, 1H), 2.92 (dd, J = 9.6, 5.9 Hz, 1H), 2.35 (dddd, J = 13.3, 6.4, 3.8, 1.7 Hz, 1H), 2.27 
– 2.18 (m, 1H), 2.15 – 2.04 (m, 2H), 2.04 – 1.86 (m, 4H), 1.82 (ddd, J = 15.1, 11.4, 4.1 Hz, 1H), 
1.73 – 1.52 (m, 5H), 1.45 (t, J = 11.7 Hz, 1H), 1.40 – 1.22 (m, 2H), 0.92 (s, 3H). 
13C NMR (176 MHz, CD3OD): δ 177.1, 176.9, 118.3, 86.4, 79.2, 79.0, 78.8, 78.5, 78.4, 75.5, 
75.2, 68.5, 62.7, 54.6, 53.7, 51.5, 47.5, 39.1, 38.2, 37.3, 37.1, 33.1, 28.2, 25.8, 17.9. 
HRMS (m/z): [M+Na]+ calcd. for C23H32O7, 443.2030; found, 443.2044 
IR (thin film, cm-1): 3323, 2943, 2832, 1449, 1024 
[α]D: +38.2 (c = 0.5 in DMSO) 
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Glycosylation of Anhydro-ouabagenin with Glycosyl Bromide 
 
Anhydro-ouabagenin 74 (6.3mg, 0.015mmol), MeB(OH)2 (1.0mg, 1.1 equiv.) and 40mg of 
powered 4Å molecular sieve were stirred in 400μL of dry dichloromethane at room temperature. 
After 3h, glycosyl bromide 77 (24.3mg, 3.0 equiv.) and Ag2CO3 (16.5mg, 4.0 equiv.) was added 
to the reaction, and the reaction vial was wrapped with aluminum foil. After stirring at room 
temperature for 18h, the reaction was quenched with Et3N, filtered through a short pad of silica 
gel/Celite, and concentrated under reduced pressure. The crude mixture was azeotroped with 
MeOH multiple times and purified by flash column chromatography (pipette column) on silica gel 
(EtOAc:Hexanes, 80:20 to 100:0 v/v) to obtain a mixture of glycosides 75 and 76 (9.1mg, 69% 
yield) as white film. The regioisomeric glycosides were separated by semi-prep HPLC (18mL/min, 
100% EtOAc) and characterized. 
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1H NMR (500 MHz, CD3OD): δ 8.08 (d, J = 7.8 Hz, 2H), 7.98 (d, J = 7.8 Hz, 2H), 7.83 (d, J = 
7.8 Hz, 2H), 7.65 – 7.58 (m, 1H), 7.51 (dt, J = 15.7, 7.5 Hz, 3H), 7.41 (dt, J = 15.6, 7.5 Hz, 3H), 
7.28 – 7.25 (m, 2H), 5.92 (s, 1H), 5.72 (t, J = 9.8 Hz, 1H), 5.65 – 5.56 (m, 2H), 5.16 (s, 1H), 5.01 
(t, J = 8.1 Hz, 1H), 4.91 (d, J = 18.0 Hz, 1H), 4.79 (d, J = 18.0 Hz, 1H), 4.36 – 4.25 (m, 3H), 4.01 
(s, 1H), 3.93 (td, J = 11.4, 4.2 Hz, 1H), 3.72 – 3.62 (m, 2H), 2.85 (dd, J = 9.7, 5.6 Hz, 1H), 2.71 – 
2.68 (m, 1H), 2.26 – 2.20 (m, 1H), 2.12 (ddt, J = 12.4, 9.3, 5.1 Hz, 2H), 2.08 – 1.85 (m, 5H), 1.83 
– 1.58 (m, 4H), 1.50 – 1.40 (m, 2H), 1.39 (d, J = 6.0 Hz, 3H), 1.28 (s, 1H), 0.93 (s, 3H). 
13C NMR (176 MHz, CD3OD): δ 174.3, 173.2, 165.9, 165.8, 165.7, 133.9, 133.6, 133.4, 130.0, 
129.9, 129.9, 129.2, 129.1, 129.1, 128.8, 128.6, 128.5, 118.5, 98.2, 86.1, 77.5, 77.3, 76.2, 73.7, 
73.6, 71.1, 71.1, 70.1, 68.3, 62.0, 52.6, 50.5, 49.7, 48.3, 47.0, 38.0, 36.7, 35.9, 35.9, 33.1, 27.3, 
25.2, 17.8, 17.5. 
HRMS (m/z): [M+Na]+ calcd. for C50H54O14, 901.3406; found, 901.3403 
IR (thin film, cm-1): 3445, 2928, 1729, 1451, 1263 
[α]D: +99.9 (c = 0.14 in CHCl3) 
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1H NMR (500 MHz, CD3OD): δ 8.11 (d, J = 7.7 Hz, 2H), 7.82 (d, J = 7.9 Hz, 2H), 7.79 (d, J = 
7.9 Hz, 2H), 7.63 (t, J = 7.5 Hz, 1H), 7.51 (t, J = 7.8 Hz, 3H), 7.45 (t, J = 7.5 Hz, 1H), 7.31 (t, J = 
7.7 Hz, 2H), 7.28 (t, J = 7.8 Hz, 2H), 5.99 (dd, J = 10.5, 3.0 Hz, 1H), 5.94 (s, 1H), 5.66 (t, J = 10.0 
Hz, 1H), 5.55 (t, J = 2.4 Hz, 1H), 5.12 (s, 1H), 5.06 – 4.99 (m, 1H), 4.88 (d, J = 18.2 Hz, 1H), 4.35 
(d, J = 10.4 Hz, 1H), 4.30 (s, 1H), 4.21 (td, J = 11.4, 4.2 Hz, 1H), 4.15 (dt, J = 12.2, 6.1 Hz, 1H), 
4.08 (t, J = 8.3 Hz, 1H), 4.03 (d, J = 10.4 Hz, 1H), 3.69 (s, 1H), 3.00 – 2.93 (m, 2H), 2.79 – 2.72 
(m, 1H), 2.49 (d, J = 4.4 Hz, 1H), 2.42 – 2.39 (s, 1H), 2.25 (q, J = 9.8, 7.9 Hz, 1H), 2.18 (dt, J = 
11.9, 5.5 Hz, 2H), 2.15 – 2.07 (m, 2H), 2.07 – 1.99 (m, 2H), 1.90 – 1.78 (m, 2H), 1.75 (d, J = 13.6 
Hz, 1H), 1.63 (t, J = 12.6 Hz, 1H), 1.53 – 1.46 (m, 2H), 1.41 (d, J = 6.2 Hz, 3H), 1.39 (m, 1H), 
1.38 – 1.30 (m, 1H), 1.15 (s, 3H). 
13C NMR (176 MHz, CD3OD): δ 174.2, 173.7, 166.8, 165.8, 165.6, 134.0, 133.8, 133.8, 130.1, 
130.1, 129.5, 129.3, 129.0, 128.8, 128.6, 128.6, 118.4, 97.7, 86.0, 78.3, 75.9, 74.8, 74.2, 73.6, 71.5, 
71.0, 70.2, 68.6, 68.6, 68.3, 53.0, 50.8, 49.2, 48.5, 47.2, 39.0, 38.8, 38.0, 36.9, 31.9, 29.9, 27.3, 
25.0, 18.1. 
HRMS (m/z): [M+Na]+ calcd. for C50H54O14, 901.3406; found, 901.3403 
IR (thin film, cm-1): 3405, 2924, 1726, 1451, 1261 
[α]D: +60.5 (c = 0.26 in CHCl3) 
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Deprotection of Anhydro-ouabagenin Glycosides 
 
Scheme 5.14. Deprotection of C3-rhamnoside of anhydro-ouabagenin (75).  
 
75 (8.5mg, 9.7μmol) was dissolved in 2mL of MeOH, and NH3 gas was bubbled through the 
solution for 20 minutes. After stirring in sealed tube for 24h at room temperature, the reaction was 
concentrated under reduced pressure. The crude was purified by flash column chromatography 
(pipette column) on silica gel (CH2Cl2:MeOH, 80:20 v/v) to obtain 75a (4.2mg, 76% yield) as 
white film.  
1H NMR (700 MHz, CD3OD) δ 5.93 (d, J = 1.9 Hz, 1H), 4.99 (dd, J = 18.4, 1.8 Hz, 1H), 4.91 
(dd, J = 18.5, 1.7 Hz, 1H), 4.83 (d, J = 1.7 Hz, 1H), 4.69 (t, J = 7.6 Hz, 1H), 4.20 – 4.12 (m, 2H), 
3.93 (td, J = 11.6, 4.3 Hz, 1H), 3.75 (t, J = 2.4 Hz, 1H), 3.68 – 3.62 (m, 2H), 3.60 (dd, J = 9.5, 3.2 
Hz, 1H), 3.38 (t, J = 9.5 Hz, 1H), 2.93 (dd, J = 9.7, 5.9 Hz, 1H), 2.36 (dt, J = 13.2, 5.7 Hz, 1H), 
2.26 – 2.19 (m, 1H), 2.18 – 2.09 (m, 2H), 2.02 – 1.89 (m, 4H), 1.82 – 1.63 (m, 5H), 1.55 – 1.44 
(m, 2H), 1.27 (d, J = 6.2 Hz, 3H), 0.92 (s, 3H). 
13C NMR (176 MHz, CD3OD) δ 177.4, 177.0, 118.3, 100.8, 86.5, 78.6, 77.5, 75.4, 74.3, 73.9, 
72.5, 72.4, 70.5, 62.5, 53.8, 51.6, 50.3, 47.3, 38.4, 37.7, 37.0, 36.0, 33.3, 28.3, 26.2, 18.0, 17.8. 
HRMS (m/z): [M+Na]+ calcd. for C29H42O11, 589.2619; found, 589.2622 
IR (thin film, cm-1): 3375, 2927, 1736, 1627, 1451, 1384 
[α]D: -9.6 (c = 0.14 in CHCl3) 
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Scheme 5.15. Deprotection of C19-rhamnoside of anhydro-ouabagenin (76).  
 
76 (7.0mg, 8.0μmol) was dissolved in 2mL of MeOH, and NH3 gas was bubbled through the 
solution for 20 minutes. After stirring in sealed tube for 24h at room temperature, the reaction was 
concentrated under reduced pressure. The crude was purified by flash column chromatography 
(pipette column) on silica gel (CH2Cl2:MeOH, 80:20 v/v) to obtain 76a (3.2mg, 71% yield) as 
white film.  
1H NMR (700 MHz, CD3OD) δ 5.94 (s, 1H), 4.99 (dd, J = 18.3, 1.7 Hz, 1H), 4.95 – 4.89 (m, 
1H), 4.67 (d, J = 1.7 Hz, 1H), 4.17 (s, 1H), 4.08 (t, J = 8.3 Hz, 1H), 4.02 (dd, J = 11.6, 4.4 Hz, 
1H), 3.99 (d, J = 10.4 Hz, 1H), 3.86 (t, J = 2.4 Hz, 1H), 3.80 (d, J = 10.4 Hz, 1H), 3.68 – 3.59 
(m, 2H), 3.40 (t, J = 9.5 Hz, 1H), 2.94 (dd, J = 9.7, 5.8 Hz, 1H), 2.30 – 2.19 (m, 1H), 2.18 – 2.08 
(m, 3H), 2.06 (dd, J = 13.7, 4.8 Hz, 1H), 2.02 (dd, J = 12.1, 4.3 Hz, 1H), 1.95 (td, J = 13.8, 12.8, 
6.7 Hz, 2H), 1.71 (dd, J = 13.4, 8.9 Hz, 1H), 1.66 – 1.52 (m, 4H), 1.49 (t, J = 11.7 Hz, 1H), 1.26 
(d, J = 6.3 Hz, 3H), 0.95 (s, 3H). 
13C NMR (176 MHz, CD3OD) δ 177.5, 177.0, 118.3, 102.7, 86.9, 80.1, 76.1, 75.9, 75.4, 73.9, 
72.4, 72.2, 70.4, 69.4, 68.8, 53.8, 51.6, 49.8, 49.5, 49.5, 49.4, 49.3, 47.4, 39.4, 38.9, 38.1, 37.6, 
33.0, 28.4, 25.7, 18.1, 17.9. 
HRMS (m/z): [M+Na]+ calcd. for C29H42O11, 589.2619; found, 589.2626 
IR (thin film, cm-1): 3379, 2922, 2851, 1736, 1627 
[α]D: +6.65 (c = 0.07 in CHCl3) 
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